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Abstract 
This thesis comprises of studies which collectively describe the development and application 
of novel metabonomic approaches to the investigation of xenobiotic metabolism and toxicity. 
Both computational and UPLC-MS technologies are critically evaluated to facilitate the 
development of rapid, robust and high throughput analytical approaches for the analysis of 
compounds in biological matrices, particularly applicable in the area of drug discovery.   
Pattern recognition statistical modelling approaches were employed on both a small scale 
metabolism study of diclofenac and a large toxicology of acetaminophen. This methodology 
highlighted large differences between the test groups in both studies; however these 
discriminations were only compound related in the latter study. In a study with low statistical 
power, the probability of biologically unrelated processes, overwhelming the statistical 
significance of the compound related effects are quite high. Application of statistical 
normalisation for the correction of batch effects was also performed in an attempt to 
emolliate the issue of limited continuous LC-MS instrumental capacity. Batch correction was 
attempted using variance stabilisation with a glog function prior to median fold change 
normalisation. However, this approach was unable to correct the data to the extent where it 
was suitable for combined downstream analysis.  
A rapid gradient microbore UPLC-MS method is then described to provide a high-throughput 
solution for metabolic phenotyping of large sample collections. This method increases the 
flow rate, decreases the column diameter and the gradient elution time, reducing the length 
of the analysis of each individual while retaining the diagnostic capability of the experiment.  
The combined insights gained through this method development process are then applied to 
two separate toxicity studies of 2-bromophenol, one of acute and one of chronic exposure. 
UPLC-MS analysis coupled with 1H NMR spectroscopy identified the major metabolites as 
the sulphate and glucuronide conjugates, and other changes in endogenous metabolites. 
 
 xi 
However the lack of reactive intermediates or other toxic metabolites indicate that 2-
bromophenol is not a nephrotoxin. While these studies failed to discover any compound 
related toxicity, they have exemplified the utility of the metabonomic approach in this area. 
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CHAPTER ONE 
Introduction 
This chapter provides an introduction into the background of xenobiotic 
metabolism, as well as the use of metabonomics in its study. The theory 
behind the analytical technologies employed within metabonomics will also 
be discussed. 
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 2 
1.1 Introduction to Toxicology and Drug Metabolism 
1.1.1 Principles of Xenobiotic Metabolism 
a. Xenobiotics and Drugs 
The term Xenobiotics, derived from the Greek ξένος (xenos) to mean foreign and βίος (bios) 
to mean life or entity, describes any chemical substance which is not normally produced or 
expected to be found in an organism. While xenobiotics may be food additives, chemicals of 
abuse, pesticides, chemical pollutants or industrial by-products, a major category of concern 
are drugs. Understanding the behaviour of the drug inside a patient is key for their correct 
use for the treatment of disease and the prevention of adverse side effects. The routes by 
which an organism eliminates the xenobiotic is called metabolism, and this term describes 
the total fate of the xenobiotic, and includes absorption, distribution, biotransformation and 
excretion (collectively termed ADME); although this term is often used synonymously with 
biotransformation, especially when applied to drugs, as the products of drug 
biotransformation are called metabolites. Chemicals which are native to the body are also 
subject to similar processes and routes of biotransformation, called endogenous or 
endobiotic metabolism, although these pathways of metabolism are highly specific and 
carefully regulated. However, due to similarities and cross-over of enzymatic activity 
xenobiotics can also have effects on endogenous metabolism. 
The combinations of biotransformation reactions are central to the behaviour of the foreign 
chemical entity within the body. Indeed few xenobiotics are actually directly excreted from 
the body unchanged as the parent compound. In most cases biotransformation of the 
xenobiotic precedes elimination from the host system, therefore any factor that affects the 
rate and type of metabolism that occurs is likely to alter the overall pharmacokinetic 
behaviour of the chemical. In most instances metabolic reactions alter the xenobiotic in a 
way that renders it inactive. However, in the case of some compounds this transformation 
can result in an active compound that may be responsible for the pharmacological effect 
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(drug activation). However, depending on the metabolic route taken and the parent 
compound, it is also possible that the biotransformation may result in a reactive intermediate, 
or a toxic metabolite, which may cause toxicity. Covalent binding of reactive intermediates to 
cellular proteins, inhibition of host cell endogenous metabolism, enzymatic inhibition or 
induction can all lead to unexpected toxicity. 
b. Classification of Metabolism 
The routes through which xenobiotics can be metabolised are many and varied; they 
included reactions of oxidation, reduction, hydrolysis, conjugation with endogenous moieties 
such as e.g. glucuronic acid, but also condensation. Traditionally these metabolic processes 
are separated into ‘phases’; Phase I reactions, which include all the functionalisation 
reactions and Phase II reactions which involve conjugation. A third phase has recently been 
defined, Phase III, which involves the active transport of metabolites, however, this will be 
discussed separately. Phase I reactions have been described as being the preparatory step 
for Phase II metabolism; the initial functionalisation of the chemical by creating a chemical 
‘handle’, through which Phase II reaction may occur. As such Phase II reactions are thought 
to be the main process of detoxification, with conjugates thought to be relatively inactive. 
These conjugates are usually more polar than the parent compound (although reactions 
such as e.g. N-acetylation actually increase lipophilicty) and may thus be more easily 
excreted from the body. However, despite the apparently logical order described above, 
frequently compounds can be targeted by both phase I and II reactions, and there is no clear 
order of metabolism; a product of Phase II may also be a suitable substrate for Phase I 
enzymes which in turn may lead to further conjugative reactions. Furthermore, after entering 
circulation, metabolites may be further modified by the gut microbiota, as gut microbes are 
known to de-conjugate many compounds (Ilett et al. 1990). The metabolism of a compound 
is therefore difficult at best to predict. However, it is important to study the main pathways as 
these are the most common routes through which pharmacological or toxicological activities 
are mediated.  
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c. Phase I metabolism – Particularly Cytochrome P450 mediated 
Phase I metabolic reactions, as mentioned before, have been thought of as functionalisation 
reactions and include oxidation, reduction, hydrolysis, hydration and isomerisation. The main 
avenue of phase I reactions are through the microsomal mixed-function oxidases, more 
commonly known as cytochrome P450 or CYP superfamily of enzymes (although flavin 
monoxidase, or FMO’s etc. can also be involved in oxidative metabolism as described 
below) (Gibson and Skett, 1994). 
Cytochrome P450s are heme-containing monooxygenases, with an iron protoporphyrin as 
the prosthetic group, and are the terminal component of the electron transport system 
present in the endoplasmic reticulum. These P450s are embedded in the membrane of the 
endoplasmic reticulum and have a broad range substrate specificity (Rendic and Di Carlo, 
1997). CYP enzymes are heavily involved in endobiotic metabolism and are responsible for 
the biotransformation of steroids and cholesterol as well as bile acid biosynthesis, while they 
also mediate a large part of xenobiotic metabolism. As there are hundreds of CYP enzymes 
members of the superfamily are categorized into families and subfamilies and then further 
into isoforms based on amino acid homology. The system of classification is complex but 
essentially amounts to enzymes of the same subfamily have 70% or greater sequence 
homology with each other and members of the same family are at least 40% identical 
(Nebert et al., 1987). CYP subfamilies one, two three and four, are the major variants 
involved in the metabolism of xenobiotics. However, adding to the complexity is the fact that 
many isoforms are differentially expressed and also largely polymorphic, especially in 
humans, contributing to the differences observed in xenobiotic metabolism from individual to 
individual (Ingelman-Sundberg et al., 1999). 
Some of the main isoenzymes involved in drug metabolism are CYP1A2, CYP2C9, 
CYP2C19, CYP2D6, and CYP3A4, and are of clinical significance. CYP1A2 has been shown 
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to metabolise a wide range of substrates, including caffeine and phenacetin, with common 
inducers of this isoform being compounds with aromatic rings. CYP2C9 is thought to 
generally metabolise drugs which are weak acids such as phenytoin, ibuprofen and losartan, 
the efficacy of which are greatly affected by the hypervariable properties of the gene. CYP 
2C9 is of particular note as it is easily modulated, being inhibited by many drugs (e.g. 
uconazole, and amiodarone) and activated by many (e.g. rifampicin); consequently it is an 
avenue of potentially severe drug-drug interactions (Smith et al., 1995). Many important 
drugs, such as omeprazole, diazepam, and propranolol, are substrates for CYP2C19 
(Wrighton and Stevens) whilst CYP2D6 is the main route of the metabolism of many 
anticancer drugs and CNS agents; both enzymes target hydrophilic weak bases. Finally 
CYP3A4, the most abundant of the Cytochrome P450s found in both the liver and intestine, 
is responsible for the metabolism of almost 50% of all known drugs with a wide, structurally 
diverse, substrate pool including common drugs such as paracetamol, midazolam and 
cyclosporine (Wrighton et al., 2000). 
The underlying metabolic reaction for all CYPs however is the catalysis of an oxidation; this 
reaction is generally described as: 
 
Where R-H is the target drug and R-OH is the hydroxylated metabolite. During this reaction 
reduction agents are derived from reduced nicotinamide adenine dinucleotide phosphate 
(NADPH), and one atom of heterolyticlly-cleaved molecular oxygen is incorporated into the 
substrate resulting in C-, N- or S-hydroxylation and simultaneous release of water 
(Hannemann et al., 2007). Central to this process is the electron transfer from NADPH to the 
P450, which is mediated by another membrane bound protein, cytochrome P450 reductase. 
Cytochrome P450 reductase is a flavin-containing protein with a flavin adenine dinucleotide 
(FAD) and a flavin mononeucloetide (FMN) sub domain. The electrons, initially accepted 
from NADPH, are shuttled sequentially through the FAD and FMN domains of the 
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cytochrome P450 reductase and then donated to the ferric protoporphyrin centre of the 
cytochrome P450 (Guengerich and Macdonald, 1984). The process is visually depicted in 
figure 1.1 below. 
 
 
 
 
The initial addition of the oxygen during this process will usually be followed by a 
rearrangement or decomposition in the substrate depending on the type of chemical 
resulting in the formation of various types of final products. The more common reactions 
include. 
Aromatic hydroxylation. This is the most common reaction for compounds which contain an 
aromatic ring. The hydroxyl group is attached to the ring resulting in a hydroxylated-
derivative, as depicted in figure 1.2 
Fig 1.1 Visual representation of the P450 mediated hydroxylation in the endoplasmic reticulum 
membrane. Initial binding of the substrate to the cytochrome P450 (CYP) activates the 
cytochrome P450 oxidase (CPR). CPR acts as a transducer shuttling two electrons through its 
two Flavin domains (FAD and FMN) and subsequently donating these sequentially to CYP. This 
allows for the heterolysis of molecular oxygen one atom of which is incorporated into the 
substrate, also resulting in the release of water. 
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Aliphatic hydroxylation. This is another common reaction, and the oxygen is usually added to 
terminal (ω) or penultimate (ω-1) carbon atom in the substrate, as shown in figure 1.3. 
 
 
 
Epoxidation. Epoxides are generally cyclic ethers with a highly strained three atom ring, 
which makes them highly reactive. Generally epoxides are unstable intermediates, and can 
be highly toxic; they are able to bind DNA and cause genetic toxicity through point mutations 
and deletions are considered potent mutagens (Ehrenberg and Hussain, 1981). Most 
epoxides isolated are formed from polycyclic compounds and it has been suggested that 
they are the first step of aromatic hydroxylation (Gibson and Skett, 1994).  
 
 
N- and S- oxidation/hydroxylation. Both N- and S- oxide formation are possible reactions that 
may be mediated by P450s, although N- oxidation is also possible through other cellular N-
oxidases. Many different substrates may be oxidised including amines, amides, hydrazines 
Fig 1.2 Visual representation of P450 mediated Aromatic hydroxylation. The example here shows 
the formation of a 3-hydroxy derivative, where R may be any prosthetic group or chain 
Fig 1.3 Visual representation of P450 mediated aliphatic hydroxylation. The example here shows 
the hydroxylation on the terminal carbon, where R may be any prosthetic group or chain.  
Fig 1.4 Visual representation of P450 mediated epoxidation. The example here shows the 
creation of the three atom ring, where R 1 to 4 may be any prosthetic group or chain.  
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and heterocyclic compounds. The oxides can then obtain a hydrogen from the environment 
to become a hydroxyl group. 
 
 
Dealkylation. This is a common reaction with compounds containing amines an alkoxy group 
or an alkyl; it is characterised by a loss of an alkyl group and is classified as N-, O- or S- 
dealkylation depending on what type of atom the alkyl group is attached to. The reaction is a 
two-step process where initial hydroxylation of the methyl group followed by a decomposition 
of the intermediate and the release of formaldehyde. 
 
 
 
Fig 1.5 Visual representation of P450 mediated S-oxidation (a) and N-hydroxylation (b). The 
examples here show the creation an S-oxide in the a) and formation of a N-hydroxyl in b) which 
would be subsequent to a N-oxidation, and where R 1 and 2 may be any prosthetic groups or 
chains.  
Fig 1.6 Visual representation of P450 mediated N- dealkylation (a), S- dealkylation (b) and O- 
dealkylation (c). The examples here show the two step process for the removal of the methyl in 
a), but omit the intermediate for b) and c); R 1 and 2 may be any prosthetic group or chain.  
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Oxidative deamination. The final P450 mediated reaction to be discussed involves amines 
and results in the release of ammonia. It is an aliphatic hydroxylation next to the hetoroatom 
which forms a reactive intermediate which spontaneously decomposes to the deaminated 
form. P450s specifically target amines with the –CH(CH3)-NH2 structure, making this process 
distinct to other deaminations such as those of monoamine oxidase or in amino acid 
metabolism (Gordon and Skett, 1994) 
 
 
 
d. Phase I – Other reactions 
This section has primarily dealt with P450-mediated oxidative metabolism but there are 
many other enzymes which contribute to Phase I xenobiotic metabolism. These reactions 
are non-P450 oxidations, reductions, hydrolysis and hydration and will be summarised 
below. 
Non-P450 Oxidation. Oxidation by other enzymes is also possible and is mediated mainly by 
alcohol dehydrogenase, aldehyde dehydrogenase or the previously mentioned amine 
oxidases (although many other enzymes are involved). Alcohol dehydrogenase is the 
primary source of ethanol clearance, and is involved in the metabolism of many other 
alcohols. Alcohol dehydrogenase forms a dimer and utilises coenzyme NAD to deprotonate 
two zinc ions within its active site to bind to the hydroxyl group of the alcohol, subsequently 
releasing the aldehyde product. Aldehyde dehydrogenase is one of a small group of 
enzymes which are able to oxidise aldehydes (the others being xanthine oxidase and 
aldehyde oxidase – they all operate in a similar manner). Through the reduction of 
Fig 1.7 Visual representation of P450 mediated oxidative deamination. The example shown here 
includes the unstable intermediate which decomposes to release the ammonia; R may be any 
prosthetic group or chain.  
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nicotinamide adenine dinucleotide (NAD) to NADH an initial hydrate is produced, resulting in 
the formation of the related carboxylic acid (Gordon and Skett, 1994).. Finally amine 
oxidases, either monoamine or diamine oxidase, are flavin-containing enzymes which 
degrade a wide range of both xenobiotic and endobiotic amines; the former is responsible for 
the endogenous metabolism of many catecholamines and important neurotransmitters such 
as nonepinephrine, dopamine and serotonin (Weyler et al., 1990) and the latter is mostly 
involved in the breakdown of endogenous polyamines. While amine oxidases primarily 
metabolise endogenous compounds, monoamine oxidases have been shown to participate 
in the metabolism of certain dietary components and drugs. The main avenue of reaction is 
the N-oxidation of their target. Generic examples of the discussed reactions are given below 
in figure 1.8. 
 
 
 
Reduction. Hepatic microsomes are known to be sites of reduction for a variety of chemicals; 
these include epoxides, heterocyclic compounds, halogenated hydrocarbons and azo- and 
nitro- compounds.  Epoxides, which may have been the product of earlier epoxidation, are 
able to be converted back to parent chemical, and heterocyclic compounds may have their 
Fig 1.8 Visual representation of non-P450 mediated oxidation. The examples shown here are a) 
oxidation by alcohol dehydrogenase of an alcohol, b) oxidation of an aldehyde to its 
corresponding carboxylic acid by aldehyde dehydrogenase and c) monoamine oxidase mediated 
N-oxidation where the N=O is a dative bond; R may be any prosthetic group or chain.  
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ring structure cleaved. Halogenated hydrocarbons such as fluorocarbons can be 
dehalogenated. Azo- and nitro-reductions however are thought to proceed in two ways; 
either the double bond is severed to produce two derivatives or a NADPH mediated step-
wise process which requires two molecules of the parent compound. Examples of each case 
are given bellow (figure 1.9) (Gordon and Skett, 1994). 
 
 
 
Hydrolysis/Hydration. Hydrolysis is a common reaction that occurs with many classes of 
compounds, but most commonly in esters and amides, catalysed by plasma esterases and 
amidases respectively, although esterases have been seen to hydrolyse the equivalent 
amide albeit with lower specificity. The hydrolytic reaction involves the breaking of bonds 
with a water molecule. Other compounds which can be hydrolysed include hydrazides and 
carbamates, and other compounds which already contain a functional moiety; more 
importantly hydrolysis of proteins and peptides is observed in the gut, which contributes to 
Fig 1.9 Visual representation of reductive reactions. A)  heterocyclic reduction, b) the 
defluorination of halothane, c) nitro-compound reduction and d) aromatic nitro-group reduction; 
where R 1 and 2 may be any prosthetic group or chain.  
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the secondary metabolism of conjugates (including de-conjugation). Ester and amide 
hydrolysis is depicted below (figure 1.10). 
 
 
Hydration is a very specific case of hydrolysis, and is the catalytic addition of water to a 
compound without the disassociation of the parent. In the body the most common form of 
this reaction is the transformation of epoxides into 1,2-diols or glycols by the enzyme 
epoxide hydrolase (Meynert et al., 1970). This is one of the preferred routes of epoxide 
removal within the cell. The generic reaction is described in figure 1.11. 
 
 
e. Phase II – Conjugative metabolism 
As mentioned previously, conjugative reactions have traditionally been thought to serve as 
the detoxification endpoint of xenobiotic metabolism. The main conjugation reactions are 
glucuronidation, sulphation, glutathione conjugation and acetylation. 
Glucuronide conjugation. Glucuronidation is a common, and possibly the most important, 
Phase II reaction. Glucuronidation is part of the metabolism of many endogenous 
compounds such as hormones, hydroxysteriods, bilirubin and thyroxine (Kiang et al., 2005), 
Fig 1.10 Visual representation of hydrolysis of a) esters and b) amides. These reactions are 
catalysed by the specific plasma enzymes, either esterases or amidases. R 1 and 2 may be any 
prosthetic group or chain.  
Fig 1.11 Visual representation of the hydration of an epoxide. This reaction is generally mediated 
by epoxide hydrolase, and produces either a glycol or, as in this case, a trans-diol. R1 and 2   
may be any prosthetic group or chain.  
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but is also associated with the preparation of drugs for excretion. Uridine diphosphate 
(UDP)-gucuronosyltransferases (UGTs) are a superfamily of enzymes, and members of the 
UGT1 and UGT2 families are the key enzymes involved in the conjugative reaction, and due 
to the high levels of glucuronic acid in the cell, and the relative promiscuity of these 
enzymes, many xenobiotics are subjects for glucuronidation; in fact up to 70% of known 
drugs are processed, at least in part, this way (Wells et al., 2004). UGTs are membrane 
bound enzymes, similar to P450s, located in the endoplasmic reticulum, although their active 
site is located in the lumen. The UGTs utilise the co-factor UDPGA to transfer glucuronic 
acid onto a nucleophilic atom on the substrate, forming a conjugate which is highly polar, 
therefore with increased water solubility which allows easier excretion in the bile or urine. O-
glucuronidation is the most common, and is the preferred substrate recognition site. The 
glucuronic acid in UDPGA is in the alpha configuration and in the drug glucuronide is 
converted to the beta form both in ether and ester linkages. The figures below depict the 
glucuronic acid (fig 1.12) and the O-linked glucuronidation of the common drug paracetamol 
(acetaminophen) (fig 1.13). 
 
 
 
 
 
Fig 1.12 The molecular structure of a glucuronide. Glucuronic acid is normally attached to uridine 
diphosphate (UDP), which is then removed by UGT for the incorporation of the glucuronide into 
the target compound, at the site labelled ‘Drug’. 
 
Fig 1.13 The glucuronide conjugation of acetaminophen (paracetamol), shown prior to 
metabolism on the left. O-linked glucuronidation occurs on the hydroxyl group and is the most 
abundant acetaminophen metabolite. GA is the added glucuronic acid. 
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Sulphation. Sulphation, or sulphoconjugation, constitutes another common route of 
conjugation in the detoxification process but is also heavily involved in endogenous 
metabolism. Sulphation is mediated by another superfamily of enzymes called 
sulfotransferases (SULTs), and generally involves the incorporation of a sulphonate to a 
hydroxyl or amino group on the target compound (O-/N- linked sulphation). The sulphonate 
is transferred from 3‘–phosphoadenosine 5‘– phosphosulfate (PAPS) and results in the 
formation of a sulfuric acid ester (Klaassen and Boles, 1997). Sulfotransferases are 
generally separated into two classes: membrane associated sulfotransferases and cytosolic 
sulfotransferases. The first class are embedded in the Golgi body and are concerned with 
the sulphation of large endogenous biomolecules such as carbohydrates, proteins and other 
peptides. For endogenous compounds sulphation has also been shown to increase target 
compound activity and is able to activate or modulate the function of many steroid hormones 
by altering binding site configuration (Gordon and Skett, 1994).  The second class are 
cytosolic SULTs which while also involved in the metabolism of  endogenous compounds 
such as hormones, catecholamines and vitamin D, are central to the sulphoconjugation of 
many xenobiotics (Glatt and Meinl, 2004). Similarly to glucuronidation, the addition of the 
sulphonyl group to the target leads to the formation of a more polar, water soluble, chemical 
which is then usually more readily excreted from the body. However, sulphation has also 
been implicated in the mutagenicity of many pro-mutagens such as 2-aminofluorene and 2-
acetylaminofluorene (Chou et al., 1995). The SULT iso-enzyme SULT1A1 is perhaps the 
most important for drug metabolism as it is responsible for the sulphation of acetaminophen, 
minoxidil, dopamine and also most monocyclic phenols (such as 4-bromophenol) (Glatt and 
Meinl, 2004). The figure below describes the sulphoconjugation of 4-bromophenol. 
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Glutathione conjugation. Glutathione (GSH) is a tripeptide comprised of an unusual 
glutamyl, cysteinyl and glycine linkage (shown in figure 1.15).  
 
 
GSH is an important factor in the cellular protection against reactive oxygen species and the 
general regulation of the redox state of the cell; indeed depletion of GSH is usually indicative 
of oxidative stress and lack of GSH is thought to instigate apoptosis (Hutter and Greene, 
2000). Such thiol-containing compounds are reducing agents and GSH is also involved in 
the metabolism of both endogenous and exogenous compounds. GSH is also important as a 
means of detoxifying reactive intermediates formed through other metabolic reactions such 
as the the oxidative Phase I metabolism of xenobiotics such as paracetamol. This 
detoxification process for reactive metabolites can occur directly via a simple chemical 
reaction or can be mediated by the glutathione S-transferase group of enzymes. These 
enzymes catalyse the nucleophilic attack of GSH on lipophilic compounds which contain an 
electrophilic component (usually a S-), but are also capable of mediating the 
hydroxyperoxide reduction of oxygen species (Gordon and Skett, 1994). Glutathione S-
Fig 1.14 The sulphoconjugation of 4-bromophenol, shown prior to metabolism on the left. O-linked 
sulphation occurs on the hydroxyl group, although if prior hydroxylation on another carbon 
occurred prior then the location of the sulphonate may differ. 
 
Fig 1.15 The molecular structure of glutathione. The three amino acid components are indicated.  
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transferases are classified into sub families’ and with a similar system to other 
metabolism enzyme superfamilies based on sequence homology. These enzymes exist as 
dimers and one sub unit contains a glutathione binding site while the other contains the 
binding site for the electrophilic component of the target compound. As with most 
conjugative reactions the product is more polar and is quickly excreted into the bile (not the 
urine however) or may be transported to the kidney to undergo further transformation. The -
glutamyl transpeptidase enzyme in nephrocytes is able to remove the -glutamyl unit of the 
GSH conjugate; the exposed cysteine will then usually be acetylated to a mercapturic acid, 
which is excreted in the urine (Commandeur et al., 1995). The process of glutathione 
conjugation is shown below in figure 1.16. 
 
 
 
 
Other phase II reactions. There are many other phase II reactions. These include: 
 Methylation: The addition of a methyl group (CH3) to the target compound, 
mediated by methyltransferases (Robertson, 2001). 
 Acetylation: The addition of an acetyl group (COCH3) to the target compound, 
usually mediated by either N-acetyltransferase or acetyl coenzyme A (Sim et 
al., 2008). 
Fig 1.16 Visual representation of glutathione conjugation. Glutathione is added to the target drug 
through the action of glutathione S- transferase (GST), on an electrophilic atom. This conjugate is 
the either excreted via the bile or transported to the kidney where the second reaction takes 
place. Glytamyl transpeptidase (GTP) calatyses the removal of the glutamyl unit, leaving the 
cysteine residue exposed. This intermediate will usually be acetylated to form the mercapturic 
acid. The red box labelled ‘drug’ is the target compound. 
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 Amino acid conjugation: The addition of an amino acid, usually glycine, to the 
target compound. It is thought that this process occurs in the mitochondria on 
previously carboxylated substrates (Vessey and Kelley, 2001). 
In general methylation and acetylation are primarily involved in the metabolism of 
endogenous compounds, but xenobiotic metabolism through these mechanisms has been 
seen.  Amino acid conjugation, has been known for many years to be involved in xenobiotic 
metabolism and as there has been a recent resurgence of interest in this topic, it is being 
recognised as an important factor.  
 
 
f. Transport 
The traditional classification of Phase I and Phase II metabolism, discussed thus far, was 
introduced by Williams in 1959, and has generally become the ‘go to’ model for the 
metabolism of chemicals introduced into an organism. However, there exist issues with this 
metabolic workflow; studies observed that that Phase I and II reactions do not necessarily 
occur sequentially, as touched upon previously, but also this model ignores how the 
compounds involved move in and out of the cell. Metabolism studies had previously 
assumed that the compounds ‘passively’ diffuse in, and then diffuse out once modified, or 
altogether avoided the subject. It was not until the cloning of the drug transporter multi-drug 
resistance protein 1 (MDR1, also known as permeability glycoprotein) by Roninson et al. 
(1986) that transport was recognised as an important part of distribution and therefore 
relevant to drug metabolism. Following on from this first study Ishikawa (1992) and Zimniak 
et al. (1993)  proceeded to characterise the carrier-mediated efflux of glutathione conjugates 
by multi-drug resistance-associated protein 1 (MRP1 – not to be confused with MDR1). It 
was then understood that these transporters are part of the ABC class of transmembrane 
carriers and are crucial for the elimination of the drugs and their metabolites. This process of 
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cellular efflux was termed ‘phase III detoxification’ which was then expanded to also include 
carrier mediated influx of parent compound (although this is sometimes separately termed 
Phase 0) (Petzinger and Geyer, 2006). Note that it is incorrect to call this phase ‘phase III 
metabolism’ as during the transport of the compounds there are no chemical alterations of 
the substrates. The importance of phase III is becoming ever more apparent as it has been 
recognised that in toxic situations, aberrations of normal transporter function, perhaps due to 
the saturation of carriers or the competitive binding of xenobiotic metabolites may be the 
mechanism of toxicity. Intracellular transport between sites of metabolism and transporters is 
carried out by cytosolic binding proteins and the cytoskeleton (Petzinger and Geyer, 2006). 
A simplified overview of the three phase system is included in the diagram bellow (figure 
1.17). 
 
 
 
Fig 1.17 Diagram showing the various stages of the three-phase metabolism model as proposed 
by Petzinger and Geyer. Initial influx of parent compound into the cell is mediated by transporters 
mainly belonging to the solute carrier family of organic anion transporter polypeptides (OATPs) 
(Phase III/0). In this example the drug is initially subjected to Phase I functionalisation 
(hydroxylation in this case) and then Phase II conjugation (glucuronidation in the example). The 
conjugate is then secreted from the cell via the ABC antiporter transmembrane protein with the 
use of ATP during phase III detoxification. 
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1.2 Introduction to Metabonomics 
1.2.1 Principles 
Within the pharmaceutical industry the process of drug development has become riskier and 
more expensive. Traditional methods of compound screening frequently fail to identify 
unsuitable compounds early enough in the pipeline, resulting in much time and money being 
wasted in the validation steps. Indeed only around 1 in 50 validated lead compounds reach 
Phase I and only one in six drugs progresses to Phase IV clinical trials (Bains, 2004). There 
has therefore been a drive for the development of new techniques for the improvement of 
our understanding of the molecular and cellular alterations occurring and how these relate to 
pathophysiological and toxic events.  
The role that ‘-omic’ technologies can fulfil in improving our understanding of the 
mechanisms of toxicity and in adverse drug reaction monitoring have been extensively 
discussed previously (Cockerell et al., 2002). Metabonomics has been identified as one of 
the emerging, and now possibly established, components of the systems approach to 
toxicology. Indeed metabonomics has been applied extensively in the investigation of 
xenobiotic toxicity, and represented one of the first serious applications of the approach (see 
e.g. Nicholson et al., 2002). Metabolomics was defined as ’the quantitative measurement of 
time-related multiparametric metabolic response of living systems to pathophysiological 
stimuli or genetic modification‘ (Nicholson et al., 1999). As such Metabonomics can provide 
a direct picture of cellular activity, health status and the effects of drugs or the environment 
(Martis et al., 2011) and therefore is an ideal tool for the identification of biomarkers and 
pathways of toxicity (Craig et al., 2006), the construction of models for the prediction of 
toxicity (Schnackenberg et al., 2009) and for regulatory purposes. 
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1.2.2 Technologies in Metabonomics 
The experimental process a metabonomic study requires involves the combination of 
sensitive analytical instruments for the profiling of metabolites and small molecules in the 
target biological sample, such as serum, CSF, urine, saliva, and faeces (Kaddurah-Daouk et 
al., 2011). The two main analytical platforms utilised are nuclear magnetic resonance (NMR) 
spectroscopy and mass spectrometry (MS). Here these technologies are quickly introduced, 
with the theory underlying their function discussed in more detail later in this chapter. 
 
 
a. NMR-Based Metabonomics 
In the case of the NMR platform, both 1H and 13C NMR spectroscopy have been used 
extensively, and the technique has played a pivotal role in the establishment of 
metabonomics. The advantages of using NMR spectroscopy include the quantitative nature 
of the output and the relatively simple sample preparation required. The technology is non-
destructive and can also be used for non-invasive in vivo investigations (Serkova et al., 
2008). NMR spectroscopy is able to provide robust, reproducible quantitative and structural 
information, unlike other platforms where there are complications in both reproduction and 
quantification of results. A further advantage of the platform is through the utilisation of 
Magic Angle Spinning NMR spectroscopy (MAS) it is possible to obtain very high quality 
proton NMR spectra on small (10-mg) samples of whole tissue. MAS involves spinning the 
sample at 54.7° to the magnetic field direction, and requires no sample preparation, such as 
the arduous extraction methods required for MS tissue analysis. The drawbacks however, of 
NMR spectroscopy, include the lengthy instrument set up and run times, and most notably 
relatively low sensitivity resulting in the inability of the platform to detect low concentration 
molecules. These disadvantages however, are being addressed by the implementation of 
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automated workflows to reduce experimental time; the use of cyroprobes and higher 
strength magnetic fields has also improved the limits of detection. 
b. MS Based Metabonomics 
Recently the number of metabonomic studies using MS based technology has increased 
dramatically. MS is inherently a very diverse platform; there are both a wide range of 
ionisation methods and the biological sample under investigation can be delivered to the ion 
source either by direct infusion/injection (DIMS) or following a chromatographic step (so 
called “hyphenation”) e.g. liquid chromatography (LC-MS). While DIMS is simpler and can be 
faster, due to the simultaneous ionization of many analytes, of widely different ionisation 
efficiency, the phenomenon of ion suppression renders the detection of low ionisation 
efficiency molecules difficult or impossible. The introduction of a chromatographic front end 
allows molecules of different polarities to elute from the chromatographic column and be 
analysed separately, allowing for distinction of isobaric compounds. The two main types of 
chromatography employed are GC (gas chromatography) and LC (liquid chromatography), 
and their variants. These are usually paired with either Electron Impact (EI) ionization or 
Electrospray Ionization (ESI) respectively to deliver the ions to a mass analyser. There are in 
turn various types of mass analysers including Time-Of-Flight, Orbitrap and Fourier 
transform – ion cyclotron resonance (FT-ICR) mass spectrometers. 
The individual properties of the various MS methods that are generally employed will be 
further discussed later in this chapter however, in general, the obvious advantage of MS is 
its, structure-dependent, high sensitivity and fast run times; MS is able to detect many subtle 
differences in all biofluids and tissue extracts. Furthermore, with the recent scientific interest 
in Mass Specrometric Imaging (MSI) (Li et al., 2008; Sugiura and Setou, 2010) it is now 
possible to explore the distribution of small molecules on tissue surfaces or other complex 
structures. However, all of these techniques require, to some extent, arduous sample 
preparation and complex instrumental set up. While data rich, the output is not directly 
   Introduction 
 
 
 22 
quantitative, as signal intensity is dependent on both concentration and on the ability of the 
molecule to ionize; a targeted quantitative assay is normally required after the identification 
of a compound of interest if concentration data are required. Furthermore analytical 
reproducibility is low, even within a run where detection variability is normalised using quality 
control samples; comparisons between runs are difficult to perform. Despite the drawbacks 
MS is a most sensitive analytical method and will continue to provide the backbone of 
hypothesis free metabonomic studies. 
1.3 Nuclear Magnetic Resonance 
Nuclear magnetic resonance spectroscopy was first developed shortly after the Second 
World War by American scientists working in Harvard and Stanford, and since then its 
applications within science have expanded much further than its original use for structure 
determination following chemical synthesis. In the subsequent 60 years NMR evolved into a 
major tool for the investigation of organic substances, from purity testing of drug compounds 
to medical radiology with Magnetic Resonance Imaging (MRI) technology routinely used in 
hospitals throughout the world. Although this technology is widely used, the underlying 
phenomena on which the spectroscopy technology is based on can be quite complex and 
conceptually hard to grasp. This is due to the fact these are grounded on physical concepts 
of electricity, nuclear magnetism and quantum mechanics; areas which, while familiar to the 
physical or organic chemist, may be beyond the expertise of the biologist or medical 
practitioner. It is possible for the technology to be used empirically, as a ‘black box’, and the 
output considered as just another experimental variable; however, an understanding of the 
underlying principles will surely enrich the appreciation of the system under study. Thus here 
an overview of the fundamental aspects of NMR spectroscopy is presented, aimed at the 
biomedical researcher or clinician. For an in-depth description of the chemical properties of 
nuclei for those more mathematically inclined the  publication of Ernst et al., (1987) is 
recommended; for more information on the many other applications of NMR spectroscopy 
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beyond those discussed here texts including Cavanagh et al. (1996) and Reid (1997) should 
be consulted.  
1.3.1 Principles of NMR spectroscopy  
Nuclei have a positive charge and some nuclei also possess a quantised property known as 
spin. The movement of any charged particle creates a magnetic field (see figure 1.18).  
 
 
 
Thus the spinning nucleus acts as a small magnet orientated along the axis of rotation, and 
the magnetic field created corresponds to a magnetic moment termed This moment is 
defined by: 


Where is the angular momentum, usually called nuclear spin and is the gyromagnetic 
ratio constant. The magnetic moment is therefore proportional to i.e. higher momentum 
means a stronger magnetic moment). Any nucleus with a non-zero nuclear spin can be 
observed by NMR spectroscopy (if the spin is zero then there is no magnetic moment). 
While it is known that empirically all nuclei with odd numbers of protons do possess nuclear 
spin, there is no currently known law governing the level of spin. What is known however, is 
that most common isotopes such as 12C and 16O do not, and that biologically relevant 
isotopes 1H, 13C and 15N all have nuclear spin quantum number of I = l/2.  
Figure 1.18. Rotation of positively charged nuclei creates a magnetic field similar to a small 
magnetic bar orientated along the axis of rotation. The created magnetic field is defined by the 
magnetic moment   
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The initial orientation of the nuclear spin is random if no external forces exist. In nuclei with a 
nuclear spin of 1/2 if an external strong magnetic field is applied to the system, then this will 
force the nucleus into one of two states: either with the orientation being parallel to the 
external field (low energy state) or anti parallel (high energy state). There is a significant 
difference in energy of the system between those two states and this is defined as and 
this is shown in figure 1.19It is important to note that in nuclei with different nuclear spin 
there may be more than two possible states, and the number of states can be calculated by 
2 + 1; e.g deuterium 2H which has a spin of  = 1 has 3 possible energy states with 
magnetic quantum numbers of 1, 0 and -1. 
 
 
 
It is much more physically favourable for the nucleus to be in the low energy state. The 
difference in energy between the two states is given by:  
ΔE = γχ 
. h . B0 
This can also be found using this equation: 
  
Figure 1.19. The axis of rotation of nuclei with spin is initially randomly orientated (a). With the 
introduction of an external magnetic field B0 a nucleus with spin  = ½ can either orientate its 
axis parallel to B0 (low energy state) or anti parallel to B0 (high energy state), where mI is the 
directional quantum number.  is difference in energy between the two states.  
   Introduction 
 
 
 25 
Where h is the Planck constant, B0 the strength of the external magnetic field and γχ the 
gyromagnetic ratio constant.  
Of course in practice there are many more nuclei present within the system, each of which 
will orientate itself within the magnetic field in one of the two states. As it is physically 
favourable to be in the low energy state one might wonder why the nuclei do not all flip to the 
low energy state. However this is a consequence of competition between thermal motion 
and the Boltzmann distribution to achieve thermomagnetic equilibrium within the system. By 
utilising the Boltzmann law it is possible to calculate the distribution, and respectively the 
difference in number between the nuclei in the two states: 
   
Where nu and nl are the number of nuclei in the higher and lower energy states respectively, 
k is the Boltzmann constant, T is the absolute temperature and ΔΕ the difference in energy 
between the two states; e is the exponential. As the difference between the energy states 
(ΔΕ) is very small when compared to the thermal energy of the system, using the principle of 
e-x ≈ 1 – x (when x is small) it is possible to simplify the distribution equation to: 
 
where the terms are as previously defined . 
What can be surmised from this equation is that the difference in number between the nuclei 
in each of the states is dependent on thermal energy of the system and the strength of the 
magnetic field. This distribution gives the population an overall magnetisation which is 
termed M0, and this magnetisation is aligned along the axis of the external field. One thing 
that must be noted is that the difference in population between the two states is relatively 
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small, although dependant on the strength of the magnetic field; for example a field of 19 
Tesla would only produce a difference of 64 nuclei per million. The overall magnetisation is 
effectively what we are able to detect as the signals from the rest of the nuclei cancel each 
other out, thus the ability to observe the nuclei is quite low, which is the reason that NMR 
spectroscopy suffers from relatively low sensitivity compared to some other spectroscopic 
techniques. 
Nuclei within the external magnetic field are able to flip between the two energy states 
spontaneously, although this happens relatively rarely. It is however possible to induce this 
flipping by applying energy equal to ΔΕ of the system. If this energy is provided to the 
system in the form of a radiofrequency pulse (short bursts of electromagnetic energy which 
are able to produce magnetic fields) the absorption of this energy by the nuclei will cause the 
transition of both high energy states to low energy states and via versa. This palindromic 
movement produces a voltage which can be detected by coils of wire and can be depicted 
as a signal called free induction decay (FID), and this resonance phenomenon is the 
quantum mechanical basis of NMR. After the end of the radiofrequency pulse the nuclei will 
return to thermomagnetic equilibrium in a process called relaxation, which will be discussed 
later. 
Mechanistically it is possible to consider that the nucleus found within the B0 magnetic field 
will have its magnetic moment initially revolve around the axis of the B0 magnetic field in a 
manner similar to a spinning top which has been spun at an angle on a friction free surface. 
This cone shaped movement is called the Larmor precession, which is shown below in figure 
1.20. 
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Now if it is assumed that there a second, but smaller, external magnetic field applied to the 
system which is orthogonal (at 90o) to the orientation of B0, which is called B1. What would 
occur is that the smaller field B1 would exert torque on the precession of  pulling the 
rotation of the magnetic moment towards its orientation; essentially increasing the angle 
returning to the spinning top analogy, it could be imagined that this effect is as the top 
wobbling as it spun. This is depicted in figure 1.21. 
 
 
 
 
Figure 1.20. The magnetic moment  of a charged nucleus within a strong external magnetic 
field B0 will move in precession around the axis of direction of B0. The angle between the 
magnetic field and the magnetic moment is termed 
Figure 1.21. The precession of magnetic moment  around the axis of B0 is affected by the 
introduction of a second smaller magnetic field, B1 which is at an orthogonal orientation to B0. 
This new field exerts torque upon the rotation of as shown by the red arrow. Thus the angle of 
precessionis increased causing a ‘wobble’. 
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If however the B1 field rotates at a speed equal to the rotation of the magnetic spin then 
there will be an additive and continuous effect on .  
From what has already been discussed, it can be concluded that in a real situation there will 
be many more nuclei within the sample and that for nuclei with nuclear spin of I = ½ the 
nuclear spins of these nuclei will align either parallel or anti parallel to B0, and that 
furthermore the differences of number between the two states will cause an overall 
magnetisation of the system, M0 which is parallel to B0. If the orientation of B0 and M0 are 
defined as the ‘z axis’ then it is possible to visualise the system as nuclei in the low energy 
state precessing around the positive z and those  in the high energy state precessing around 
negative z, as shown in figure 1.22. 
 
 
 
The frequency of the precession vo can be described by extending the equation discussed 
previously: 
 
Figure 1.22. Each one of the arrows represents the magnetic spin of a nucleus. In a sample with 
many nuclei the segregation of nuclei between the high and low energy states in the presence of 
an external magnetic field B0 will cause a net magnetisation M0 which is parallel to B0. If we term 
this axis as Z then low and high energy state nuclei will precess around z and –z respectively. 
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However using the Bohr condition,  = h . V, therefore: 
 
 
This is called the Larmor equation. Where vo is the Larmor precession frequency and the 
other terms as previously defined, and the angular frequency is expressed as: 


Where is the angular frequency. While all these equations may seem convoluted and 
their significance vague, the essential concept equates to the following; to achieve nuclear 
magnetic absorption, the frequency of the radiation (the radiofrequency pulse) must be 
adjusted, and applied until the Larmor equation holds.  
The application of a B1 radiofrequency pulse, with a frequency appropriate for the type of 
nucleus that is being targeted, will result in nuclear magnetic absorption, and perturbation of 
the thermomagnetic equilibrium of the system. If this B1 pulse is orientated along the x axis 
then the torque applied to the nuclear spins will be on the yz plane, pulling the spins in a 
manner that rotates the magnetisation of the system M0 along that yz plane (Ernst et al. 
1987) In one type of nuclear magnetic resonance experiment the B1 pulse is maintained until 
the orientation of M0 has rotated 90
o and is then stopped (also called a /2 pulse), leading to 
the aforementioned relaxation and return to equilibrium, and the production of the FID signal.  
While it is beyond the scope of this thesis to fully discuss relaxation quantum physics, one 
note which will be briefly touched upon is signal broadening, and spin interactions. The 
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energy state switching from application of the B1 pulse will eventually lead to saturation 
where the number of nuclei in each state is equal. From this situation the time it takes 
relaxation to return the system to equilibrium depends on two factors, spin-lattice interactions 
and spin-spin interactions, each is a first order rate process with its own time constant T1 
and T2. Spin-lattice interactions occur because there is energy transfer between the target 
nuclei and the heteronuclei in the environment, such as the medium, and spin-spin 
interactions occur when energy is transferred between the different target nuclei either intra- 
or inter-molecularly. These factors alter relaxation times and influence the FID signal 
received. Thus, it is thought that T2 affects signal width under certain circumstances, and is 
a major problem in the study of macromolecules which have large numbers of identical 
nuclei interacting with each other reducing relaxation times, broadening peaks and thus 
reducing spectral resolution as broad peaks may overlap or completely obscure other 
signals.  
The FID signal is initially represented dependent on the time domain; therefore a Fourier 
Transform is applied to the original signal. The Fourier Transform is a mathematical 
transformation which transforms a function into oscillatory functions, effectively decomposing 
a signal into its constituent frequencies. In the case of the signal-averaged FID signal, the 
output is converted into a frequency domain signal which is represented as the NMR 
spectrum. 
While the above is theoretically true, in reality atoms are not comprised solely of the nucleus, 
but of the nucleus surrounded by electrons. These electrons are in the form of a negatively 
charged electronic cloud, and as moving charged particles are also subject to 
electromagnetic laws, and therefore also affected by the application of the B0 magnetic field. 
Indeed B0 induces circulation within the electron cloud which as predicted by Lenz’s law will 
produce a small local magnetic field which is opposed to B0. This field is named B’ and is 
shown in the below figure. 
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Despite the B’ field being very small and in practice perhaps a millionth of the size of field 
B0, it does serve to partially reduce the strength of the actual field experienced by the 
nucleus. This means that the frequency required for resonance will be slightly increased. 
This phenomenon is called screening or nuclear shielding and is expressed by a non-
directional constant termed . This is important because this means that while the nuclei of 
different atoms will have different resonance frequencies due to the different spins, nuclei of 
the same atom can also have different absorption frequencies dependant on their local 
electromagnetic environment.  
Initially one might think that this phenomenon is a disadvantage, as the presence of nuclear 
shielding results in uncertainty of the precise value of the field experienced by the nucleus 
and therefore makes the measurement of the gyromagnetic ratios difficult. However, in 
conventional NMR experiments the determination of the value of allows for a very robust 
way of elucidating molecular structure, as the screening constant is further affected by the 
electronic current of other nearby nuclei. As mentioned before the difference in resonance 
frequencies can be a million times smaller than the applied field, in the order of a few Hertz, 
Figure 1.23. The application of external magnetic field B0 causes rotation within the electron 
cloud, as shown by the curved arrows. This movement of electric charge produces a small 
localised magnetic field termed B’, which is opposed to B0. 
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and furthermore this difference is dependent on the strength of this applied field. To 
overcome this problem is determined relatively to a reference signal, and it is possible to 
calculate the relative positions of two signals with high precision. This relative position is 
expressed in parts per million (ppm) or chemical shift (and is calculated by dividing the 
difference between the target signal and the reference signal in Hertz by the strength of the 
magnetic field (usually MHz). 
A further complication to the spectral signal produced is the fact that there are interactions 
between the spin states of the nuclei involved. This is interaction is able to further alter local 
electromagnetic environments and the effective magnetic field. If a nucleus with spin  = ½ is 
considered , i.e. only two possible energy states, such as hydrogen. When two of these 
nuclei are close enough to each other to exert a magnetic effect and the external B0 field is 
applied, for each of the nuclei one of two possible scenarios exist. First that the orientation of 
the spin of the adjacent nucleus is such that its local magnetic field aligns with the applied 
field or second that it is opposed. This means that the B0 field is either reinforced or 
diminished. This concept is more clearly demonstrated in the below figure. 
 
 
 
Figure 1.24. Let us assume two homonuclei labelled A and B, which are close enough to each 
other to exert a observable magnetic effect on each other. The application of an external 
magnetic field B0 will result in nucleus A aligning it’s spin, and therefore its local magnetic field 
(BA), either parallel or anti-parallel to B0. In case a) BA is parallel to B0 and therefore the effective 
magnetic field applied to B is B0 + BA (green block arrow). In case b) BA is opposed to B0 and 
therefore the net magnetic force on B is B0 – BA (red block arrow). In either case the effective field 
exerted on B will be either greater or lower than expected and will produce a slightly altered NMR 
signal. B will also affect A in the same way (not shown here). Note that the depicted green and 
red arrows greatly exaggerate the net effect on B0 for demonstration purposes. 
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In practice, there will be a much larger number than two nuclei in a sample, and as each of 
the two spin orientations are equally as likely then the NMR signal of the above example 
would be split into two peaks, which are called doublets. The number of peaks a signal can 
be split into depends on the spin and number of nuclei which are in the close environment. 
This is called indirect spin-spin coupling. We will now work through a real example. 
1,1,2 trichloroethane (C2H3Cl3) is a small molecule which contains only three  hydrogen 
atoms (see image below). The two hydrogens on the first carbon (circled red) are chemically 
equivalent as they share the same environment, whereas the hydrogen on the second 
carbon (circled blue) differs. If proton (H1) NMR spectroscopy was performed on this 
molecule, two signals would be expected, one for the blue hydrogen and one larger signal 
from the two red hydrogens. These signals would be at 3.95 and5.77. However, on 
examination of the NMR spectrum it is obvious that there are multiple peaks in both 
positions. In the case of the first doublet, using previous discussions it is possible to deduce 
that the splitting here occurs because blue hydrogen has aligned either parallel or anti-
parallel to the applied field leading to two strengths of field being felt by the red hydrogens. 
Why, however, is the other signal a triple peak (triplet). This is because the blue hydrogen is 
affected by both of the red hydrogens. There are four possible combinations possible of spin 
orientation for the red hydrogens: 1) both can oppose the applied field reducing the magnetic 
force applied; 2) both could reinforce the applied field increasing the magnetic force applied; 
3) the first hydrogen could be parallel and the second anti-parallel 4) the first can be anti-
parallel and the second parallel. In options 3) and 4) as the nuclei are identical the net effect 
is zero. This means that the signal will be split into three peaks, with the middle peak 
representing 3) and 4) being twice the height as the other two. 
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The final consideration for NMR experiments involving nuclei of  = ½  is the nuclear 
Overhauser effect (NOE), which was first theorised by Albert Overhauser in the early 
nineteen fifties but wasn’t experimentally proven until 1962 by Anderson and Freeman. The 
previous examples have considered nuclei which are close enough to magnetically interact 
due to scalar coupling; the interaction is through chemical bonds. However, it is possible that 
nuclei can interact as a result of the fact that they are spatially close to each other, because 
of the 3-dimensional configuration of the molecule rather, than being close due to chemical 
bonds. This is called dipolar coupling. In the situation where there are two dipole-dipole 
coupled nuclei during the relaxation process it is possible for the spins to affect each other.  
If two nuclei are considered, again called A and B the figure below  (fig 1.26) shows the four 
possible combinations of nuclear spins within an external field are shown, numbered one to 
four. If irradiated at the absorption frequency of A for long enough there will be a net 
movement from the low energy state of A to the high energy state leading to saturation, with 
Figure 1.25. The NMR spectrum of 1,1,2 trichroloethane, with the chemical structure shown 
above. The red hydrogens produce the doublet while the blue hydrogen produces the triplet in the 
process explained above.  
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an equal number of nuclei in each energy level. After saturation has occurred during 
relaxation some high energy state A nuclei will flip to the lower state to achieve initial 
equilibrium. While for two uncoupled nuclei the process by which this would occur would be 
by the relaxing nuclei to flip independently, due to the dipolar interaction between the two 
nuclei in the example the flipping of A will ‘drag’ B along with it causing it to flip also. This 
means that the pair will either move from scenario 1) in the figure to scenario 2) in what is 
called double quantum shift (W2) or from 3) to 4) in a zero order transition (W0). If a double 
quantum shift happens then the effect on the population levels of B is that a nucleus in the 
higher state is forced into the lower energy state. If previous discussions are recalled about 
equilibrium and how there are more nuclei in the lower energy state normally this means that 
the difference in populations of B increases. As it is the difference in population that NMR 
detects what this means is that the signal received from B is bigger, thus a larger peak. 
Inversely when zero order transition occurs then a B lower energy state nucleus is forced 
into the higher energy level therefore decreasing the population difference and resulting in a 
smaller signal.  
 
 
 
 
Figure 1.26. The various combinations of energy level states between the two nuclei A and B. 
The arrows pointing up or down next to the nucleus name indicate the low or high energy states 
respectively. During relaxation of two dipolar coupled nuclei the switching of state of A will also 
drag B into a forced switch by either the double quantum shift (W2) pathway by a zero order 
transition (W0). These transitions are the basis of the nuclear Overhauser effect. 
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1.4 Mass Spectrometry 
The other major technology employed within metabonomics, and also many other fields of 
study, is mass spectrometry. Mass spectrometry is an analytical and structural chemistry 
technique that measures the mass to charge (m/z) ratio of ions. In contrast to spectroscopic 
techniques, such as NMR spectroscopy, which use some form of electromagnetic signatures 
to reveal chemical structure, i.e. to ‘scope’, mass spectrometry relies on chemical and 
physical reactions and therefore is a type of experiment. Coupled with this is the fact that 
mass spectrometry is a destructive technique that consumes the sample, and this is the 
reason for the term ‘spectrometry’. While stand-alone use of mass spectrometry (direct 
infusion) is possible, within metabolic profiling mass spectrometry is generally employed with 
a front end hyphenated technology, most commonly liquid chromatography, but other 
technologies such as gas-chromatography or an inductively coupled plasma are also used. 
In these sections we will first explore the various methods of sample introduction into the ion 
source, before moving on to mass spectrometry itself.  
1.4.1 Principles of Liquid Chromatography 
Liquid chromatography is a technique used to separate different components of mixture, with 
each component being separated based on its interaction between two phases: a stationary 
phase, and a mobile phase which moves in a definite direction. Due to the fact that there are 
many different combinations of stationary and mobile phases that can be used for the 
separation, these various types of chromatography are categorised by the physical state of 
these phases. Chromatography was first developed at the beginning of the 20th century by 
Russian botanist Mikhail Tsvet, who separated plant chlorophylls by eluting the sample with 
ethanol through calcium carbonate. This rudimentary methodology was subsequently refined 
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in the 50s and 60s into what is today recognised as high performance liquid 
chromatography. 
While this section will discuss the basic principles and underlying science behind liquid 
chromatography and its implementation, it is not an exhaustive description and a more 
detailed description of LC kinetics and technology can be found in e.g., ‘Liquid 
Chromatography: Fundamentals and Instrumentation’ by Fanali et al. (2013). 
The general scheme of liquid chromatography is as follows. The components of the sample 
are separated by distribution between the two phases. The chemical and physical properties 
of each component determine what affinity that particular compound has for the mobile and 
stationary phases. Therefore, as the sample passes through the separation column sample 
components with high affinity for the stationary phase will progress through the column at a 
slower pace than those with a lower affinity, and thus will separate into bands and exit the 
column, or ‘elute’, at different times. These ‘bands’ can then be analysed with another 
analytical techniques, such as mass spectrometry. This concept is summarised in figure 1.27 
below. The basic set up for liquid chromatography is also summarised in figure 1.28 
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Figure 1.27. The separation of a two part sample through a LC column. The green area in the 
column represents the entry of the mixture into the column. As elution proceeds, the mixture 
separates into its two components, represented by the blue and yellow bands. The yellow 
component has a higher affinity for the stationary phase (column) therefore moves through the 
column at a slower pace than the blue component which has a lower affinity for the stationary 
phase. As the blue component elutes earlier its chromatographic peak is detected earlier in the 
chromatogram.  
Time 
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The chromatogram produced by the detector at the end of every LC run provides several 
important parameters which are crucial in the analysis of the acquired data and are 
necessary for the quantification and identification of the components of the sample. 
a. Void time 
After the start of every chromatographic run, it takes some time for the mobile phase to 
reach the column from the point of injection, which is called the void time (or void volume). 
This will normally produce a distorted peak, or a baseline fluctuation, where any compounds 
which are not retained at all by the column pass through in the solvent front, and therefore 
also represents the amount of time any compound spends within the mobile phase. 
 
 
Figure 1.28. The components of a typical high performance liquid chromatography system. 
There are two solvents, possibly an organic and an aqueous, which are pumped through a 
degasser before the sample is injected. These then flow through the separation column, and 
the eluting compounds produce a chromatogram from a detector which converts the digital 
information acquired from the separation in to a visual representation. 
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b. Retention time 
Chromatography is a time dependant separation; therefore the amount of time a particular 
compound spends within the system is the key characteristic of interest. This is measured by 
retention time tR, which is defined as the time taken from injection to peak maximum for an 
individual component. This effectively calculated as: 
tR = tS + tM 
Where tS is time spent by the solute in the stationary phase and tM is time spent in the mobile 
phase. As mentioned before, all components spend time equal to the void time, so retention 
time is often adjusted to take into account only time spent within the stationary phase. 
c. Retention factor 
Sometimes during chromatographic analysis it is necessary to identify whether a shift in 
retention time of a compound is due to actual retention within the column or if the shift is due 
to some change within the system. To differentiate between the two the retention factor k is 
used which is defined as the degree of retention of the compound of interest relative to 
another un-retrained analyte. This is calculated by: 
 
Where tR is the retention time of the peak in question, and t0 is the retention time of the 
unretained peak, also equal to the void time. If k is consistent then the shift in retention is 
due to the system. 
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d. Selectivity 
For two different compounds to be detected their retention times must be different, i.e., they 
must have different affinities for the stationary phase, or else they will elute at the same time, 
and it would be impossible to distinguish between them. As such the ability for a given LC 
system to separate two analytes is measured by the selectivity factor a which is the ratio of 
retention factors between the two compounds expressed as: 
 
Where kA and kB are the retention factors of the two analytes in question. For the system to 
be able to separate the two compounds the selectivity factor must be greater than one (a > 
1). Selectivity is directly related to the chemistry of the system, and depends on factors such 
as the type and strength of solvent used, column packing, temperature (an oft overlooked 
factor) and possibly mobile phase pH. 
e. Resolution 
While the selectivity factor is an indicator of the ability of the system to separate two 
chemicals it does not however, take into account peak shape or width. As retention time is 
measured from the peak maximum it is possible for two compounds to elute separately but 
have such broad peak base width that they are not resolved well. To quantify how well two 
(normally adjacent peaks) are resolved the resolution factor Rs is used and can be 
calculated as follows: 
 
Where TR1 and TR2 are the retention times of the two peaks, and Wb1 and Wb2 are the peak 
width at the peak base of the same two peaks. 
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The figure below (figure 1.29) illustrates how two peaks with the same selectivity (a) can 
have different resolutions. 
 
 
 
 
f. Peak symmetry 
In the ideal scenario, chromatographic peaks would be symmetrical. However, most peaks 
exhibit a small degree of ‘peak tailing’  where the latter half of the peak is significantly wider 
than the first half; ’peak fronting’, the reverse of peak tailing, although less common is also 
possible. This usually occurs due to the fact that more than one retention mechanism is 
present during separation and one of these mechanisms is being saturated. This 
phenomenon renders the acquisition of chromatographic signal data quite problematic, as it 
obfuscates calculations of retention time, peak area and peak width. Furthermore if there is a 
smaller peak eluting a short time after, it may be obscured in the former peak’s tailing, 
especially if background noise is high.   
Figure 1.29. The two peaks shown here share the same selectivity value, 1.5, which is over 1 
therefore of an acceptable range. However the two peaks on the left have wide peak bases and 
therefore overlap, leading to poor resolution, hence the low Rs value. The two peaks on the 
right however, have narrow peak bases and therefore have a better Rs. The situation on the 
right is therefore more favourable. 
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To quantify this skewedness the asymmetry factor is used which is calculated using the peak 
width at 10% height. The asymmetry factor As is defined as: 
 
Where B is the width of the latter half of the peak at 10% height and A is the width of the first 
half of the peak at 10% height. A value of 1 (As = 1) indicates that the peak is perfectly 
symmetrical  whereas if As > 1 then the peak is tailing and if As < 1 then the peak is fronting.  
g. Plate number 
In traditional chromatography theory, the theoretical plate model is used to describe the 
chemical processes that are occurring in the separation column. In this theoretical model the 
column is composed of a series of stacked plates, a concept derived from distillation theory. 
As the mobile phase passes through the column it must equilibrate with each of the plates 
before it may pass to the next plate. Therefore the analytes proceed through the column 
through equilibrated mobile phase from plate to plate. Figure 1.30 depicts the column made 
up of the theoretical plates. It is important to note that these plates do not actually exist but 
are a convenient way of representing the elution process within the column. 
 
 
 
Figure 1.30. The theoretical plate model of chromatography. The separation column is made 
out of many theoretical plates, and a separate equilibration between the stationary and mobile 
phase occurs at each plate. The eluting analytes pass through the column by riding the 
equilibrated mobile phase through each plate. 
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The number of plates a real column possesses can be determined by utilising a single peak. 
The number of plates, N, is calculated thus: 
 
Where tR is the retention time of the selected peak, and w1/2 is the peak width at half height 
and the 5.55 coefficient comes from 8ln2 (peak width). The number of theoretical plates can 
also be used a measure of column efficiency, either by directly quoting the number of plates, 
N, (where a higher number of plates means higher column efficiency) of by calculating the 
height of the plates. This plate height measurement is called the ‘Height Equivalent to a 
Theoretical Plate’ or HETP and is calculated as follows: 
 
Where L is the column length and N is the number of plates. HETP is inversely proportionate 
to N and therefore a lower HETP is desirable. However this measurement is dependent on 
many parameters of the selected peak, and can change with different solutions. HETP is 
therefore not a measure of overall column quality but rather an indication of the relative 
suitability of the column for the specific experiment.  
h. Band broadening 
Band broadening is a phenomenon that occurs after a sample has entered a column and 
results from different molecules of the same band traveling through the column at different 
speeds. Generally this reduces the efficiency and quality of column separation, and can 
complicate both analyte identification and quantification. Furthermore the longer a particular 
analyte takes to pass through the column, the better it is retained, the higher the likelihood 
that it will be affected by band broadening. This band broadening can originate from various 
sources, which will be discussed below, and can include both characteristics of the column 
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but also may originate from other sources such as the sample injector or the detector. To 
measure the degree of band broadening the van Deemeter equation is used (Gritti and 
Cuiochon, 2013). 
The van Deemter equation calculates the relationship between the HETP and the three 
sources of band broadening, eddy Diffusion (A), longitudinal diffusion (B) and Mass transfer 
within the stationary and mobile phase (C)`. The van Deemter equation is as follows: 
 
Where u is the linear flow velocity and the other terms are as before. The van Deemter 
equation also demonstrates the dependence of plate height (HETP) to the flow velocity. 
The three factors contributing to band broadening are as mentioned previously eddy 
diffusion, longitudinal diffusion and mass transfer: 
 Eddy diffusion. Eddy diffusion is the generic term used to describe variations in the 
flow rate of mobile phase through the column, or the analyte flow path. This relates to 
the fact that there are small inconsistencies in the homogeneity of the column 
packaging and the fact that some molecules of the same compound will take different 
paths through the column packing particles, resulting in some paths being longer 
than others. This phenomenon is directly related to column particle size, therefore 
columns with smaller particle size will reduce the effect of eddy diffusion, as there will 
be less space between particles and a more uniform trajectory for mobile phase flow. 
Eddy diffusion is not effected by linear velocity.  
 Longitudinal diffusion. After injection the components of a chromatographic band will 
disperse outwards due to the naturally occurring concentration gradient present at 
the outer edges of the band. This is called longitudinal diffusion and results in the 
widening of the chromatographic band. While this diffusion is possible during the 
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whole time a compound is within the LC system, it is most prominent within the 
separation column where the diffusion is orientated along the axis of separation. As 
this is natural diffusion, the extent of diffusion is dependent on the time spent within 
the column, and as time spent is itself dependant on linear velocity, it follows that the 
dispersion will be inversely proportional to this velocity (the faster the mobile phase is 
flowing, the less time the compound has time to disperse within the column). 
 Mass transfer.  Mass transfer, or more specifically the resistance to mass transfer, is 
possibly the most important of the contributing factors to band broadening. As 
molecules are proceeding through the separation column they are constantly 
diffusing between the mobile and stationary phases. However, each molecule does 
not attain equilibrium between these stages with the same efficiency, and therefore 
disparities arise in the length of time taken for the migration of each molecule. The 
origins of this disparity are twofold. Firstly the depth of diffusion into the stationary 
phase particles varies, and therefore the deeper a molecule has diffused the longer it 
takes to diffuse back out into the mobile phase. On the other hand the 
microarchitecture of the column particles include depressions within the particle 
surface to maximise interface area. These however, may create localised ‘stagnant’ 
pools of mobile phase which are harder for the analytes to traverse, thereby reducing 
the distribution rate of the solutes between the phases. Both these phenomena result 
in variability in the time it takes each molecule to pass through the column, creating 
band broadening.   
Besides what has been described above there are also other factors that could affect 
chromatographic performance and produce band broadening effects. Extra column factors 
include the sample injector, system tubing and the detector itself (Gritti and Guiochon, 2010). 
Furthermore these factors become increasingly important as their effect on columns with 
smaller diameter is (ID < 2.1mm) or columns of small particle size is much greater (Fountain 
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et al., 2009). This is important as the use of as special modifications to the system are 
necessary to use column of these types.  
 
 
 1.4.2 Modes of High pressure liquid chromatography 
There are a wide range of chemicals and sample mixtures which can be analysed by liquid 
chromatography. However, there are different modes of operation for LC and each type is 
more suitable for a different set of target analytes. Indeed there are different combinations of 
mobile and stationary phase which make the system more specific to certain classes of 
compounds. The most commonly used modes of operation are the traditional normal phase 
chromatography (NPC) and reversed-phase chromatography (RPLC). Another widely used 
type of chromatography, geared towards separation of polar compounds, is hydrophilic 
interaction chromatography (HILIC). There are many other types of chromatography such as 
ion-exchange (IEC) (Light et al., 1957) and size exclusion chromatography (Hong et al., 
2012) as well as many way of combining the chromatographic modes (mixed mode 
chromatography) (Oehme and Peters, 2010). However, within the realm of metabonomics 
reversed-phase and hydrophobic interaction chromatography are the two most widely used 
so only these two will be described in detail. 
a. Reversed-phase liquid chromatography (RPLC) 
The traditional method of performing chromatography, normal phase, revolved around a 
polar stationary phase, typically silica, and a non-polar mobile phase such as hexane. This 
interaction between analyte and the phases, mediated by the mobile phase, relied mostly on 
dipole-dipole and hydrogen bonding. While this is a very powerful separation technique for a 
very large number of chemicals, due to the emergence of RPLC and HILIC NPC has fallen 
out of favour.  
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The currently most widely employed form of LC is reversed-phase chromatography. RPLC is 
preferred due to the fact that is highly reproducible and is suitable for a wide range of 
chemical separations including charged and moderately polar molecules. RPLC separation 
is dependent on the interaction between the analyte and a non-polar stationary phase and a 
more polar mobile phase. This is the opposite of traditional normal phase chromatography, 
hence the name ‘reversed-phase’. The stationary phase is usually composed of a silica base 
upon which hydrophobic alkyl chains are attached, usually C18 chains. The mobile phase as 
mentioned before is polar and is usually comprised of a mixture of an organic solvent such 
as methanol and an aqueous buffer. The separation of the analyses is based upon the 
hydrophobic interactions between the lipophilic areas of the analyte and the stationary 
phase. This results in non-polar compounds being better retained as the hydrophobic 
interactions with the stationary phase will be stronger. Another benefit of RPLC is the 
possibility to regulate the composition of the mobile phase by varying the respective levels of 
organic and aqueous solvents in the mobile phase composition. This allows the polarity of 
the mobile phase to be modulated also affecting the level of retention within the column; the 
more polar the mobile phase, the faster elution will occur. 
b. Hydrophilic Interaction Liquid Chromatography 
Compounds of weak or moderate polarity can be generally well separated by both normal 
and reversed-phase chromatography, albeit with opposite orders of elution. However, 
analytes with high polarity tend to be very weakly retained in RPLC, eluting very close to or 
within the solvent front. Conversely these same polar analytes tend to be very insoluble 
within the mobile phases used for NPLC, resulting in excessive retention within the column. 
In both scenarios it can be very difficult to acquire useful data for these compounds.  
While it is possible to separate highly polar compounds with normal phase chromatography 
by using highly aqueous mobile phases it is not easy to do this in a repeatable way. This 
type of separation was extended by Alpert in 1990 into what is today known as HILIC. HILIC 
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can be simply described as a chromatographic technique that utilises a polar ‘normal phase’ 
stationary phase, with a reversed-phase type mobile phase with a very high percentage of 
organic solvent. In HILIC retention increases as polarity increases, similarly to NPLC, 
however due to the high organic content the mobile phase is less viscous, and therefore 
shows better separation for polar compounds. HILIC stationary phases are generally based 
either on silica or are hybrid materials including amides, amino and diol chains which offer a 
wide range of retention specificities.  
HILIC has become ever more popular within the scientific community, and has been 
employed in the investigation of a wide range of biological important polar compounds. 
HILIC has also proven to be very suitable for hyphenation with mass spectrometry, and is 
therefore widely used within metabonomic experiments. While HILIC has been studied 
extensively, the underlying mechanism of the interactions occurring within the column are 
still being debated, with a hypothesised interactions including dipole-dipole interactions, 
hydrogen bonding and ion exchange (Mcalley, 2010).   
1.4.2 Principles of Mass spectrometry 
Mass spectrometry is an analytical chemistry technique which is used to quantify known 
compounds, identify unknown chemicals within a sample and for structural elucidation of 
unknown analytes. The spectrometry process involved the conversion of the sample into an 
ion in the gas phase and then analysis by an ion detector which will sort the ions according 
to mass to charge (m/z) ratios and provide data on the relative abundances of each ion. The 
general concept is summarised in the below figure (figure 1.31) which details the typical 
components of a mass spectrometer. The ions generally must be in the gas phase for the 
application of either an electric or magnetic field to allow for ion separation. 
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While the general components for every mass spectrometer are consistent as shown in the 
above diagram, there are a variety of different Ionisation techniques which have been 
employed, together with different types of mass analysers.  
a. Ionisation 
Mass spectrometry depends on the ionization of the target compounds to be able to detect 
and quantify them. Furthermore, for charge-to-mass ratio separation to occur the ions must 
be introduced in the gas phase into the vacuum of the detector. While this is relatively simple 
for samples already in the gas phase, such as after gas chromatography, or samples with 
heat volatile chemicals, it is more complicated when dealing with a LC interface. Traditional 
ionisation techniques include electron impact (where a gas phase sample is bombarded with 
electrons) and fast atom bombardment (where ionisation of non-volatile compounds is 
achieved by bombardment with a stream of either Ar or Xe atoms). These ionisation 
Figure 1.31. A block diagram depicting the general components of a mass spectrometer. After 
sample introduction gas phase ions are created in the ion source (ionisation), and these ions 
are then separated according to mass to charge ration in the mass analyser. The relative 
abundance of these ions is then calculated in the ion detector and a mass spectrum produced 
by the signal processing data system. 
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methods are however, not very suitable to combination with liquid chromatography. The 
most commonly used methods are discussed below. 
Electrospray Ionisation. Electrospray ionisation (ESI) is the ionisation method that has 
become the most widely used technique, especially in combined LC-MS systems (Fenn et 
al., 1989). In this form of ionisation the sample solution is passed through a thin capillary 
tube, over the opening of which a large electrical charge of a few thousand volts is applied, 
at atmospheric pressure. This produces a spray of small charged droplets. The electrical 
current creates a potential difference between the capillary and a counter electrode which is 
situated near an opening in the vacuum system of the mass analyser.  Depending on the 
voltage used this difference may be either positive or negative, which would attract ions of 
different charge. This results in two modes of operation for ESI, negative or positive 
ionisation, and each mode is efficient at ionising a wide range of molecules. As the droplets 
move through the ionisation chamber a desolvation gas is applied causing the solvent to 
evaporate increasing both the ion concentration but also the internal charge within the 
droplet. As the droplet gets smaller the increase in charge causes a ‘coulombic explosion’ 
releasing the ions. There are two chemical models by which this explosion is hypothesised 
to happen, the ‘charge residue model’ and the ion evaporation model. A detailed description 
of these models can be found in either Dole et al. (1968) or Thompson and Iribarne (1976). 
An overview of the electrospray process is summarised in the below figure. 
 
 
 
Figure 1.32. A diagram illustrating the ionisation process by electrospray. The application of an 
electrical current across a capillary opening naturally produces a fine mist spray. The electric 
potential differences between the capillary and the counter electrode at the other end of the 
ionisation chamber causes the droplets to move across the chamber, where the application of a 
desolvating gas, such as nitrogen, will cause solvent evaporation, increasing the internal 
concertation of ions. Once a charge threshold is reached, a coulombic explosion is caused 
releasing the ions which then enter the vacuum system of the mass analyser.   
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Electrospray ionisation has a wide range of suitable target compounds, and is especially 
useful for the detection of charged polar or basic compounds. Its utility is extended by the 
simple control of fragmentation by changing the interface potentials, and is very suitable for 
tandem MS/MS experiments, although this form of ionisation can be easily contaminated 
and requires quite complicated hardware. Extensions of ESI have been developed such as 
nano-spray variants which use a very low flow rate, or desorption electrospray ionisation, 
which extracts ions from a surface sample using the ESI spray. 
Atmospheric pressure chemical ionisation (APCI). This method of ionisation is uses similar 
hardware to ESI, and is another form of soft ionisation (Straube et al., 2004). However, 
instead of the voltage being applied to the spray itself, it is applied to a needle size nebulizer 
which produces a corona discharge to produce ions (mostly H3O
+). The sample solution is 
then introduced into the spray at atmospheric pressure, together with a heated gas that 
causes the mixture to become volatile. Ionisation occurs in the gas phase through proton 
transfer from the spray ions resulting in the production of analyte ions. These ions then 
collide with each other resulting in high ionisation efficiency and the production of both 
positive and negative analyte ions. APCI is predominately used for less polar compounds, 
for which ESI is unsuitable, and while the ionisation efficiency is very high, it is generally 
produces very little fragmentation. 
Inductively coupled plasma (ICP) mass spectrometry. ICP is an ionisation method that is 
used for the quantification of specific elements of interest within a sample (Profrock and 
Prange, 2012). It is therefore fundamentally different from other types of mass spectrometry 
as it is not used for structural identification, but it is however innately quantitative, and will 
give an accurate measurement of the number of atoms within a sample of the target 
element. ICP is based on the use of a plasma torch to ablate the components of a sample 
into its constituent atoms. Initially the sample solution is introduced into a nebulizer where 
small droplets are formed on the injection needle through the action of argon gas. The 
sample aerosol then passes through a second needle into the torch.  
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The torch consists of three concentric quartz tubes around which a copper induction coil is 
wrapped. Argon gas is pumped into the space between the tubes and a spark is introduced 
to it from a Tesla unit, causing some of the gas to ionize. An oscillating radio frequency 
electric current is passed through the copper coil which causes the argon ions to interact 
with the magnetic field and accelerate in alternating directions colliding with other argon 
atoms creating very high temperatures. With sufficient argon and a high enough oscillation 
frequency, the plasma will reach equilibrium at temperatures over 6000oC. The sample spray 
is then introduced to the plasma where it will absorb high amounts of energy and be 
atomised. These atoms then pass through a vacuum chamber through two cones for rapid 
cooling of the ions, after which they will be introduced to the mass analyser (Skoog et al., 
2007). The general schematic is described in figure 1.33 below.  
 
 
 
 
 
 
 
b. Mass analysers 
Once the ions have been produced, they are accelerated through a vacuum into a mass 
analyser that will separate them according to their mass to charge ratio (M/Z). Various types 
Figure 1.33. A diagram illustrating the plasma induction process. The sample is first nebulized 
by the introduction of argon gas. In the quartz tubing, argon gas is ignited by a spark and a 
radio-frequency oscillation causes the ionised gas to superheat. The sample is introduced into 
this plasma where it is atomised. The ions are then cool in a vacuum chamber before they are 
introduced into the mass analyser.  
Modified from Elkadi et al., 2014. 
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of mass analysers have been developed and each type has its own advantages and 
limitations. However, all mass analysers utilise electromagnetic fields to manipulate the ions 
and the net force applied on the ions can be summarised by Newton’s second law from 
basic physics theory: 
F = m a 
Where F is the applied force, m the mass of the ion and a the acceleration. As this force is 
electromagnetic the above law can be extended by the inclusion of the Lorentz equation: 
F = e (E + vB) 
Where e is the charge of the ion, E is the strength of the electric field and vB is the product 
of ion velocity and the applied magnetic field. With the above two mathematical relationships 
we can surmise that the force applied to the ion is dependent on both the mass of the ion 
(m) but also the charge of the ion (e), and hence the mass analysers ability to separate by 
mass to charge ratio. 
Quadrupole mass analyser. The quadrupole mass analyser is comprised of four parallel 
rods, as depicted in figure 1.34, which operates as a mass filter. Two of the rods are applied 
with a direct current, while the other two with a radio frequency current.  Ions from the source 
are focused and then enter the space between the rods. The oscillations produced by the 
electromagnetic fields of the rods are such that the ions will experience a trajectory 
dependant on the mass to charge ratio. Ions with the correct trajectory for a specified m/z 
will reach the other side of the mass analyser and are able to reach the detector. Ions with 
the incorrect m/z ratio will have an unstable trajectory and collide with the rods and never 
reach the detector. The radio-frequency can be adjusted to allow only ions with a specific 
charge to enter the detector, and as such full mass range can be achieved by slowly 
scanning through the voltages. Further details for the underlying physics of ion behaviour, 
and how the force applied to the ion can be derived from what is called the Mathieu 
equation,  the review by March (1997) is highly recommended.   
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Quadrupoles are also sometimes utilised in tandem, and combined in sequence to provide a 
system that enables fragmentation of the ions. This is very useful for structural elucidation of 
unknown compounds. The most common form of tandem quadrupole mass analyser is a 
triple quadrupole, where three quadrupoles are combined. The first set is used to select the 
ions of interest, the second set uses guide rods with only the radio-frequency current, and 
collision energy in combination with an inert gas such as nitrogen to fragment the ion and the 
third set of quadrupoles separates the fragments thereby allowing them to be detected. 
 
 
 
Time of flight analyser. Time of flight (TOF) instruments are some of the most extensively 
utilised with mass spectrometry. TOF analysers operate on the basic principle of the time 
needed for a charged particle to travel through a homogenous electric field being dependant 
on the particle mass to charge ratio. After acceleration of ions by a regulated electric field 
their velocity will be dependent on the ionic charge. As the length of the mass analyser is 
known, it is possible to calculate the mass of the ion by using the time taken to travel across 
the flight tube. The kinetic energy (T) of a charged particle can be calculated by: 
Figure 1.34. A diagram showing a rudimentary quadrupole mass analyser. Ions with the correct 
m/z matching the radio-frequency current applied to the rods will pass through the mass 
analyser and reach the detector. 
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Where e is the ion charge, v is the velocity of the ion and m is the mass. However, the 
velocity of the ion is the length of the flight tube divided by the time taken to traverse it. By 
substituting this into the above equation and then solving for time: 
 
Where t is the flight time, L is the length of the flight tube and the other terms are as before, 
it is possible to calculate the mass of the ion. 
While the TOF analyser has the advantage of being able to analyse all ions, the length of the 
flight tube is of central importance as the separation depends on flight time. A longer flight 
tube will increase the resolution of the separation, and as such length of flight tube has 
always been the limiting factor for high resolution analysis. Recently the implementation of 
reflection technology has gained popularity. By introducing a linear field reflection and 
reversing the flight of the ions the effective length of the flight tube is extended. Furthermore 
this provides better resolution by eliminating some of the kinetic drift that arises from small 
variations in the initial kinetic energy of the ions; ions with larger kinetic momentum will 
penetrate the reflection field more, therefore will take a longer time to be reflected back.  
Quadrupole time of flight analysers. As it is possible to combine several quadrupole 
analysers, it is also possible to combine quadrupole with TOF analysers to produce hybrid 
Q-TOF instruments. The combination of a quadrupole, a collision chamber and a TOF 
analyser has become the choice hybrid. The selectivity of the quadrupole for fragmentation 
coupled with the high resolution and accuracy of the TOF for fragment detection is the 
reason for this popularity in MS/MS experiments.   
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1.5 Multivariate Statistical Analysis  
 
a. Necessity for use with Metabonomics  
As previously mentioned metabonomics produces a very data rich output, that many times 
will include complicated or noisy data, which is multicollinear and can contain variation from 
multiple sources, including electronic noise. For the adequate interpretation and 
comprehension of the signals, visualisation and identification of the main sources of 
variation, the need for the use of more variables to characterise observations is apparent. 
The data analysis techniques routinely utilised within metabonomics include projection 
based statistics which can be unsupervised, such as Principal Component Analysis, or 
supervised, such as Partial Least Square Regression and its variants (Eriksson et al, 2004). 
Once again the underlying mathematical theory of the statistical techniques employed is 
beyond the scope of this thesis, thus only a basic overview and possible applications will be 
discussed.  
 
b. Principal Component Analysis (PCA)  
Principal Component Analysis is a very useful analytical technique because it is hypothesis 
free, and requires no previous information on the data. As with all projection based methods, 
a basic assumption of PCA is that the system under study is controlled by an unknown, yet 
limited, number of Latent variables. Latent variables are hypothetical variables that are 
inferred, therefore not directly observed. Thus, after obtaining our observed variables, PCA 
is used to construct further artificial variables which explain the variation in the observations. 
These artificial variables are called principal components, and can then be used for 
prediction in further models. PCA is in essence an eigenvector based analysis, the function 
of which is to identify underlying structures within data, revealing trends and outliers (Trygg 
et al, 2007).  
While PCA is a powerful tool for pre-processing, most metabonomic studies, as indeed in 
most biomedical research, is concerned with the need to find the underlying stratification 
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which distinguishes between samples of different groupings. This of course includes classes 
of pathological, disease and metabolic status, different treatment groups and traditional 
case-control studies. In such cases sample classification can be incorporated to drive the 
analysis. This can be achieved by the implementation of supervised methods as described 
below.  
Since in metabonomics the output includes a very large amount of variables (around 20,000 
on an average resolution setting) PCA is used to describe the data in a lower dimension 
theoretical space. Each model may have a number of components equal or less than the 
number of variables in observation. The first model component is constructed using least 
square regression in a way that the component has the highest variance possible, thus 
explaining the largest variation within the observations. The second component will have the 
second largest variation, and so forth (Eriksson, 2006). Initially the n observations are 
projected onto a hyperspace with p dimensions, where p is the number of observed 
variables. In this theoretical hyperspace, a hyperplane with dimensions K is constructed from 
the principal components (K1, K2, K3 ...), each component being linearly orthogonal to each 
other. The position of every of the n observations within the plane is measured by a value 
called the score (T), and the position within the space by the loading (P). Each variable 
therefore has two co-ordinates. Any variation that is not explained by the model is called the 
residual, and is noted by E. Thus in summary the whole PCA model of a data set ‘X’ with 
observed variable number n can be given by:  
 
X = T1P1T + T2P2T + ....TnPnT + E 
 
 
c. Partial Least Square regression (PLS)  
Partial least square regression is a method used to project data on latent structures. Normal 
PLS is used when a quantitative relationship between two matrices X and Y is being 
investigated; the goal is to predict Y given X. While traditionally this could be achieved using 
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traditional multiple regression, due to the multicollinear nature of metabonomic datasets this 
is impossible. The X matrix could be spectral data, NMR signals or similar and Y would 
normally contain quantitative measurements of metabolite concentrations, a situation where 
the number of predictors is large compared to the number of observations. Even if Multiple 
Linear Regression was used, due to the large number of factors, the resultant model would 
be over-fitted, i.e. while the observed data is well explained, the model fails to predict new 
data (Trygg et al, 2007). However PLS avoids this problem, thus allowing for accurate 
interpretation of the data. Indeed by using linear regression multiple PLS components are 
created which can explain much of the sample variation.  
Orthogonal PLS (O-PLS) and Orthogonal PLS Discrimination Analysis (O-PLS-DA) Are 
extensions to the PLS procedure. O-PLS uses a orthogonal signal correction to create an 
orthogonal component to remove unrelated sources of variation, and by using discriminate Y 
data can be further extended to O-PLS-DA; Y data can also be other outputs such as clinical 
parameters or toxicity score. Even though O-PLS-DA is very suitable for metabonomic 
studies, cross validation is routinely applied to minimise any potential over fitting. This cross 
validation involves removing a certain portion of data (usually one seventh) and testing the 
model to see how accurately it can infer the removed part. This process is repeated until 
every variable has been omitted once, and then the average percentage of successful 
imputation is acquired, which comprises the often quoted Q2 value. If the Q2 value is above 
0.5 (i.e. more than 50% successful prediction) then the model is considered fit for data 
interpretation, though there are exceptions to this threshold, due to its arbitrary nature 
(Eriksson, 2006). A further step in model quality control can include creating random Y data 
and comparing Q2 values between the real and random models. If the Q2 values are 
significantly different this is a further indication that the model is appropriate.  
In PLS the X and Y scores of the components are computed in a fashion so that consecutive 
scores can have the strongest possible correlation, making the model much more robust 
than in other redundancy analyses. PLS can also be extended in several ways; in many 
cases the Y matrix could comprise of qualitative “dummy” data used to represent 
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discrimination between classes. In this case PLS can be modified to a discriminate analysis, 
called PLS-DA. Here the model of X can be given by:  
X = T . PT + E 
Where the symbols are as before in PCA.  
However, as mentioned before metabonomic data, especially 1H NMR spectroscopic data, 
can be noisy, and can include variation which has no relation to the process under study. To 
negate this problem orthogonal-partial least square regression has been employed. Here the 
regression is modified so as to split the variation within the observations into two parts, one 
which is related to the Y data in a linear fashion and depicts the variation caused by it, and 
one part which is orthogonal to Y and includes all variation which is unrelated to Y (Cloarec 
et al, 2005). Thus in this situation the X model is given by:  
X = TpPp
T + ToPo
T + E 
Where Tp and Pp are the scores and loadings of the predictive variation and To and Po are 
the scores and loadings of the Y-orthogonal components.  
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1.5 Structural Assignment  
The final step, and ultimate goal, of metabonomic studies is the identification the metabolites 
that drive the discrimination between groups to obtain “biomarkers” which relate to specific 
phenotypes. These biomarkers may offer a direct link to the underlying biological pathways 
which result in the phenotype under study. To be able to identify which metabolite(s) are the 
ones detected by the statistics various techniques are used. Basic assignment involves 
observation of e.g., the NMR signal peak, chemical shift and comparing this to a list of 
standards available on central databases. Furthermore the J-coupling values of the peaks 
can be compared for a more confident assignment. However, sometimes due to the complex 
nature of NMR spectroscopic signals, peaks may overlap or be obscured making 
assignment difficult. In this situation 2D-NMR spectroscopy can be utilised, for separation of 
peaks. Statistical Total Correlation Spectroscopy (STOCSY) is an alternative approach 
which computes the correlation between variables in the spectrum, by taking advantage of 
the multicollinear nature of NMR data. This allows for the identification of related peaks and 
produces a pseudo- two-dimensional spectrum aiding the metabolite identification process 
(Cloarec et al, 2005). For the identification of compound via MS the M/Z is first used to 
construct a list of potential chemicals which fit the observations, and also any isotopic 
patterns present. These are then supplemented by fragmentation data and tandem MS/MS 
experiments depending on the instrumentation used. This will then lead to the final step 
which would be the development of a targeted method for the most confident assignments. 
1.6 Aim and Objectives 
As described earlier, drug discovery, is a complex process, with a very high failure rate.  
These failures can result from many causes but one major source of these has been toxicity 
and as part of a strategy to address this, the Consortium for Metabonomic Toxicology 
(COMET) was established in the early 2000s as international collaboration between Imperial 
College London and five major pharmaceutical companies: Bristol-Myers-Squibb, Eli Lilly & 
Co., Hoffmann-La Roche, NovoNordisk, and Pfizer, Inc. The objectives of COMET were a) to 
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provide a detailed multivariate description and biochemical characterisation of selected rat 
and mouse strains; b) to assess the ability of metabonomics to differentiate between toxic 
and non-toxic compounds and identify target organs of toxicity and c) the development of 
expert systems for the detection of toxicity of xenobiotic molecules (Lindon et al., 2003). To 
this end the project performed metabonomic studies deploying 1H NMR spectroscopy as the 
analytical platform, and using urine and serum samples from rodents exposed to 147 
selected compounds, in combination with histological and chemical data. The project was 
very successful and the results were used to generate a spectral database describing the 
model compounds (Lindon et al., 2005), which is still widely used for the drug discovery and 
development process within these companies (Spagou et al., 2011). 
One other potential reason for late stage failure in drug development is that the full 
characterisation of drug metabolism in both preclinical species and man is often incomplete 
until the definitive radiolabelled studies have been performed. Until these studies are 
undertaken the detection of drug metabolites in the samples available from e.g., preliminary 
studies in vitro, or in animals (particularly in regulatory toxicology investigations) and early 
human clinical investigations, relies on the expertise of the DMPK scientist. Metabolite 
identification in this instance is heavily dependent on the skill of the operator, and this may 
result in some metabolites not being detected. However, the failure to fully characterise the 
metabolic fate of compounds at an early stage can result in delayed compound progression 
through development when they are finally identified in later investigations. This is especially 
the  case where it is found that the species used for toxicity do not replicate the metabolic 
fate of the compound in humans requiring further  toxicology studies in different species. 
However, in many metabonomic studies where drugs have been administered it has been 
the case that, on multivariate statistical analysis, both the parent compound and metabolites 
themselves have been found to be, at least in part, responsible for discriminating between 
dosed and control animals. The potential therefore exists to use the metabonomic approach 
as a method for the unbiased detection of the metabolic fate of compounds to supplement 
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the existing, expert-based, approaches to metabolite discovery. Given that the COMET 
project resulted in some 35.000 or so biological samples, an investigation of the potential for 
metabonomic detection of xenobiotic metabolism, based in the main on LC-MS analysis of 
samples, but also employing other analytical approaches where informative, was considered 
an appropriate use of this rich legacy. In addition, the re-profiling of COMET samples using 
LC-MS provides an opportunity to compare the results obtained with those previously 
acquired using 1H NMR spectroscopy as a means of detecting biomarkers of toxicity. The 
aim of the research presented here was therefore as follows: 
1. Evaluate the use of LC-MS based strategies as a means for the automatic and 
unbiased detection of xenobiotic metabolites in biofluids such as urine following the 
administration of drugs at therapeutic or toxic doses to rodents. 
2. Examine, in addition to the detection of drug metabolites, a subset of the COMET 
samples to see if LC-MS-based methodologies could be applied used to detect 
signatures specific for mechanism-based toxicity. 
3. Compare these LC-MS methodologies, where appropriate to the data that could be 
acquired using current methods based on 1H NMR spectroscopy including cryoprobe 
technology. 
4. Determine whether it would be practical to devise a workflow that allowed both 
biomarkers of toxicity and drug metabolites to be performed. 
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Computational technologies as a tool for 
the investigation of metabolism 
Chapter Two 
The utility of computational approaches for metabolism studies has long since 
been discussed. In this chapter the utility of such methods are evaluated in 
both a small scale metabolism study but also in a large scale toxicity study. 
Furthermore the inherent limitations of the LC-MS platform are explored, with 
statistical techniques for the correction of batch effect applied. 
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2.1 Metabonomics as a tool for the investigation of xenobiotic metabolism 
The introduction (chapter one) has already touched upon the utility of metabonomics in the 
investigation of both the metabolism of xenobiotics, but also xenobiotic induced toxicity.  
All living organisms are continuously exposed to a variety of exogenous chemicals, through 
diet, environmental exposure and drug administration. These compounds are actively dealt 
with by the biological system in the ADME process (absorption, distribution, metabolism and 
excretion). While there is certainly biological machinery dedicated to the elimination of 
foreign chemicals, the metabolic fate of the xenobiotic is not as easy to predict as one might 
initially think. Endogenous metabolism has evolved in a manner that has produced tightly 
regulated and constrained metabolic pathways. Enzymes are highly specific and the 
probability of the correct reaction occurring is maximised to ensure maximal chemical 
efficiency.  
This is not the case with metabolism of xenobiotics where it is not possible for cellular 
biology to have adapted specific metabolic protocols for every possible compound in 
existence. In this case the foreign compound is altered in a manner purely reliant on the 
statistical probability that it will come into contact with an enzyme that will be able to interact 
with. As the enzymes which are able to catabolise xenobiotic reactions tend to have broader 
specificities than endogenous metabolism, both the type and order of metabolic alteration a 
xenobiotic may encounter is not determined absolutely (Wilson and Nicholson, 2003). It is 
therefore apparent that specific combinations of genetic variation and environmental 
exposures may result in widely different toxic outcomes. Furthermore, the xenobiotic, or 
metabolites of the xenobiotic, have the potential to alter the innate metabolic processes, and 
this in itself can be a possible origin of the toxic effects of certain compounds (Klaassen, et 
al., 2002). 
While the metabolism of xenobiotics has been long since studied (Williams, 1947) traditional 
metabolism techniques are generally hypothesis driven and require specific target 
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compounds (Lenz and Wilson, 2007).  These approaches are useful, but with metabolic 
outcomes being so hard to predict, there are quite obvious limitations, and can result in 
incorrect conclusions being reached, which in the realm of drug development can have 
serious consequences. It is apparent therefore that it is necessary for a hypothesis free 
approach for the investigation of the effects of exogenous compounds on the metabolic 
equilibrium. Metabonomics, based on high throughput and robust analytical technologies, is 
able to detect thousands of metabolites simultaneously within any given biological sample 
and therefore take a ‘snapshot’ of the metabolic status present.  
By using multivariate statistical comparisons between large datasets acquired from 
analysis of the samples it is possible to detect subtle changes and identify both markers of 
xenobiotic exposure and also changes within the endogenous metabolism of the organism 
simultaneously. Through statistical modelling it is possible to position every sample within a 
theoretical hyperspace. By constructing a model containing the targets of comparison it is 
possible to consider the relative positions of each subject in relation to each other. By 
comparing the statuses of the various individuals it is possible to infer directions of influence, 
and also identify which variables contribute to this influence. Given enough statistical power 
it is therefore possible to ‘blindly’ identify which are the most influential metabolites, on a 
purely statistical level. Further targeted work is possible to then identify these metabolites, 
and also pave the way for the elucidation of metabolic pathways and mechanisms of toxicity. 
Metabonomics is therefore potentially a valuable tool in xenobiotic metabolism studies. 
Two examples of the use of a statistical approach are described here. The first uses a small 
“traditional” drug metabolism protocol, with a limited number of animals and a 
pharmacological dose of the drug diclofenac (Section 2A). The second adopts a toxicological 
study design with larger doses and numbers of animals to look at the fate of the drug 
acetaminophen (paracetamol) (Section 2B). 
 
  
 
 
  
Computational technologies as a tool for 
the investigation of the metabolism of 
diclofenac in the HRN mouse 
Chapter Two [A] 
Previous work by Sarda et al. had utilized HPLC-MS to investigate the 
metabolism of Diclofenac in the mouse. The major routes of metabolism were 
thought to be glucuronic acid and taurine conjugation. This study was 
repeated here in the HRN and wild type mouse, with UPLC-MS metabolic 
profiling. Multivariate statistical analysis was used to identify the metabolic 
differences. Computational analysis failed to identify the previously known 
metabolites of diclofenac, as diurnal variation predominated the statistics. 
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SUMMARY: 
 
 Diclofenac, a non-steroidal anti-inflammatory drug, is a known hepatotoxin. 
 Diclofenac was dosed orally by gavage to three male HRN null and three 
male wild type mice (strain: C57BL/6J). Urine was collected at regular 
intervals, and after two days the animals were sacrificed and livers retrieved.  
  Urine samples were analysed by LC-MS (UPLC-MS) to determine both the 
effects of diclofenac on urinary endogenous metabolite profile and the 
metabolic fate of the compound itself. 
 Chemometric analysis showed that the main discriminators between the pre 
dose and 24 hour time points were unassigned analytes 1 (m/z 203.14, 
7.93RT) and 2 (m/z 314.02, 7.65RT). These did not match the previously 
identified metabolites of diclofenac. 
  Manual interrogation of the spectrometry data showed that both diclofenac 
and major metabolites were present in the urine samples. 
 The conclusion from this investigation was that classic manual investigation of 
the urinary profiles showed presence of diclofenac metabolites. However, the 
combination of low dose, small sample size and low statistical power rendered 
the computational approach unable to identify these same metabolites. 
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2A.1 Introduction 
2A.1.1 A Metabolism study in Mice following administration of Diclofenac 
Diclofenac (2-[2-(2,6-dichlorophenylamino)phenyl] acetic acid), molecular weight 294.01, the 
chemical structure of which is shown below in figure 2A.1, is a non-steroidal anti-
inflammatory drug (NSAID), widely used to reduce inflammation or for pain relief in certain 
conditions. It is prescribed for the treatment of many inflammatory conditions including 
rheumatoid arthritis, osteoarthritis and acute muscle pain, but is also used for the pain 
management of severe migraines and menstrual cramps (Small, 1989). Diclofenac is 
generally administered as a sodium salt, although in some countries a potassium salt is 
used. 
 
 
 
Diclofenac has been associated with a wide range of adverse drug reactions, some of which 
include increased risk of heart disease, serious gastrointestinal events, and renal toxicity 
characterised by increased serum creatinine (Novartis report, 2014). Administration of 
diclofenac has also been linked to rare, but severe, hepatotoxicity in around 4% of patients 
(Boelsterli et al., 1995). Curiously as these toxic episodes typical present with delayed onset 
of symptoms, and a lack of a clear relationship between dose and severity, they have been 
defined as idiosyncratic toxicity rather than individual susceptibility (Banks et al., 1995).  
Figure 2A.1 The molecular structure of diclofenac as a sodium salt. 
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Due to these characteristics diclofenac has been the subject of intense scientific interest, 
and many studies have attempted to elucidate the mechanisms underlying the toxicity. 
Studies of diclofenac toxicity have been performed both in vivo and in vitro, with studies in 
animal models (Kallio et al., 2010) and in human patients (Poon et al., 2001). This research 
effort has provided some insight into the metabolism that diclofenac is subject to. Highly 
reactive quinone-imine metabolites of diclofenac are thought to be produced by the 
microsomal mixed function oxidase mediated oxidation of initial hydroxylation products 
(Tang et al., 1999). Ester glucuronides of diclofenac itself have been detected as have both 
ether and ester glucuronide conjugates of the drugs downstream hydroxy-metabolites. 
Generally ether glucuronides have been shown to be quite inert but acyl glucuronides, on 
the other hand, are chemically reactive and have been proposed as a key component in 
many toxic events (Faed, 1984). Diclofenac acyl glucuronides have been widely observed in 
studies in animals and humans (Kretz-Rommel and Boelsterli, 1994). In addition glutathione 
conjugates of diclofenac have also been observed in rat bile (Waldon et al., 2010). It is 
generally accepted that the presence of glutathione conjugates indicates the presence of 
reactive intermediates of the parent compound (Sims and Grover, 1974) as one of the 
primary protective mechanisms of the cell against such chemicals is inactivation through the 
action of glutathione S-transferase. These conjugates are then generally excreted in the 
urine as the mecapturate (Wood, 1970); indeed Poon et al. (2001) identified the mecapturic 
acid metabolite of diclofenac in both human and rodent urine.  
  
2A.1.2 The hepatic reductase null mouse model 
The potential toxic metabolites of diclofenac includes both the quinone-imine and acyl 
glucuronides however, as these will be produced at the same time in normal mice it is hard 
to pin point which, if not both, are responsible for the observed toxicity or, if both are toxic, to 
what degree each contributes. Traditional metabolism experiments to try to deconvolute this 
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problem would involve the use of chemical inhibitors of the enzymes responsible for the 
production of these two groups of metabolites, and then look for their effects in modifying 
toxicity. However, while this is generally quite easy in vitro or in synthetic systems, such as 
those used in the above mentioned work by Kretz-Rommel and Boelsterli (1994), this 
approach is harder in vivo as these inhibitors can have unpredictable effects on the 
organism under study, which can be clinically significant (Lynch and Price, 2007).  
Within biomedical research the use of genetically modified animals for the investigation of 
genes which have been sequenced but whose function is unknown has been extensive. 
These ‘knock out’ animals have the gene of interest either replaced or deactivated through 
insertion of foreign DNA. This technology is highly applicable to studies focusing on the 
contribution a particular enzyme to the metabolism of a xenobiotic. Mice that have a 
particular P450 isoenzyme deactivated have been used to identify the role that particular 
CYP has in the toxicity of various compounds (Pineau et al., 1995). More recently Le and 
Sauer (2001) described a knock out mouse model, created using the Cre/LoxP system, 
which has only the hepatic P450 enzymes silenced, called the Hepatic Reductase Null 
(HRN) mouse model. Cre recombinase, the enzyme upon which the knock out is dependent, 
catalyses recombination at very specific 34-base pair sequence (LoxP). Furthermore this 
gene ablation can be tightly controlled and targeted to certain cell types and can therefore 
be used to create such conditional knock outs (Gu et al., 1994). The HRN mouse, whilst 
have no activity with respect to liver P450’s, will contain maintain normal functional P450s in 
all other tissues, thereby avoiding the embryonic lethality that an animal with no P450 would 
suffer. The HRN mouse is therefore the ideal animal model for the investigation of the role of 
diclofenac acyl glucuronide vs oxidative metabolism in liver toxicity, as it is thought the 
majority of its metabolism occurs within the hepatocytes. If coupled with metabonomic global 
metabolic profiling, the comparison of the HRN metabolic fingerprint with wild type animals 
could potentially be used to identify which non-P450-derived diclofenac metabolites are 
produced by hepatic metabolism.  
 Chapter Two [A] 
 
 
 84 
 
2A.1.3 Traditional vs Statistical drug metabolic investigation 
Previous work by Sarda et al., (2011) in the mouse, has already identified the key urinary 
metabolites of diclofenac using radiolabelled diclofenac and radio-HPLC and MS detection 
using an ion trap mass spectrometer. This work identified that the main routes of metabolism 
in the mouse involved direct taurine conjugation, or 4 and 5 hydroxylation followed by taurine 
or glucose conjugation. Furthermore the authors reported on how the main route of 
conjugation was via formation of   the ether, not the acyl, glucuronide. This was somewhat 
different to previous results, as there no mecapturic acid or quinone-imine derivatives of 
diclofenac  were detected, although most of previous the work in rodents had been 
performed in the rat.. Other minor metabolites of diclofenac were also described including 
sulfate, glucose and ribose conjugates of the Phase l diclofenac metabolites. 
This previous work utilised the skills of experienced spectrometrists, combined with 
radiotracer experiments to detect the diclofenac metabolites amongst the mass of 
endogenous compounds. This process is both time intensive and demands highly skilled 
individuals for good results. Furthermore without multivariate statistical comparisons 
between the groups this approach may fail to identify other subtle effects on endogenous 
metabolism. The aim of this initial pilot study described below was to ascertain whether it is 
possible to perform an investigation into the metabolism of diclofenac utilising purely 
computational based methods. As this was a ‘worked example’, where the metabolism has 
already been described using conventional methods, the aim was to see if mining the data 
using multivariate statistical methods could derive the same results. Global metabolic 
profiling was performed on the samples using UPLC-MS and then chemometric techniques 
were employed to discern what differences were present between the metabolic landscapes 
of the HRN and wild type mice. 
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2A.2 Materials and Methods 
  
 2A.2.1 Study Design and Sample Collection 
The analytical chemistry in this study was performed on urine samples samples previously 
collected in a diclofenac metabolism study (courtesy of Dr H Lees) at AstraZeneca (Alderley 
Park). Diclofenac was dosed orally by gavage to three male HRN null and three male wild 
type mice (strain: C57BL/6J). Male wild type mice aged between 8 and 10 weeks were 
supplied by the AstraZeneca Rodent Breeding Unit, Alderley Park. The HRN (strain: B6.Cg-
Portm1WolfTg(Alb-cre)21Mgn N7) mice aged between 7 and 8 weeks were purchased from 
Taconic (Taconic Farms Inc., Germantown, NY, USA). Mice were treated with 10mg/kg of 
diclofenac as the sodium salt, with a total dose volume of 5mL/kg. Mice were housed in 
metabolic cages according to strain and urine was collected for metabonomic analysis. Spot 
urine was collected at 16 hours pre dose and then total urines were collected for the time 
periods of 0-12 hours and 12-24 hours. Clinical observations and body weight were recorded 
daily. The animals were sacrificed 24 hours after dosing by fluothane inhalation. Kidneys and 
livers were removed and were examined histopathologically. Samples were stored at -80 °C 
prior to analysis. 
2A.2.2 Sample Preparation and Experimental 
Prior to analysis the sample order was randomised. Of the 18 samples, one sample (animal 
three HRN, 0-12 hours) had insufficient volume and was therefore omitted from the study. A 
40 µL aliquot of urine was mixed with 40 µL water to dilute the salt concentration for each 
sample. These samples were vortexed and left at -20 °C overnight before centrifugation for 5 
min at 12 000 G at 4 °C. For reversed-phase chromatography, 50 µL of sample was taken 
and added to 150 µL water in 350 µL 96-well plates (Waters Corporation, Milford, USA). A 
pooled quality control (QC) sample was prepared by combining 10 µL of each sample and 
diluting 1:4 with water. Five injections of the pooled QC sample were used to condition the 
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column with a QC sample injected prior to analysis of the individual urines and then after 
every 10 injections. Each sample was injected twice. 
Reversed-phase liquid chromatography was performed on an Acquity UPLC system (Waters 
Ltd, Elstree, UK) coupled to a Xevo G2 triple quadrupole time-of-flight mass spectrometer 
(Waters MS technologies, Ltd., Manchester). UPLC-MS conditions for urine analysis were 
those  previously described for the reversed-phase analysis of urine (Want et al., 2010) with 
the separation was performed using a Acquity BEH C18 (1.7 µm, 2.1 x 100 mm) column and 
2 µL per sample were injected. Mass spectrometry was performed with electrospray 
ionisation operated in positive (ESI+) ion mode. The instrument was operated in sensitivity 
mode and set to acquire data over the m/z range 50 – 1200 with a scan time of 0.1 s. All 
mass spectral data were collected in centroid mode using the MSe data acquisition function. 
For mass accuracy, leucine encephalin (MW = 555.62) was used as a lock mass at a 
concentration of 200 pg/uL (in 50/50 CH3CN:H2O, 0.1 % formic acid) infused at a flow rate of 
20 µL/min via a lock spray interface. The data were collected using MassLynx V 4.1 software 
(Waters Corporation, Milford, USA). 
2A.2.3 UPLC-MS Data analysis and statistical modelling 
The UPLC-MS data set was pre-processed using XCMS Bentobox (Tautenhahn et al. 2012) 
software in order to convert the three-dimensional LC-MS raw data into time-aligned 
detected features of retention time, m/z ratio and intensity (peak area). The ion intensities for 
each peak detected were then normalised, within each sample, to the median peak intensity 
in that sample. The resulting peak marker tables, comprising m/z, RT and normalised 
intensity values for each of the 1732 variables in every sample, were exported to SIMCA-P+ 
11.0.4 software (Umetrics, Umea, Sweden) to perform multi-variate statistical analysis. 
Prior to any statistical modelling the QCs were evaluated, through the use of positioning 
within the PCA plots. If there was significant variation within the quality control data, or if 
there was significant drift within the position of the QCs within PCA scores plots the data 
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would have been unfit for analysis. SIMCA-P+ 11.0.4 was used for the statistical modelling; 
Principal component analysis (PCA) was utilised to explore any underlying stratification 
within the data. OPLS S-plots were used to investigate any differences within the sample 
groups and the loadings were used to identify which (if any) variables were driving the 
separation. 
2A.3 Results and Discussion 
 2A.3.1 Quality control 
As previously discussed LC-MS techniques are subject to instrumental instability resulting in 
possibly unreliable data. For quality assurance purposes aliquots from every sample were 
combined in a pooled sample which was then analysed at regular intervals throughout the 
experiment. Initial PCA scores plots used to scrutinise analytical drift showed that the QCs 
together with the conditioning injections grouped well together in the centre of statistical 
space, as can be seen in figure 2A.2 below. As this experiment contained very few injections 
(44 including both the duplicates and the QCs), it was not expected that there would be any 
major analytical inconsistencies due to excessive drift during the run due to column/detector 
contamination, and this seems to be borne out in the results. 
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 2A.3.2 Chemometric analysis 
As the aim of this pilot study was to ascertain the suitability of computational methods as a 
means of detecting drug metabolites in metabolic studies, a ‘blind’ hypothesis free approach 
was utilised in the statistical analysis. Initial PCA modelling of the complete dataset revealed 
significant differences between the metabolic profiles of the wild type and HRN mice. It is 
therefore apparent that there are significant metabolic differences in the two strains, both 
initially and after dosing, as knocking out the hepatic p450 would undoubtedly have 
significant effects. Figure 2A.3 illustrates the separation between wild type and HRN mouse 
and in addition shows a time-dependant progression within each strain. Pre-dose and 0-12 
hour samples from the HRN mice seem to be metabolically very similar, whereas there is 
significant deviation from pre-dose metabotype of the wild type animals over the same time 
period. Maximal differences in metabolic phenotypes for the HRN mouse were found 
Figure 2A.2 A PCA scores plot of unfiltered, paretto scaled data. The red highlighted area 
indicates where the pooled sample QCs have clustered together in the centre of statistical 
space, indicating that there was good analytical stability throughout the run. 
 Chapter Two [A] 
 
 
 89 
between 12 and 24 hours. In both strains it seems that the maximal response occurred 
within these first 24 hours. This matches previous results from Sarda et al., (2012) as they 
identified that the majority (49.7%) of excretion of drug-related material occurred in this time 
period.  
 
 
 
 
 
 
 
For the identification of the key metabolic differences after administration of diclofenac, the 
pre-dose wild type samples were compared to the wild type samples at 24 hours post dose. 
PCA modelling showed a clear difference between the metabolic states of the mice. In this 
comparison the pre-dose samples act as a control group. Figure 2A.4 shows the PCA scores 
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Figure 2A.3 A PCA scores plot of the complete dataset, coloured according to strain and time 
point. 
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plot for this comparison. To identify the key metabolites driving this separation S-plots were 
constructed. The S-plot highlights which variables are contributing the most to the 
differences between the groups (figure 2A.5). The signals identified by the scores plot are 
detailed in table 2A.1. 
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Figure 2A.4 A PCA scores plot comparing the pre dose and 12-24 hour samples of the wild type 
mice. There are clear differences in the metabolic phenotypes of the mice with time after 
diclofenac dosing, the influence of which is described along the first principal component. 
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 Accurate Mass Retention Time(min) Up/Down regulated 
Unassigned 1 203.14 7.93 Up 
Unassigned 2 203.11 6.65 Up 
Unassigned 3 314.02 7.65 Up 
Unassigned 4 132.08 0.71 Up 
Unassigned 5 297.16 3.50 down 
Table 2A.1 Description of the major metabolic changes in the wild type mouse after 
diclofenac administration 
 
The identified ions described in the table above do not match either the parent compound 
(diclofenac has a molecular mass of 294.91) or indeed any of the previously identified major 
metabolites, nor any of the product ions or fragments of those metabolites. In addition, none 
of these compounds displayed the diagnostic isotope pattern that would be expected for a 
molecule containing 2 chlorine atoms (see Sarda et al, 2011). This suggests that the 
metabolites detected are not from diclofenac but are of endogenous origin. As such they 
might reflect the pharmacological effects of the drug on metabolic processes in the animals 
or simply factors such as diurnal variation. As the aim of this pilot study was to determine 
how well an unbiased statistical approach to data mining for detecting xenobiotic metabolites 
Figure 2A.4 S-plot of the PCA model comparing the pre dose and 12-24 hour samples of the 
wild type mouse. The highlighted points at the top represent the metabolites which are up 
regulated after diclofenac dosing, while the ones at the bottom left are down regulated. 
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could replicate results found by a human expert these endogenous markers were not 
investigated further. 
There was however, the possibility that the failure of the  analysis to detect the metabolites 
that had been characterised in the previous study could have been due to their not being 
present in these samples. To ascertain whether our analytical method was successful, 
standard mass spectrometry practice was used to manually search for and identify these 
known metabolites. As indicated above diclofenac contains two chlorine atoms, and enabling 
the identification of drug related products more easily through the use of the well-known 
chlorine-isotope pattern. The same MS data that had been analysed using statistical 
methodology was therefore analysed using this targeted, expert-based approach and, as 
indicated in table 2A.2, a large number of diclofenac metabolites were found in this fashion. 
 
Compound Mass Formula Key Ions 
Diclofenac 294.0086 C14H10O2N1Cl2 250, 214, 178 
Hydroxy 310.0033 C14H10O3N1Cl2 266, 230, 194, 166 
Di-hydroxy 325.9983 C14H10O4N1Cl2 290, 282, 246, 210 
Hydroxy, sulfate 389.9599 C14H10O6N1Cl2 S1 310, 266, 230, 194 
Taurine 401.0123 C16H15O4N2Cl2 S1 124, 107, 80 
Hydroxy, taurine 417.0070 C16H15O5N2Cl2 S1 381, 345, 317, 292, 237, 
124, 80 
Demethylated, Acyl 
glucuronide 
456.0245 C19H16O8N1Cl2 280, 276, 244, 200, 175 
1-β 
-O-Acyl glucuronide 
470.0040 C20H18O8N1Cl2 193 
Hydroxy, glucose 472.0558 C20H20O8N1Cl2 428, 266, 230, 161 
Hydroxy, glucuronide 486.0350 C20H18O9N1Cl2 310, 266, 193, 175, 131, 
113 
Table 2A.2 Summary of the metabolites of diclofenac which were identified using 
conventional mass spectrometry methods. 
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2A.4 Conclusion and future perspectives 
The discovery of the known metabolites within the LC-MS data signified that the statistical 
approach lacked the sensitivity to identify drug related compounds within our data set. This 
could be attributed either to the small sample size, or to the low dose administered. In either 
case the presence of  diclofenac and its metabolites in the sample was masked by 
underlying diurnal variation and changes in endogenous metabolism. The untargeted 
analysis simply lacked the statistical power to unearth the presence of diclofenac and its 
phase I and II metabolites hidden in the endogenous metabolic profile, because these 
changes were subtle compared to other fluctuations. This highlights a potential limitation of 
the computational approach, which generally is biased towards the greatest numerical 
difference, irrespective of whether this difference is biologically relevant or not. For future 
work, it was decided that a much greater sample size and higher dosing levels could offer a 
more robust approach to statistical metabolic evaluation.   
 
  
 
  
Application of computational analysis and 
batch correction normalisation to the 
investigation of the metabolism of 
acetaminophen 
Chapter Two [B] 
After the work described in the previous sub chapter (2A), application of 
computational analysis was performed on an acetaminophen toxicity study. 
UPLC-MS was performed on a large number of urine samples from a COMET 
study of chronic acetaminophen exposure, which were split into four batches. 
Data analysis of the individual batch datasets identified clear differences 
between the metabolic profiles of the different dose groups. These differences 
were driven by the presence of both high concentrations of parent compound 
and the major metabolites. These major metabolites were identified to be the 
glucuronide and sulphate conjugates. Attempts to merge the data from the 
different batches were made using median fold change normalization after 
variance stabilization using a glog function. However, this was largely 
unsuccessful as the resultant data had lost much biologically relevant 
information. 
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SUMMARY: 
 
 Acetaminophen, also known as paracetamol, a commonly used analgesic and 
antipyretic drug, is a human and rodent hepatotoxin at high doses.. 
 40 Sprague Dawley rats were split into four equal groups and were 
administered with a single IP dose of either vehicle (carboxymethylcellulose), 
200 mg/kg, 400 mg/kg or 800 mg/kg of acetaminophen. Urine was collected at 
regular intervals for seven days resulting in a total of 680 samples.  
  Urine samples were split into four batches and then analysed by LC-MS 
(UPLC-MS) to determine both the effects of acetaminophen on urinary 
endogenous metabolite profiles and the metabolic fate of the compound itself. 
 Chemometric analysis of each batch showed that the main discriminators 
between dosed and control animals were associated with metabolites of 
acetaminophen. 
 A number of acetaminophen metabolites were identified in urine, including 
with the glucuronide and the sulphate, and the detection of the N-
acetylcysteinyl conjugate, itself a metabolite of the glutathione conjugate of 
acetaminophen, evidence for the production of reactive metabolites. 
 Batch correction was attempted by using median fold change normalisation 
after variance stabilisation with a glog function, with the QCs as a measure of 
normalisation. While this approach did normalise the data, when the complete 
data set was analysed much of the biologically interesting variation had been 
masked. 
 
 Chapter Two [B] 
 
 
 96 
2B.1 Introduction 
 2B.1.1 Acetaminophen 
Acetaminophen (APAP, N-acetyl-p-aminophenol), molecular weight 151.16, widely known in 
Europe as paracetamol, the structure of which is shown below in figure 2B.1, is a commonly 
used, over the counter analgesic and antipyretic. As a mild analgesic is it used in the 
treatment of headaches and other minor pains in addition to fever management however, it 
exhibits limited anti-inflammatory action. The mechanism of action of acetaminophen 
appears to involve the inhibition of prostaglandin synthesis, a group of hormone-like 
glycoproteins which are involved in pain perception and temperature control (Kanada et al., 
2013). 
 
 
 
Despite being readily available, acetaminophen has been linked to a wide range of side 
effects and toxicity; in fact acetaminophen overdose is the most common cause of acute 
hepatic failure in western populations (Bernal et al., 2010). This situation may be in part due 
to unintentional overdosing due to concurrent use of multiple acetaminophen-containing 
medications. Nonetheless concerns over the rising incidence of mortality due to 
acetaminophen triggered multi-organ failure lead the Food and Drug Administration (FDA)  in 
the USA to introduce new legislation in February 2014 limiting acetaminophen content to 325 
mg per unit dose (FDA guidelines, 2011).  
Figure 2B.1 The molecular structure of paracetamol. 
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After oral dosing acetaminophen is rapidly absorbed through the gastrointestinal tract after 
which it undergoes extensive hepatic metabolism. The majority of the drug is subject to 
phase II metabolism, with approximately 50-70% of acetaminophen glucuronidated by UDP-
glucuronosyltransferases and a further 20-30% sulphated by sulphotransferase enzymes 
(Prescott, 1980). These conjugates are then readily excreted into the urine. A further 10% of 
the dose of acetaminophen is oxididised by microsomal mixed function oxidases, primarily 
CYP2E1 in humans, to the reactive intermediate N-acetyl-p-benzoquinone imine (NAPQI) 
(Dahlin et al., 1984). NAPQI is then conjugated with glutathione, either spontaneously or 
catalysed by glutathione-S-transferase enzymes (GST), into acetaminophen-GSH, which is 
then subject to further biotransformation  into cysteinyl and related compounds, the 
acetaminophen N-acetyl-L-cysteinyl (mercapturate) and acetaminophen cysteinyl-glycine 
conjugates. These metabolites together with the glutathione conjugate are excreted in the 
bile, or excreted as the cysteinyl and or the mercapturic acid derivatives in the urine. Urine is 
also seen to contain the parent compound and catechol derivatives. The hepatic metabolism 
of acetaminophen is summarised in figure 2B.2 below.  
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At toxic doses continued production of NAPQI results in eventual glutathione depletion. The 
reactive electrophilic NAPQI will then cause cell damage by protein binding (Mitchell et al., 
1973). This glutathione depletion and covalent binding to proteins will trigger a plethora of 
downstream events, the generation of reactive oxygen species oxidative stress leading to 
mitochondrial failure and eventual cell death (Jones et al., 2010), although the precise 
cellular pathways by which this occurs are still under investigation.  
2B.1.2 Metabonomic profiling as a tool for the investigation of acetaminophen 
metabolism and toxicity  
AS mentioned previously metabonomics comprises a suitable platform for the 
comprehensive investigation of the metabolism and toxicity of xenobiotics, with the added 
Figure 2B.2 Diagram illustrating the hepatic metabolism and fate of acetaminophen. At normal 
doses major metabolites APAP-glucuronide, APAP-sulphate and mercapturic acid derivatives are 
excreted in the urine. At toxic levels however, high levels of NAPQI result in glutathione 
depletion and a cascade of further hepatotoxic events. 
Modified from Hodgman and Garrard (2012) 
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benefit of enabling the assessment of any perturbation on endogenous metabolism. As one 
of the most well studied, but also most clinically relevant drugs, acetaminophen has been the 
subject of many metabolic profiling studies. Indeed one of the first studies utilising 1H NMR 
spectroscopy for profiling urine (Bales et al., 1984) succeeded in identifying acetaminophen 
and its major metabolites, the glucuronide, sulphate and cysteine conjugates, in human urine 
samples after dosing at therapeutic levels. Furthermore the authors were able to describe 
alterations in the excretion of the endogenous metabolites creatinine, citrate, hippurate and 
sarcosine, although the latter signal is now known to be dimethylamine (Coen et al.,2003). 
Further work by the same group (Bales et al., 1988) involved a pioneering toxicology study 
which identified markers of toxicity of acetaminophen using the same metabolic profiling 
approach. Evidence of the saturation of sulphoconjugation, increased production of of 
NAPQI, in addition to altered quantities of amino acids, were seen as indicative of hepatic 
cell damage. 
1H NMR spectroscopy-based metabolic profiling has also been used to extensively study the 
metabolism of acetaminophen in many animal models. The introduction of a 13C stable label 
into the acetyl group of the compound, coupled with NMR spectroscopy allowed the 
demonstration of so-called “futile de-acetylation”  i.e., the cyclic deacetylation and re-
actylation of the compound in the rat and human, a process which had previously been 
largely overlooked (Nicholls et al., 1995). Animal models have also been used in 
metabolome-wide mapping for the comprehensive evaluation of the effect acetaminophen 
has on endogenous metabolism. In combination with traditional clinical chemistry, 1H NMR 
spectroscopy was used to identify elevated amounts of triglyceride and monounsaturated 
fatty acids and a decrease in the amounts of polyunsaturated fatty acids in the mouse (Coen 
et al., 2003). Monounsaturated fatty acids are linked to mitochondrial dysfunction while 
polyunsaturated fatty acids are indicative of beta-oxidation inhibition (Osmundsen and 
Bjørnstad, 1985), which suggests that acetaminophen may cause dysregulation of cellular 
energy metabolism.  
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Building upon these previous results, the COMET consortium undertook two large scale 
animal toxicology studies to study both single and chronic exposure to acetaminophen.  
These 1H NMR-based studies identified further treatment associated biomarkers, with 
increases in the relative amounts of taurine and creatinine, with a decrease in allantoin and 
succinate (internal COMET report, 2003). 
A small proportion of studies have employed the UPLC-MS platform for metabolic profiling of 
acute exposure (Sun et al., 2009), screening for reactive APAP intermediates (Li et al., 
2011) and even utilising hyphenated combined HPLC-NMR-MS techniques for the detection 
of the minor APAP metabolite ether glucuronide of 3-methoxy-acetaminophen which was 
undetectable by direct 1HNMR of urine (Godejohann et al., 2004). However, there have been 
few comprehensive studies on the long term metabolic perturbations of chronic 
acetaminophen administration with analysis by LC-MS. As such, the aims of this study were 
to utilise previously collected urine samples, from the chronic COMET acetaminophen study, 
in an untargeted UPLC-MS metabolic profiling approach for the combined elucidation of 
acetaminophen metabolites and biomarkers of toxicity and treatment. A further secondary 
objective was evaluation of computational techniques (discussed in the previous section) in 
a larger cohort, with a relatively high dose. 
 
2B.2 Materials and Methods 
 2B.2.1 Study details 
The reanalysis performed in this study was performed on the samples collected in the 
COMET study S09 where urine and serum samples were collected after the administration 
of acetaminophen by gastric intubation, to male Sprague-Dawley rats for seven days. The 
rats (10 animals/group) were dosed with 200 mg/kg, 400 mg/kg or 800 mg/kg of 
acetaminophen in 0.2% carboxymethylcellulose, (control rats were dosed with 0.2% 
carboxymethylcellulose only). Rats were housed in metabolic cages and urine was collected 
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for metabonomic and clinical analysis. Urine samples were collected at 16 hours pre-dose, 
at time of dose and at 8, 24, 32, 48, 56, 72, 80, 96, 104, 120, 144, 168, 192, 216, 240, 264, 
288 and 312 hours post dose, with a total of 680 samples collected. Clinical observations 
and body weight were recorded daily. The rats were split into two equal sacrifice groups 
(Groups A and B). Clinical chemistry was performed on study days 8, 24 hours after last 
treatment (Group A) and on study day 14, 168 hours after last the treatment (group B). 
Necropsy examinations were performed on the same days. Half of the animals from each 
group were sacrificed on study day 8 and the other half were sacrificed on study day 14. 
Kidneys were removed and were examined histopathologically. Samples were stored at -40 
°C prior to analysis. 
2B.2.2 Sample Preparation and Experimental Methods 
Prior to analysis the sample order was randomised using the Microsoft excel random 
number generator function. The urine samples were then separated into four equal batches 
of 170 samples each, which were prepared simultaneously but analysed separately. A 150 
µL aliquot of urine was mixed with 300 µL water to dilute the salt concentration before 
protein removal via precipitation with acetonitrile (1:2 v/v). These samples were vortexed and 
left at -20 °C overnight before centrifugation for 5 min at 12 000 G at 4 °C. For reversed-
phase chromatography, 50 µL of sample was taken and added to 150 µL water in 350 µL 
96-well plates (Waters Corportation, Milford, USA). A pooled quality control (QC) sample 
was prepared (Want et al., 2010) by combining 15 µL of each sample (across all batches, 
i.e. the QCs contained urine from all 680 samples) and diluting 1:4 with water. Dilutions of 1 
in 2, 1 in 4 and 1 in 8 of this QC sample in water were made. The 96-well plates were stored 
at -20 °C until the analysis by LC-MS as described below. The plates were centrifuged at 
1700 g before being placed into the autosampler at 4 °C. 
Reversed-phase liquid chromatography was performed on an Acquity UPLC system (Waters 
Ltd, Elstree, UK) coupled to a Xevo G2 triple quadrupole time-of-flight mass spectrometer 
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(Waters MS technologies, Ltd., Manchester). UPLC-MS conditions were those  previously 
described for the reversed-phase analysis of urine (Want et al., 2010) with the separation  
performed using a Waters HSS T3 (1.8 µm, 2.1 x 100 mm) column. For UPLC-MS analysis 2 
µL per sample were injected. The chromatographic mobile phase was composed of 0.1 % 
formic acid in water (A) and 0.1 % formic acid in acetonitrile (B).  The column temperature 
was maintained at 40 °C and linear gradient elution was performed at either 0.5 mL/min. The 
starting composition was 1 % B, held for 1.0 min before increasing to 15 % at 3.0 min, 50 % 
at 6.0 min, 95 % at 9.0 min for a 1.0 min wash and returning to 1 % B for a 2 min re-
equilibration step (total cycle time 12 min).  Mass spectrometry was performed with 
electrospray ionisation operated in positive ESI. The instrument was operated in sensitivity 
mode and set to acquire data over the m/z range 50 – 1200 with a scan time of 0.1 s. All 
mass spectral data were collected in centroid mode using the MSe data acquisition function. 
For mass accuracy, leucine encephalin (MW = 555.62) was used as a lock mass at a 
concentration of 200 pg/uL (in 50/50 CH3CN:H2O, 0.1 % formic acid) infused at a flow rate of 
20 µL/min via a lock spray interface. The data were collected using MassLynx V 4.1 software 
(Waters Corporation, Milford, USA). In between batches the inlet of the mass specrtrometer 
and the ESI source were cleaned, and the instrument and detector recalibrated.  
 
2B.2.3 Data Analysis 
The raw data from each of the four individual batches were processed by Markerlynx XS 
data analysis software (Waters Corporation, Milford, USA) for peak picking, alignment and 
normalization, to produce peak intensities for retention time (RT) and m/z data pairs.  Further 
statistical analysis was performed on the resulting normalized peak intensities using SIMCA 
P 13.0.2 (Umetrics, Umea, Sweden) as described previously.   
 
2B.3 Results and Discussion 
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 2B.3.1 Quality control 
As mentioned in the previous chapter it is common practice that aliquots from every sample 
are combined in a pooled sample and then analysed at regular intervals throughout the 
experiment for the purpose of quality assurance/control (Want et al., 2010). As each batch 
was analysed separately each data set was assessed individually.  
 Batch one. Initial visual inspection of the QC chromatograms showed that there was 
significant variation in intensity and some fluctuations of retention times in the major 
chromatographic peaks. Figure 2B.3 shows the overlaid chromatograms of the QCs 
of batch one. These results were mirrored in the initial PCA scores plot of the 
unfiltered data (figure 2B.4), with a time-related drift across the second component 
(PC2). Taken together these data would generally be seen as in need of further 
examination before further analysis. 
 
 
 
 
 
Figure 2B.3 Overlaid chromatograms of the QC injections for the first batch. There is 
considerable intensity variation coupled with small retention time shifts, although the majority 
of the major peaks seem to elute at a consistent time. 
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 Batch two. Initial inspection of the QC chromatograms showed that there was much 
better analytical stability in the second batch. Figure 2B.5 shows the overlaid 
chromatograms of the QCs of batch two, illustrating the more consistent results this 
time. These results were also mirrored in the initial PCA scores plot of the unfiltered 
data (figure 2B.6), which show the QCs well grouped in the centre of the plot. The 
data acquired was considered to be of good quality, and suitable to be taken forward  
for statistical analysis without further investigation. 
 
Figure 2B.4 PCA scores plot of the unfiltered data for batch one, coloured by dose group. The 
black points are the QCs and exhibit a time dependant drift across the second component. The 
red arrow shows the direction of the drift across statistical space. 
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 Batch three. Similar evaluation of batch three revealed that this batch showed subject 
to both retention time shifts, and a general reduction of intensity as the run 
Figure 2B.5 Overlaid chromatograms of the QC injections for the second batch. There 
chromatographic peaks match up well, with little evidence of chromatographic drift. 
Figure 2B.6 PCA scores plot of the unfiltered data for the second batch, coloured by dose group. 
The black points are the QCs and cluster well in the centre of statistical space. This suggests a 
high level of analytical stability throughout the second run. 
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progressed, resulting in data with a time-related bias. These effects are illustrated in 
figure 2B.7 and 8 chromatograms (figure 2B.7) and the scores plot (figure 2B.8) for 
the QC data. This data of this batch was considered, like batch 1 to be of lower 
quality than the data acquired on batch 2, requiring investigation before further 
statistical analysis. 
 
 
 
 
 
 
Figure 2B.7 Stacked comparison of the chromatograms of the QCs 1 (top), 10 (middle) and 18 
(bottom) for batch three. There are small retention time shifts in addition to a general loss of 
intensity throughout the run.  
Figure 2B.8 PCA scores plot of the unfiltered data for the third batch, coloured by dose group. 
The black points are the QCs and show (similarly to batch one) a significant time related drift, 
the influence of which is across the second component. The red arrow show the direction of the 
time related bias. 
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 Batch four. The QC chromatograms of this batch showed that there was much better 
analytical stability in the fourth batch, similar to that seen for batch two than seen for 
batches 1 and 3. Figure 2B.9 shows the overlaid chromatograms of the QCs of batch 
four, and the PCA scores plot (figure 2B.10) which also shows the QCs well grouped 
in the centre, albeit with  a small time related effect. The data acquired from this run 
were considered to be of acceptable quality, and suitable for statistical analysis. 
 
 
 
 
 
 
 
 
Figure 2B.9 Overlaid chromatograms of the QC injections for the fourth batch. There 
chromatographic peaks match up well, again with little evidence of chromatographic drift. 
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After the quality control, batches one and three were deemed to be of lower quality than 
batches two and four, which were considered to be more suitable for chemometric analysis. 
Batch one detected 27558 ions, while batches two, three and four detected 16365, 35934 
and 40824 respectively. While there was a considerable amount of variation in detected 
signals, there seems to be no correlation between quality of the data and number of ions 
detected. This high level of variability between the data from each batch, is despite using 
identical methods on the same instrument. 
However, whilst it is clear that there are a number of problems with the data generated from 
these analysis that require further investigation with respect to normalisation etc., it is also 
evident that for all four batches similar grouping of the dose groups is seen when PCA is 
performed. From this it is apparent that there is a clear distribution of the data that relates to 
acetaminophen administration and dose level. What is not possible with these results, in 
Figure 2B.10 PCA scores plot of the unfiltered data for the fourth batch, coloured by dose group. 
The black points are the QCs and cluster well in statistical space, although there is a slight time 
related influence along the second component. This suggests a reasonable level of analytical 
stability throughout the fourth run. 
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their present state, is the direct comparison of the results from one batch with another, or 
their combination into a single data set for further statistical analysis. This is clearly a major 
limitation and, for this reason, an investigation of the nature of the differences in the batches 
was undertaken. 
 
2B.3.2 Determination of batch effects. 
The analytical drift observed here produced data which exhibited both within and between 
batch variations. It was therefore impossible to concurrently analyse the data from all the 
batches before extensive corrections were applied to remove batch bias. Batch effects are 
an existential problem for large scale metabolic profiling when performed using MS for 
detection, and as such have attracted much scientific research attention. Indeed, it was the 
realization that changes, in particular to sensitivity, through the course of an analytical run 
could lead to variability that led to the adoption of the use of the QC approach to monitor for 
such effects (Sangster et al., 2007).  Assessments of batch to batch variations have been 
previously performed, and the need for robust methods for removing batch bias has been 
extensively discussed.  
Analytically, variation in detector response etc., has typically been compensated for by the 
application of an internal standard. The inclusion of a chemical with similar properties to the 
compound(s) under study makes it possible to calibrate and curve fit with the internal 
standard eliminating systematic sources of bias. This approach, however, whilst stable 
isotope labelled internal standards are widely used for target compound analysis it is difficult 
to apply this approach for hundreds if not thousands of analytes performed in 
multicomponent metabolic phenotyping analysis using MS-based methods. This is due to the 
large differences in seen ionisation for different metabolites, even when these may seem to 
be structurally similar. Furthermore, in a hypothesis free metabolic profiling experiment is it 
impossible to pre-emptively select a single, or indeed a representative set, of internal 
standards as many the metabolites present in the sample are unknown before the analysis 
has been undertaken.  
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Previously a range of computational and statistical techniques have also been employed to 
correct both within- and between-batch variations. When there is heteroscedastic disparity 
between the batches, i.e. when the variation of each chromatographic peak between each 
batch is unequal, scaling can be employed for correction, as is routinely used in microarray 
gene expression data (Luo et al., 2010). Scaling typically is applied by the use of a scaling 
factor (which is usually the standard deviation or square root of the standard deviation); this 
factor is then subtracted from each feature and then the result is divided by the same scaling 
factor. This approach is limited by the fact that the scaling factor and the relative abundance 
for each peak must be calculated for each sample which may not always be possible (i.e. 
peaks are not present in all samples) and must also be recalculated each time a new batch 
data set is acquired. 
Other methodologies have been based upon normalisation of the data using the QC 
samples. As the QCs should be representative of the entirety of the analytes within the 
samples, assessment of the QCs by calculating the relative standard deviation of peak 
intensity for each ion across the QC samples gives a good indication of reproducibility. Such 
QC based normalisation is either based upon quantile normalisation where the peak 
intensities of all samples are adjusted to account for time- related effects in a sample wide 
manner (Draisma et al., 2010) or linear regression normalisation which corrects each ion 
individually using a (typically weighted) regression curve (Kamleh et al., 2012). A wide 
variety of statistical packages and workflow strategies have been developed, for LC-MS 
(Wang et al., 2012), DIMS (Kirwan et al., 2012) and even for comparisons of data originating 
from heterogeneous sources (Kirwan et al., 2014). While all these various methods exist for 
data correction, each approach based upon algorithms of ever increasing complexity, their 
use is still not wide spread, and there seems  be no consensus on the ‘best’ method, nor 
does there seem to be an approach which is universally applicable to every dataset.  
For the determination of the extent of batch related bias within the data derived from the LC-
MS analysis of these rat urine samples, the retention times, peak areas (before 
normalisation) and mass accuracy was compared across the four batches using the QCs. 
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Any feature which was not present in the QCs of all four batches was removed and 
remaining features were matched by mass to charge ratio, with a window of 0.01 Da. Plots 
comparing the retention time and m/z of the features were constructed, and are shown 
below (figures 2B.11 and 2B.12). The comparisons showed that there was little disparity in 
the RT and m/z between batches, showing a consistency of detected features across the 
batches. 
 
 
4 
 
 
Figure 2B.11 Line plot, plotting the retention times of detected features between batch one and 
two (a), one and three (b) and one and four (c). R2 values (highlighted red) are an indication of 
the match between the two batches (expressed as a goodness of fit). The closer the value to 1, 
the more consistent the retention times are between the batches. 
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For the assessment of any intensity related effects the chromatographic peak area of the five 
most intense features of the QCs were compared. There seems to be a distinct yet 
consistent trend with batches one and three showing a sharp decline in intensity throughout 
the run, with batches two and four being more stable. This is illustrated in figure 2B.13. To 
ascertain whether these trends were only limited to a specific types of ions which ionise well 
we blindly selected nine new features which spanned the intensity range. Hippurate was also 
evaluated as this is a biologically significant metabolite to a toxicology study to make sure 
these trends were also mirrored in analytes relevant to the study. These are illustrated in 
figure 2B.14. 
Figure 2B.12 Line plot, plotting the mass to charge ratios of detected features between batch 
one and two (a), one and three (b) and one and four (c). R2 values (highlighted red) are an 
indication of the match between the two batches (expressed as a goodness of fit). The closer 
the value to 1, the more consistent the mass to charge ratios are between the batches. 
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Figure 2B.13 Bar plot, plotting the peak area of (a) the first (m/z 152.07, RT 2.41), (b) second (m/z 
144.10, RT 0.56), (c) third (m/z 152.07, RT 2.94), (d) fourth (m/z 313.08, RT 3.51) and (e) fifth (m/z 
105.03, RT 3.79) most intense features across the QC of the four batches. The intensities show a 
consistent trend across all the features. 
 Chapter Two [B] 
 
 
 114 
 
 
 
 
 
Figure 2B.14 Line plot, plotting the comparison of peak area of (a) and peak height (b) for the nine 
randomly selected metabolites and hippurate across the QCs of each batch. Each metabolite is 
represented by a coloured line. The trends observed match those seen previously, showing that the 
systematic bias is consistent across all ions. 
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2B.3.3 Application of median fold normalisation for batch correction 
As discussed above there are many strategies available for the correction of batch effects. It 
was therefore important to evaluate which approach would be most suitable for the dataset. 
Diagnostics of the variation in overall intensity between samples revealed large relative 
variation between both samples of the different batches but also within the same batch. If it 
is assumed that up to half of peak intensities are increased or decreased due to biological 
effects, the log ratios of non-differentially abundant metabolite peaks should have a 
comparably small spread around zero across samples (as shown by the box in figure 2B.15) 
and a median of zero.  However, the peak intensities of non-normalized samples exhibit 
large variation (up to a 16 fold difference) in overall intensities. Thus it is apparent that the 
overall sample intensities are attenuated within the batch.  
 
 
 
 
 
 
Figure 2B.15 Box plot of sample variation of the non-normalised peak intensities, coloured by batch. Each 
(very thin) box represents the sample variation in log fold change in peak intensity. It is very apparent that 
there is a significant level of difference between the variance from sample to sample, with variation 
decreasing as the run progresses, in line with the assumption that variation decreases as intensity decreases. 
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After determining that the bias within the data had a multifaceted aspect with clear 
heteroscedastic noise structure, the application of simple scaling could result in altered 
downstream statistical analysis and was therefore unsuitable for the datasets. This is due to 
the fact that non biological sources of variation tend to have a greater effect in features of 
higher intensity (Sysi-Aho et al., 2007), what is called ‘multiplicative noise’. Most multivariate 
statistical modelling employed (including PCA and OPLS) assumes that the underlying noise 
structure is independent of signal intensity. Thus it was necessary to apply variance 
stabilisation before normalisation could be employed. 
In collaboration with Dr Kirill Vaselkov, Imperial College London, glog variance stabilisation 
was applied to the dataset. The algorithm employed has been extensively explained by 
Vaselkov et al. (2011) but in summary aims to remove the intensity dependence of the 
sample variation by transforming the multiplicative error into additive. Under the assumption 
that background noise is small glog is calculated as: 
 
Where x is the feature and x is the intensity of the feature, with c as the fitted value of the 
feature. This is an appropriate variance stabilising transformation as this approximation is 
close to linear for low intensity features, close to logarithmic for high intensity peaks and a 
smooth intermediate for features in between. The function smoothly ‘interpolates’ between 
linear and logarithmic and is therefore called ‘linear interpolation’. Figure 2B.16a illustrates 
the influence of the multiplicative noise by presenting the standard deviation as a function of 
the mean peak intensities of the QC samples; metabolites with greater peak intensities to 
exhibit larger variability when repeatedly measured. The plot to the right (figure 2B.16b) 
illustrates how the application of variance stabilisation succeeded in correcting the data. 
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Median fold change normalisation was subsequently applied to equalize the variation in 
overall intensity across the samples of all batches. Median fold normalisation has been 
extensively used in NMR spectroscopy, and removes sources of systematic variation by 
setting the median of log fold changes across the peak intensities of all samples to zero 
(Bolstad et al, 2003). The underlying assumption of this form of normalisation is that the 
analyte peaks affected only by dilution will behave in the same manner across all the QC 
samples. This fold change is calculated by: 
 
Figure 2B.16 Dot plots of the standard deviation as a function of the rank of the mean of peak intensity of the 
QC samples of (a) the original data and (b) after glog variance stabilisation. The dotted red line is the running 
median of the standard deviation. In the absence of multiplicative noise this line should be horizontal.  
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Where nk
MFC is the normalisation factor calculated from the median fold change of peak 
intensity between the kth sample (xik) and the target sample (xir). Figure 2B.17 shows the 
variance box plots of the samples from each dataset after median fold normalisation. As the 
box plots align it is apparent that the samples are now directly comparable across batches.  
 
 
 
2B.3.4 Effect on acetaminophen metabolites 
To identify the effect the normalisation had on the biologically relevant acetaminophen 
metabolites the data was interrogated to find the major expected metabolites, 
acetaminophen glucuronide and acetaminophen sulphate, in addition to the parent 
compound.   
Initial multivariate assessment of the peak area normalised data for each batch was 
conducted. The analysis was the same for each batch and involved initial PCA modelling to 
reveal distribution patterns. All four batches showed discrimination between dose groups, 
Figure 2B.17 Box plot of sample variation of the normalised peak intensities, coloured by batch. Each (very 
thin) box represents the sample variation in log fold change in peak intensity. The variation has been 
normalised across the four batches, suggesting that the datasets are now directly comparable. 
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with maximal response to dosing for the high dose group between 48 and 56 hours, with the 
metabolic profiles of the recovery animals returning to ‘normal’ (i.e. similar to control animal 
profiles) by the 192 hour time point (8 days after initial dose and within 48 hours after dosing 
had ceased). The response seemed to be dose and time dependant which could indicate 
that the metabolic strain caused by acetaminophen is accumulative. Subsequent OPLS 
modelling of the high dose (800mg/kg) group against the control animals provided strong 
results for each of the batches (summarised in table 2B.1); these models were then used to 
identify the signals driving the separation. Figure 2B.16 shows the OPLS-DA scores plots for 
each batch with 2 orthogonal components. The variables with the greatest influence on the 
separation were consistent throughout the models for each of the batches and represented 
acetaminophen (m/z 152.07), acetaminophen glucuronide (m/z 328.10 or 350.08 as the 
sodium adduct), acetaminophen sulphate (m/z 232.02) and N-acetylcysteinyl-
acetaminophen (m/z 313.08). This is illustrated in figure 2B.17 which presents the S- plots of 
the OPLS-DA models for each batch. 
Batch R2 Q2 P Value (CV) 
One 0.62 0.54 3.15883e-012 
Two 0.64 0.54 3.34866e-013 
Three 0.65 0.53 1.06355e-010 
Four 0.75 0.64 1.82352e-017 
Table 2B.1 Summary of the statistics for the OPLS-DA models for each batch 
  
 Chapter Two [B] 
 
 
 120 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2B.18 Scores plot from the OPLS-DA models for each batch. There is a clear separation between the 
high dose samples (red) and the controls (blue), with a time related trend. The red arrow shows the direction 
of the time influence. The high dose samples within the pink circle are samples after dosing has ceased and 
therefore exhibit a recovery.  
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These results showed that for each batch separately, it is possible to differentiate between 
the dose groups and, crucially, the signals driving this separation are the acetaminophen 
metabolites (unlike the diclofenac example discussed in the first part of this chapter). After 
the batch correction was applied the effect this had on these signals for the drug metabolites 
was investigated. Thus the chromatographic peaks for acetaminophen, and the sulphate and 
glucuronide conjugates were evaluated. Figure 2B.20 shows the variation that these 
analytes exhibited in the QC samples even after batch correction. PCA modelling of just the 
Figure 2B.19 Composite s-plot derived from the OPLS-DA models comparing high dose (800mg/kg) and 
control animals. The S-plot shows which variables exact the greatest influence on the model, driving 
separation of the classes. Variables in the top right are more abundant in the dose group, while variables in 
the lower left are more abundant in controls. The dots highlighted in the red boxes relate to the signals from 
the parent compound acetaminophen, in the black boxes N-acetylcysteinyl-acetaminophen, acetaminophen 
glucuronide in the cyan and acetaminophen sulphate in the purple boxes respectively. While there is 
variation in the quality of the data, and the exact statists differ slightly, it is apparent that the same 
metabolites have been detected in all batches, and are in every case the signals influencing the separation 
.the most.  
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batch corrected QCs showed that the QC samples separated into two sub groups, which 
should not be happening if the samples were analytically identical. When the same 
metabolites were compared in the total dataset, including all 720 test samples, the variation 
still followed a batch-related pattern, and differentiation between dose groups was obscured 
as the batch influence was too strong, as seen in figure 2B.19.  This seems to suggest that 
the batch correction was unsuccessful in stitching the QCs from the different batches 
together, while batch effects are also still present in the test samples themselves. 
 
 
 
 
 
 
 
Figure 2B.20 Composite plot of post batch correction data. A) The PCA scores plot of the 
combined QC samples from all four batches. The QCs segregate into two sub groups, the top left 
being from batches two and four and the group to the lower right from batches one and three; if 
the batches were directly comparable there should be no clear distinction between the QCs of 
different batches. B) The overlaid chromatograms of the QC samples, with the acetaminophen, 
acetaminophen glucuronide and acetaminophen sulphate peaks highlighted. The peaks of these 
important metabolites show high variability, despite the fact that as QCs each sample should 
produce the same signal. C) Heatmap plot indicating the log fold distance for each QC sample for 
the median. Each row signifies one sample and the colour indicates how far that m/z range 
deviates from the median. There are clearly two subgroups as indicated by the mostly red 
appearance of half the QCs while the other half are mostly blue. In the situation where there is 
little variation between the samples (i.e. all samples are close to the median for the peaks, the 
heatmap would appear mostly black. 
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Need to summarize what the actaminphen study shows – lets discuss friday 
2B.4 Discussion 
Figure 2B.21 Composite plot of post batch correction data. A) The overlaid chromatograms of the 
complete data set containing all samples, coloured by batch, with the acetaminophen, acetaminophen 
glucuronide and acetaminophen sulphate peaks highlighted. The peaks of these important metabolites 
show batch dependant variability. B) Heatmap plot indicating the log fold distance for each sample from 
the median. Each row signifies one sample and the colour indicates how far that m/z range deviates from 
the median. There are clearly batch related effects. The fold change should be dose dependant if batch 
correction was successful. C) The PCA scores plot of all the combined samples from all four batches, 
coloured by batch, with the red points being the QCs. While there is some evidence of dose related 
segregation, the influence of which is shown by the blue arrow, there are significant batch related effects 
(red arrow) for the statistical modelling to be obscured.  
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In the previous study (chapter 2A) the utility of computational methodologies for the 
investigation of the metabolism of xenobiotics, in this case diclofenac, was evaluated. The 
conclusion was that in a small scale metabolism study, using a small number of animals and 
a low dose, biological effects such as diurnal variation within the samples will dominate the 
statistics, rendering detection of both metabolites of the compound under study but also 
markers of the effect of administration quite difficult. This highlights an unavoidable limitation 
of the computational approach, as detection if based on statistical power. Indeed most 
previous studies using statistical methods have been in vitro where the system is tightly 
regulated and the relative dose is higher.  
In a larger scale toxicological study, such as the COMET acetaminophen study presented 
here, both the sample size and the dose levels are much larger than used for the diclofenac 
work. In such a study, where the parent compound and its metabolites dominate the 
metabolic landscape, statistical methods were highly applicable. PCA and OPLS-DA 
modelling were able to easily distinguish between treatment groups, and were able to also 
identify the expected key metabolites and the presence of the parent drug. However, the 
large scale nature of the study necessitated the use of multiple batches for the analysis. This 
brought the severe problems of batch-to-batch variation and within- batch injection order to 
the forefront. After the determination of the extent of the batch effects, linear interpolation 
and median fold change normalisation were applied in an attempt to make the data directly 
comparable and to merge the datasets into one. However, despite mathematically reducing 
multiplicative noise and equalising variations across the batches, this approach was unable 
to correct the data to the extent where it was suitable for combined downstream analysis, as 
not only was the variation causing the batch differences not eradicated but subsequently 
there was loss of potentially biologically related differences. 
There has been much research effort directed at the development of algorithms for the 
correction of this well-known limitation of MS based metabonomics. While many studies 
have reported varying levels of success, the method attempted here was ultimately 
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unsuccessful. There are many other normalisation methods which could have been 
attempted, including more sophisticated algorithms such as those based on locally weighted 
scatter plot smoothing (LOESS) normalization (Dunn et al., 2011). However, further 
tampering with the data could result in loss of biologically important information and was 
therefore deemed an invalid approach. Ultimately the origin of the problem lies in the 
analytical instability of the mass-spectrometry platform, and as such is in essence an 
analytical issue. It is therefore possibly more sensible to attempt to ameliorate the problem at 
the source, thereby acquiring good data, rather to continue to undertake ever more 
convoluted processes for the correction of poor data.  
 
2B.5 Conclusions 
The work described here are an evaluation of the utility of computational approaches to the 
investigation of xenobiotic metabolism. The results of the previous sub chapter (2A) showed 
that in studies where the amount of administered drug is low, the effects of biological 
processes such as diurnal variation dominate the statistical analysis of the urinary 
metabotypes. Furthermore preclinical drug metabolism studies generally involved small 
samples sizes, which results in reduced statistical power. This lack of ability to detect an 
effect coupled with the obscuring of any signals originating from the drug render statistical 
approached ineffective in such situations. Indeed in the presented work the analysis failed to 
detect the major metabolites of diclofenac, despite the fact that the presence of metabolites 
was confirmed using manual scanning of the data.  
In the case of acetaminophen presented in this sub chapter (2B), however, both the dosing 
and sample size was much greater. This set up is more common in large scale toxicology 
studies. In this situation the metabolic signatures from both parent compound and the major 
metabolites are so intense that they dominate both the metabolic and the statistical 
landscape. This enabled the successful identification of the expected metabolites through 
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the computational means. In this case the application of such technologies is highly 
favourable. 
However, the analysis of large numbers of samples in turn exposes one of the fundamental 
limitations of the mass spectrometry platform. As mentioned previously in more details it is 
necessary to split the study analysis into several batches, which results in many problems 
with trying to combine data. The fluctuations within the data, mainly due to changes in 
detector sensitivity throughout the run, require complicated algorithms to adjust for. The work 
presented here ultimately was not able to adequately correct the data. This prompted the 
further work discussed in the next chapter, where development of a rapid gradient was 
performed in an attempt to reduce analysis time and therefore alleviate the need for batches.   
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Development of a Rapid Microbore UPLC-
MS Method for High-Throughput Metabolic 
Phenotyping 
Chapter Three 
Previous large scale UPLC-MS metabolic profiling work has been hindered by the 
analytical stability of the MS platform. A rapid gradient microbore UPLC-MS 
method was developed to provide a high-throughput solution for metabolic 
phenotyping of large sample collections and employed for the analysis of urine. 
Comparison showed that traditional UPLC-MS and rapid gradient approaches 
provided peak capacities of 150 and 50 respectively, with a reduction of 
detected features from 19,000 to 6000 with similar levels of repeatability seen 
for both methods.  Despite the reduced peak capacity and the reduction in ions 
detected, the fast gradient method was able to achieve similar levels of group 
discrimination as conventional UPLC-MS when applied to two different sets of 
rodent urine samples. 
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SUMMARY: 
 
 A major limitation of the current practice in UPLC-MS metabolic profiling 
studies is the inherent lack of analytical stability of the platform. 
 Previous work detailed in chapter 2 identified the difficulties in running studies 
in batches, and the inability of satisfactory batch correction to be achieved.  
  A rapid gradient microbore UPLC-MS method has been developed to provide 
a high-throughput analytical platform for metabolic phenotyping of large scale 
studies. 
 The approach was based on miniaturizing the conventional reversed-phase 
UPLC-MS method for urinary profiling from a 2.1 x 100 mm column to a 1 x 50 
mm column and reducing run time from 15 min to 2.5 min per sample. 
 Comparison of convention and microbore methods showed that the rapid 
gradient approach resulted in a reduction of detected features from 19,000 to 
6000 with similar levels of repeatability. 
 However, despite the reduced peak capacity and the reduction in ions 
detected, the fast gradient method was able to achieve similar levels of group 
discrimination as conventional UPLC-MS when applied to both the previously 
discussed acetaminophen cohort, and a 2-bromophenol study in the rat. 
 In conclusion, the reduced analysis time in addition to the retained sensitivity, 
indicate that the proposed methodology is highly suitable for high-throughput 
metabonomic analysis of complex mixtures such as urine.   
 
  
 
 Chapter Three 
 
 
 135 
 
3.1 Introduction 
Metabonomics as a field of investigative science has progressed rapidly since its inception. 
As alluded to in chapter one, metabolic phenotyping is generally performed in either a 
targeted manner, when a marker of interest is already known, or in an exploratory, 
hypothesis free, untargeted approach where the metabolic profiles of two groups of interest 
(such as a traditional case-control) are compared. Untargeted metabolic phenotyping has 
been frequently applied in studies of toxicology and epidemiology, and in the case of the 
latter are therefore being applied to increasingly larger cohorts, with thousands of samples. 
The analytical techniques employed, as discussed previously are mainly 1H NMR 
spectroscopy and LC-MS, with ultra-performance liquid chromatography-mass spectrometry 
(UPLC-MS) having become the most used hyphenated mass spectrometry technique (Want 
et al, 2010). 
One of the key goals of untargeted profiling is to have global metabolite coverage coupled 
with high resolution and sensitivity. However, metabolites from biological samples cover a 
wide range of polarities, rendering isocratic chromatographic solvent systems (where the 
composition of the mobile phase remains constant throughout the run) unsuitable for 
metabolic profiling. A gradient system is therefore used, where the eluotropic strength of the 
solvent is increased as the analysis proceeds, allowing for compounds of different polarities 
to elute at different times. The chromatographic resolution of a UPLC run is therefore 
somewhat dependent on the solvent gradient used; in general the longer the gradient the 
higher the resolution with more ions detected as, during short runs, ion suppression and co-
elution become more apparent. While some studies which attempt complete metabolome 
coverage have used gradient lengths of over 30 minutes (Guy et al., 2008) there is a 
balance to be considered between resolution and throughput. Generally a widely accepted 
compromise seems to be a chromatographic run time of around 10 to 12 minutes with a 
short re-equilibration period of two to three minutes, providing good metabolite separation 
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combined with moderate throughput, with approximately 100 samples possible to be 
analysed per day. 
In any metabotyping study a major consideration is the analytical stability of the mass 
spectrometer. Generally during a mass spec run there is, as was shown in the studies 
reported in Chapter 2, a decrease in sensitivity as contaminants build up on the ESI source, 
and after a certain point the data retrieved will become unreliable, and difficult to compare to 
previous data. At this point the column, the mass spectrometer inlet and the ESI source 
should be carefully cleaned to ensure continued good performance. The level and rate of 
contamination depend heavily on the type of sample used, as some biofluids, such as 
serum, which are highly concentrated, can cause significant loss of performance if injected 
undiluted, and without the prior removal of proteins. For most conventional UPLC-MS 
experiments, using a 15 min run time/sample, generally approximately 100-250 rodent urine 
samples may be analysed in a single run, though this number falls to ca. 100-120 for serum 
samples (Michopoulos et al., 2009). Nonetheless for any experimental set up there will be a 
‘hard’ limit after which continued analysis is impractical and must be interrupted for source 
cleaning. Run length and therefore sample number limitations persist and constitute an 
existential problem for the continuation of LC-MS based metabonomic experiments for large 
sample sets. Various techniques have been previously employed to attempt to overcome the 
problem. The application of nano-electrospray ionization (NESI) has indeed considerably 
extended the usability of the typical MS setup, as due to the reduced volume of sample 
injected less material is introduced into the mass spectrometer and therefore less 
contaminants build up on the source (Karas et al., 2000). Another approach is to attempt to 
reduce analysis times by completely eliminating the chromatography and directly injecting 
samples into the mass spectrometer, a process known as direct infusion mass spectrometry 
(DIMS) (Madalinski et al. 2008), and the above two techniques have also been implemented 
together in nano-electrospray DIMS. The benefits of such methodology include an obvious 
reduction in analysis time, small sample volume consumption (Draper et al., 2013) and 
claimed comparable prediction and discrimination capabilities to traditional liquid 
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chromatography-mass spectrometry (Lin et al., 2010). However, these approaches can still 
take several minutes per sample, and due to the lack of chromatographic separation suffer 
from susceptibility to significant ion suppression and an inability to distinguish between 
isomeric and isobaric compounds (Giavalisco et al., 2009). Furthermore due to the loss of 
the time dimension provided by a chromatographic separation the acquired data is formed 
form a single composite and complex spectrum for each sample, with only mass to charge 
ratio and intensity values, which makes metabolite identification close to impossible (Sumner 
et al., 2007). 
A middle ground between the current ‘traditional’ UPLC-MS profiling methods and direct 
infusion would be to use shorter chromatographic analysis times, which alleviate some of the 
disadvantages of DIMS by retaining the chromatographic separation while accepting the loss 
of resolution and fewer ions detected. A previous study by Plumb et al. (2005) has 
introduced this concept, and has already showed the utility of such an approach.  In their 
experiment the authors compared a shortened run time of 1.5 minutes with a traditional 10 
minute gradient and were able to observe the same class distinction despite the decreased 
number of features detected.    
There is ultimately a need for higher sample throughput within the field of metabolic profiling. 
In this chapter, the utility of runs with shorter chromatographic analysis times is evaluated as 
a means of eliminating the need for several batches has been evaluated. In addition the 
previous methodology was also extended to include microbore liquid chromatography, using 
a 1mm ID column which has recently been shown to enhance information retention with 
increased sensitivity but also reduced solvent usage (Gray et al., 2015 ). This combination of 
microbore UPLC-MS with a rapid gradient was applied to the both the acetaminophen study 
described in the previous chapter and to a second COMET study exploring the metabolism 
and toxicity of 2-bromophenol in the rat. The resulting data were compared with conventional 
UPLC-MS for both compounds. 
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3.2 Study Details and Sample Preparation 
3.2.1 Acute 2-Bromophenol Study 
Urine samples were collected from three groups of male Sprague-Dawley rats (10 
rats/group) administered a single intraperitoneal dose of 2-bromophenol at either 100 mg/kg 
or 200 mg/kg in corn oil. A control group was treated with corn oil alone.  Rats were housed 
in metabolic cages to enable the collection of urine and samples were taken at -16, 0, 8, 24, 
48, 72, 96, 120, 144 and 168 hours after administration. The urine samples were stored at -
40 °C prior to analysis. 
 
A 120 µL aliquot of urine was mixed with 120 µL water to dilute the salt concentration before 
protein removal with acetonitrile (1:3 v/v).  These samples were vortex mixed and left at -
20 °C overnight before centrifugation for 5 min at 15,000 g at 4 °C.  For analysis, 50 µL was 
removed and added to 250 µL water in 350 µL 96-well plates.  A pooled quality control (QC) 
sample was prepared by combining 100 µL of each sample and diluting 1:4 with water.  The 
96-well plates were stored at -20 °C until analysis and the plates were centrifuged again for 
5 min at 700 g before being placed into the autosampler at 4 °C. The plate from this study 
was analysed five times, as a replicate, to assess the robustness of the approach.  
 
3.2.2 Chronic Acetaminophen Study 
Urine samples were collected and stored from four groups of male Sprague-Dawley (10 
rats/group) rats dosed orally with acetaminophen (APAP) as described in Chapter 2 (pages 
98 to 99)  
For the analyses described here a 20 µL aliquot of each urine sample was mixed with 60 µL 
methanol in order to precipitate proteins. The samples were vortex mixed and left at -20 °C 
overnight before centrifugation for 5 min at 15,000 g at 4 °C.  For analysis, 20 µL was 
removed and added to 180 µL water in 250 µL 384-well plates.  A pooled quality control 
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(QC) sample, used for system conditioning and assessment of analytical performance was 
prepared by combining 5 µL of each sample and diluting 1:9 with water.  The well plates 
were centrifuged again for 5 min at 700 g before being placed into the autosampler at 4 °C.   
 
3.2.3 Liquid Chromatography  
Liquid chromatographic analysis was performed on an Acquity I-class UPLC system, 
equipped with a binary solvent manager, sample manager and column heater (Waters 
Corporation, Milford, MA, USA), interfaced with a Synapt G2-S HDMS mass spectrometer 
(Waters Corporation, Manchester, UK).  The chromatographic separations were performed 
on a HSS T3 1.8 µm stationary phase of either 2.1 x 100 mm for the conventional analysis or 
1 x 50 mm for the fast, microscale analysis.  The chromatographic mobile phase was 
composed of 0.1 % formic acid in water (A) and 0.1 % formic acid in acetonitrile (B).  The 
column temperature was maintained at 40 °C and linear gradient elution was performed at 
either 0.5 mL/min for the 2.1 x 100 mm column or 0.4 mL/min for the 1 x 50 mm column.  For 
the conventional method the starting composition was 1 % B, held for 1.0 min before 
increasing to 15 % at 3.0 min, 50 % at 6.0 min, 95 % at 9.0 min for a 1.0 min wash and 
returning to 1 % B for a 2 min re-equilibration step (total cycle time 12 min).  A 2 µL injection 
of sample was performed using the flow through needle.  For the fast, microscale method 
the starting composition was 1 % B, held for 0.14 min before increasing to 15 % at 0.42 min, 
50 % at 0.83 min, 95 % at 1.25 min for a 0.25 min wash and returning to 1 % B for a 1 min 
re-equilibration step (a total cycle time of 2.5 min).  A 1 µL (2-bromophenol study) or 0.2 µL 
(acetaminophen study) injection of sample was performed using the flow through needle.  In 
both cases the purge solvent was 95:5 (v/v) H2O/CH3CN and sample manager wash was 
CH3OH.  For each study, prior to the analysis of the samples themselves 50 consecutive 
injections (2 µL volume) of the pooled samples were made at the start of the 
chromatographic run to ‘condition’ the column to ensure that the analytical system was fully 
equilibrated.  The QC sample was injected at the beginning of the analytical run and every 
10 injections thereafter to monitor instrument stability. 
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For use of 1 mm I.D. columns, minor system modifications were necessary to reduce peak 
dispersion (Gray et al., 2015).  For the microbore separations the standard outlet tubing i.d. 
(0.004”) was reduced to 0.0025” of minimum length and the ESI stainless steel capillary (125 
µm i.d.) was replaced with a narrow bore variant (50 µm i.d.). 
 
3.2.4 Mass Spectrometry  
Mass spectrometry for metabolic profiling was performed on a Synapt G2-S HDMS accurate 
mass instrument with electrospray ionization (ESI) operated in positive (ESI+) ion mode and 
a Xevo G2 operated in the same way.  For the Synapt G2-S the capillary voltage was 1.0 kV, 
cone voltage was 25 V, source temperature was set at 120 °C with a cone gas (nitrogen) 
flow rate of 50 L/h, a desolvation gas temperature of 600 °C and a nebulization gas 
(nitrogen) flow of 1000 L/h.  The Synapt G2-S was operated in resolution (V optics) mode 
whereas the Xevo G2 was operated in sensitivity (V optics) mode and both detectors were 
set to acquire data over the m/z range 50-1200 with a scan time of 0.1 s for the conventional 
method or 0.05 s for the fast method .  All mass spectral data were collected in centroid 
mode using the MSe data acquisition21 function to obtain fragmentation data simultaneously.  
In function one a low collision energy (4 eV) was used and in the second function a high 
collision energy (ramp 15-45 eV) was used for fragmentation.  For mass accuracy, leucine 
enkephalin (MW = 555.62) was used as a lock mass at a concentration of 200 pg/µL (in 
50:50 CH3CN/H2O, 0.1 % formic acid) infused at a flow rate of 20 µL/min via a lock spray 
interface.  Lockmass scans were collected every 15 s and averaged over 3 scans to perform 
mass correction.  The instrument was calibrated before analysis with 0.5 mM sodium 
formate solution.  The data were collected using MassLynx V 4.1 software (Waters 
Corporation, Manchester, UK). 
 
3.2.5 Data Analysis 
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The raw data were processed by Progenesis QI data analysis software (Non-Linear 
Dynamics, Newcastle, UK) for peak picking, alignment and normalization, to produce peak 
intensities for retention time (RT) and m/z data pairs.  Further statistical analysis was 
performed on the resulting normalized peak intensities using SIMCA P 13.0.2 (Umetrics, 
Umea, Sweden).   
3.3 Results and Discussion 
3.3.1 2-Bromophenol 
 a. Quality Control 
As discussed in the introduction chapter, LC-MS techniques can be subject to lengthy 
sample preparation and also fluctuation of instrumental performance leading to acquiring 
unreliable data. The data for acetaminophen presented in Chapter 2 has highlighted that 
there is period of analytical instability at the start of every run, characterized by initial 
changes in chromatographic retention time and both short and longer term effects on signal 
intensity which, in extreme cases, can lead to unusable data. This is a common observation 
and to overcome this issue the use of conditioning injections, repeated injections of matrix, 
to modify the system and therefore stabilize retention times and signal intensities prior to the 
start of an analysis, has become commonplace (Gika et al., 2007).  Other studies have 
shown that an increase in the volume of the conditioning injections coupled with a rapid 
gradient is an efficient way of decreasing the time required to achieve instrumental stability 
and increased reproducibility (Michopoulos et al., 2009). A similar approach was adopted 
here as the use of such a rapid gradient was well suited to the use of a large number of 
conditioning injections without resulting in a significant increase in the required analysis time. 
In this experiment 50 conditioning injections were performed prior to the start of the sample 
analysis, which required less than two hours of analysis time. Furthermore to enhance 
conditioning the injection volume was doubled to 2 µL to give the equivalent of 100 
conditioning QC injections.   
As well as their use for conditioning the pooled quality control samples were also used to 
monitor the performance of the method throughout the run, and in order to do this a QC 
 Chapter Three 
 
 
 142 
sample was analysed at the start and then every ten sample injections thereafter. Initial 
visual inspection of the QC chromatograms showed that there was good consistency 
throughout the whole run, with the chromatograms of the QC injections overlaying perfectly. 
Figure 3.1 depicts the last QC injection from each of the five replicate runs a good indication 
of the instrumental stability throughout the approximately 500 injections made over the 
course of the analysis. 
 
 
 
 
 
The stability of the approach was mirrored in the initial PCA scores plots used to scrutinize 
analytical drift. Figure 3.2 shows the initial un-filtered data for the negative electrospray 
ionisation (ESI) runs; the red points in the scores plot represent the QC samples. In the 
scores plot we can see that the QC samples cluster together in the center of statistical 
space, with some evidence for a small amount of time-related drift, the direction of which 
seems to proceed along the first component. This seems to indicate that there was a slight 
deviation in analytical stability as the experiment progressed, however since the deviation 
was not significant in the overall variation within the data, and as the sample data were not 
greatly affected, the data were accepted as suitable for further evaluation. 
Figure 3.1 Overlaid chromatograms of the last QC injection of each of the 5 runs. The 
chromatograms align well suggesting that there was a high level of stability throughout the analysis. 
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The reproducibility of the methodology is further demonstrated by the consistency of the 
acquired data between the replicate runs, as shown in figures 3.3 and 3.4. Figure 3.3 which 
depict the scale adjusted variation exhibited by the five replicates for each of a randomly 
selected subset of variables (detected features) shown as a line graph. As the variation does 
not intersect the first standard deviation threshold it can be surmised that there was little 
variation between replicate analyses during the run. Figure 3.4 is a PCA scores plot showing 
the statistical positioning of a random subset of control samples from the urine analysis. As 
each one of the five replicates for each sample clusters closely together, this adds further 
confidence to the repeatability of the experiment. 
 
Figure 3.2. PCA scores plot for the un-filtered data for the negative electrospray ionization RAMMP 
run. The red points in the scores plot represent the QC samples while the gray points indicate the 
samples. The QCs cluster in the centre of statistical space, with a slight time dependent drift along 
the first component. 
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Figure 3.4. PCA scores plot depicting the five replicates of a random subset of control samples from 
the 2-bromophenol urine rapid gradient study, together with Quality control samples (yellow, in the 
centre). The clustering of each of the replicates within statistical space suggests high levels of 
analytical reproducibility.  
Figure 3.3. Contribution plot showing the deviation of the QC samples for each ion from the 
statistical mean of the principal component analysis expressed in standard deviations. The plot 
displays the vector vk(xik - avgik) for each variable as a bar, the orientation of which indicates the 
direction of  the deviation. As none of the bars intersect the standard deviation threshold we can be 
confident in the analytical conditions were stable throughout the run. 
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Another method of determining data reliability is through the use of the coefficient of 
variance. By computing this value for the peak height for each of the features detected of in 
the QC samples (which should contain all compounds/features present in the sample set as 
they are pooled samples) throughout the analysis should give an indication of how robust 
detection of that particular metabolite/feature is within the analysis, and therefore how 
confident we can be of that metabolite as a biomarker. The coefficient of variation (CV) 
expressed as a percentage is defined as: 
 
Where is the standard deviation and is the expected return, in this case the mean. There 
is no particular value which would constitute a threshold for acceptance, as the criteria for 
acceptance within hypothesis free metabolome mapping have yet to be standardized, 
however values of a CV filter ranging between 15% and 30% are generally used depending 
on how rigorous an analysis needs to be. Table 3.1 shows the number and percentage of 
ions passing the various cut off CV thresholds for the negative ESI subset study. 
 
Negative  
<15% 
CV less than 
<20% 
 
<30% 
Number of ions 
Percentage 
3059 
55.2% 
3703 
67.2% 
5517 
82% 
Table 3.1 Table showing the number and percentage of ions satisfying the various CV 
threshold levels. 
 
Generally ion intensity stability is greater when the peak intensity is greater, therefore low 
intensity peaks or those suffering from ion suppression will have higher levels of variation. 
As the rapid microbore methodology has a steeper and faster gradient, there is an increased 
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likelihood of co-elution of metabolites in addition to overlap and lower resolution between 
peaks, which should result in more pronounced ion suppression effects. Thus it was 
expected that there would be smaller percentage of ions at each CV cut off in this fast 
analysis methodology than in conventional UPLC-MS. In figure 3.5 the percentage of ions 
passing each CV threshold is compared using a bar chart. Examination of the figure shows 
that there is a small reduction in repeatability, with 89% of total features detected by 
traditional 2.1mm ID UPLC-MS passing the 30% CV threshold as opposed to 82% from the 
rapid analysis method, and similarly with the lower CV criteria. However, this reduction in 
stability is small compared to the massive throughput gain achieved.  
 
 
 
 
 
 b. Comparison with traditional 2.1mm UPLC-MS profiling method 
As we have previously alluded to, the reduction of chromatographic separation time is 
expected to result in the loss of some detected features, and therefore a lower metabolic 
Figure 3.5. Bar chart comparing the percentage of ions passing the acceptance criteria for each of 
the cut off levels for both the 2.1 ID UPLC-MS and the rapid gradient method. There is a consistent 
increase of variability in the rapid profiling method (less ions pass the cut off) throughout all the cut 
off thresholds.  
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coverage scope. To ascertain the level of information loss, the a subset of the 2-
bromophenol sample set was also analysed with traditional UPLC-MS methodology with a 
2.1mm ID column and a gradient time of 12 minutes. Initial comparison of the negative ESI 
data showed that there was indeed a lower number of ions detected, with the rapid analysis 
only detecting 6,188 features, whereas the conventional mass spectrometry detected 18, 
823; a nominally significant loss. The positive ESI mode runs showed a similar loss of 
information, with 6,129 ions detected with the rapid method, compared to the 17,816 
features detected by traditional mass spectrometry. Note that comparisons of the full 
negative and positive ESI 2-bromophenol datasets for the conventional UPLC-MS method 
will be included in the main 2-bromophenol metabolism chapter, Chapter 4. 
 
However, despite the loss of detected ions, when PCA analysis was performed on the 
negative ESI data acquired for the subset of samples a similar degree of group separation 
and statistical prediction was observed between the rapid microbore analysis and the 
conventional analysis. Figure 3.5 shows the comparison between the PCA scores plots of 
the conventional UPLC-MS method and the rapid gradient method for the initial pilot study, 
while figure 3.6 shows the sample comparison for the full R16 2-bromophenol data sets, in 
negative ESI. 
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Figure 3.6. PCA scores plot depicting the same sub-set of rat urine samples taken from the R16 2-
bromophenol toxicity study analysed either via the conventional 2.1mm ID method A) or the rapid 
gradient 1 mm ID. method B). Similar trends are apparent in both PCA models, with similar data 
distribution along statistical space, despite the rapid gradient data containing less than half the 
number of variables. 
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In both figures almost identical trends for the data can be observed within the model, giving 
similar levels of discrimination between the test groups. It can therefore be concluded that, 
despite the lower number of variables within the model, the variables contributing most to the 
separation are still being observed. This allows similar conclusions to be drawn from either 
methodology with a similar patterns in the distribution of the three groups of animals (control, 
low dose (100 mg/kg) and high dose (200 mg/kg)) and the quality control (QC) observed. 
Figure 3.7. PCA scores plot depicting the complete set of rat urine samples taken from the R16 2-
bromophenol toxicity study analysed either via the conventional 2.1mm ID method a) or the rapid 
gradient 1 mm ID. method b) in negative ionisation. Similar trends are apparent in both PCA 
models, with similar data distribution along statistical space, despite the rapid analysis method data 
containing less than half the number of variables. Note that there seems to be a reduced time 
related drift (as shown by the QCs) in the rapid gradient method data indicating a further potential 
advantage of the methodology. 
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The QCs in all analyses cluster around the center of the scores plots, indicating a good level 
of analytical consistency. However, in figure 3.6 we can see that there is a reduced 
contribution in the fast method of the time related drift observed for the conventional 2.1 ID 
UPLC-MS method. This should be self-evident seeing as the total time of analysis in the fast 
method is greatly reduced, but would also suggest that the rapid analysis approach could be 
less susceptible to time dependent degradation of instrumental sensitivity. 
 
 c. Metabolite detection 
In the previous chapter, the potential for statistical group discrimination to occur due to the 
influence of variables not related to the administered drug has been explored. As such, while 
our fast method had produced similar statistical distributions between dose groups in the 
PCA models, it is necessary to investigate whether these results are driven by the same 
metabolic signals. It is, for example, possible that the rapid anlaysis methodology had an 
inherent bias towards certain ions, meaning that the nature of the metabolites highlighted as 
markers would differ. To ascertain whether this was the case, orthogonal partial least square 
regression models were constructed, for both conventional and rapid gradient analysis data 
sets. By utilizing the model residuals it is possible to determine the contribution that each 
variable makes towards the discrimination. The OPLS S-plot shown (from a model 
comparing the high dose with the control group) below highlights the fact that the major 
contributing ions are the same in both cases, lending further support for the equivalence of 
the conventional and rapid gradient methodology. It must be noted, that the predictive 
residual value (p[1]) of the fast 1mm ID method were slightly lower than conventional LC-
MS. However, while producing a slightly less predictive model, the same ions were 
identified, and the individual p-values were still significant. 
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 3.3.2 Acetaminophen 
 a. Quality control 
The increasingly large cohorts being employed in metabonomic studies have shown how 
analytical time for LC-MS methods can be very long, and can easily reach several days if not 
weeks. We have already discussed the inherent limitations of the analytical platform, and 
how there is a critical threshold of instrument stability. The interruption of runs to allow for 
cleaning and other maintenance procedures inevitably requires the separation of 
experimental samples into batches. However, the LC-MS platform is characteristically 
unstable, and is susceptible to time-related analytical drift and ion contamination. This is 
exacerbated by the process of source cleaning and the replacement of eluent with new 
batches, which have small micro- variations in composition. These can culminate in 
Figure 3.8. OPLS-DA S plot of models constructed from data of samples taken from the R16 2-
bromophenol toxicity study analysed either via the conventional 2.1mm ID method A) or the rapid 
gradient 1 mm ID method B). The same discriminating variables are identified by both methods, 
highlighted in the zoomed in regions. 
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significant fluctuations in retention times, mass accuracy and signal intensity. The data 
obtained for each batch, while valid within itself as any bias is uniform, cannot be integrated 
or compared with the data from other batches.  
In the previous chapter an attempt was made to analyse an acetaminophen toxicology study 
in the rat where urine samples had been collected over seven days (20 time points) from 40 
rats, in 3 dose and one control group, was described. This study had resulted in 680 
samples which were randomized and divided into 4 batches. The four batches were 
analysed using the convention UPLC-MS method and run by traditional LC-MS on 
consecutive days, interspaced by source cleaning and instrument maintenance. The 
resultant data was highly inconsistent across batches and was characterized by large 
variations in instrument response within and between runs, as well as some differences in 
retention times. Attempts to use statistical and computational methods to compensate for the 
observed batch effects using the QCs as a point of normalization were made, but met with 
limited success, although other groups have reported greater success using this approach 
(e.g., Kirwan et al., 2013). The extent of the drift is illustrated in the PCA scores plots for QC 
quality control (figure 3.9).  
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One of the aims of the application of the fast 1mm ID column method was to evaluate if the 
increase in sample throughput could eliminate the need for batches in LC-MS experiments. 
Indeed the 680 samples of this acetaminophen study were prepared in two 385 micro-well 
plates, and were analyzed as a single batch, with a run time for each sample of 2.5 minutes, 
resulting in a total analysis time of just over 28 hours, a fraction of the time required for 
conventional methods. The same column matrix conditioning strategy was employed as in 
the 2-bromophenol experiment. Initial visual inspection of the QC chromatograms showed 
that there was a consistency throughout the whole run, with the chromatograms of the QC 
injections overlaying perfectly. Figure 3.10 depicts every 5th QC injection spaced 
approximately 90 samples apart throughout the run, a good indication of the instrumental 
stability throughout the approximately 700 injections made over the course of the analysis. 
The chromatograms overlay almost perfectly, suggesting that the analytical conditions were 
Figure 3.9. PCA scores plots showing the initial unfiltered data colored by dose group for each 
batch (a) batch one, (b) batch two, (c) batch three and (d) batch four. This data is from conventional 
2.1mm ID LC-MS. The black points are the QC samples for that particular batch. It can be seen that 
there was significant time-related drift in batches one and three, with batch four being more 
acceptable and batch two being the most consistent. However, computational methods were not 
able to correct for batch differences even between the two most consistent batches, two and four.  
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stable throughout the run. The final QC does, however, show some deviation in one of the 
major peaks, however, potentially indicating the limit of stability of the method.  
 
 
 
 
 
 
 
 
Inspection of the unfiltered PCA scores plot for the dataset (figure 3.11) also revealed that 
the QC samples exhibited low levels of variation, and grouped together tightly in the center 
of the model hyperspace. Generally the QC samples suggested a high level of analytical 
quality and consistency with our employed methods. It is possible that the rigorous column 
conditioning has significantly reduced analytical variability, and is therefore highly 
recommended for any rapid gradient liquid chromatography method. 
 
 
 
Figure 3.10. Overlaid chromatograms of ten selected QCs, spaced approximately 90 injections 
apart. The chromatographic peaks show remarkable consistency in retention times, suggesting low 
levels of drift. The final QC (injection 766) does show a slight deviation in the retention of the major 
peak at approximately 0.55mins, however this drift is small and seems to not have affected the rest 
of the run. 
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Initial inspection of the PCA scores plots revealed that the data showed clear separation 
between the dose groups, with an obvious correlation between response and dose level. 
Maximum response for all groups was at 5 to 6 days post initial dose. A subset of animals in 
the initial study were sacrificed early, while another subset were retained for 7 days after 
dosing had ceased to identify any biomarkers of recovery. Indeed the metabolic profiles of 
the recovery animals gradually returned to normal and, by the end of the study, seemed to 
be very similar to control samples and pre dose status.  Figure 3.12 illustrates the good 
statistical separation achieved by PCA modeling of the data. These PCA scores plots match 
the trends seen within the conventional LC-MS data. 
 
 
 
 
 
 
 
With the reduction in chromatographic separation time, a loss of resolution is expected with 
the rapid analysis approach. The major metabolites of acetaminophen have already been 
discussed in chapter 2, but will be briefly summarized again. The majority of acetaminophen 
is metabolized by phase-II conjugative reactions, with acetaminophen-glucuronide and 
Figure 3.11 PCA scores plot for the positive electrospray ionization rapid analysis run of the 
acetaminophen study with all time points included, colored according to dose level. Maximal 
response is in the high dose (800 mg/kg) group at 5 days post first dose. The metabolic profiles of 
animals in the recovery group return to metabolic equilibrium after the end of dosing.  
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acetaminophen-sulphate the two most prevalent metabolites. Hepatic glutathione 
conjugation of other reactive intermediates is also apparent, and the products of these 
conjugations are further metabolized downstream into N-acetyl-L-cysteinyl- and 
cysteinylacetaminophen conjugates (Nelson, 1982). For the employed methodology to be 
robust enough to be routinely used in metabolic and toxicological studies, the above well-
known metabolites of acetaminophen should be detected in addition to the drug itself. 
Extraction of the known molecular masses from the chromatograms revealed that the parent 
compound (m/z 152.0712), and major metabolites APAP-glucuronide (m/z 328.1032), 
APAP-sulfate (m/z 232.0280) and APAP-N-acetylcysteinyl (m/z 313.0858) were all well 
resolved. The figure below shows the peaks for acetaminophen and the major sulphate and 
glucuronide metabolites detected along with their corresponding mass spectra (figure 3.12). 
 
  
 
 
 
 
 
Figure 3.12 The chromatographic peaks (bottom center) and related mass spectra of the major 
metabolites of acetaminophen detected by use of the HSS T3 1 × 50 mm 1.8 μm column. The data 
are from an animal in the high dose (800 mg/kg) group. The major metabolites identified were 
APAP glucuronide and APAP sulfate. APAP glucuronide was present mostly as the sodium adduct, 
as seen in the mass spectrum (m/z 350.08). Parent compound was detected, and contributed the 
common ion (m/z 152.07) observed in all metabolites (circled red). 
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Construction of OPLS models comparing high dose and control groups at 24 hours post 
initial dose time point provided very strong models (R2 = 0.89, Q2 = 0.63), which were used 
to identify the signals driving the separation, and determine if these signals were 
acetaminophen-related metabolites. The S-plot produced from the model loadings shows 
that the most significant ions influencing the group discrimination are indeed the major 
acetaminophen metabolites APAP-glucuronide, APAP-sulfate and APAP-NAC, in 
combination with the presence of the parent compound. This is highlighted in the below 
figure 3.13. It is interesting to note that the statistics are dominated by the major metabolites, 
and while there may be effects on the endogenous metabolism it is difficult to disentangle 
those signals from the background noise. This relates to the earlier diclofenac study (chapter 
2A) where, in contrast, the endogenous metabolites effectively masked any drug related 
products. 
 
 
 
 
 
 
 
 
Figure 3.13 The S-plot of the loadings from the OPLS-DA model comparing high dose (800 mg/kg) 
and control groups at 24 hours post first dose. The zoomed in region at the top is to illustrate the 
important variables. The ions relate to the expected major acetaminophen metabolites and the 
parent compound. 
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3.4 Conclusions 
Metabonomics is now an established field of scientific research and as such studies will 
continue to grow in scale and scope, with large scale biomarker discovery, patient 
stratification and epidemiological applications. Methodologies employed within metabolic 
fingerprinting will need to evolve to be able to cope with the increased sample numbers and 
the need for higher throughput. As one of the primary analytical technologies, the 
reproducibility, affordability and efficiency of the UPLC-MS platform must also be addressed.  
The novel approach described here using a rapid chromatographic gradient and a lower ID 
separation column, combined with fast scanning high resolution accurate mass 
spectrometry, attempts to address some of the future needs within metabolic profiling. The 
rapid method achieved analysis times comparable to direct infusion, without the loss of the 
chromatographic dimension, allowing for separation of analytes with the same molecular 
weight, and with reduced risk of ion suppression effects. Indeed, without the separation 
provided by the rapid gradient chromatography it would not have been possible to relate the 
key common ion 152.07 to the presence of unchanged acetaminophen in the samples using 
DIMS. The use of smaller diameter UPLC columns has the added benefit of requiring lower 
volumes of both sample and eluents, which both lowers environmental impact but also 
enables comprehensive analysis even with limited sample availability.  
The most obvious limitation of the approach is the reduction of resolution and incomplete 
metabolome coverage, which could result in the loss of critical endogenous metabolic 
signatures, missing potential biomarkers or other more subtle effects. However, this 
approach is a good for quick interrogation of the samples, and is sensitive enough to detect 
stratification within the cohort. This should give an indication of the suitability of the study 
and could pave the way for further, more in depth, possibly targeted, profiling. Nonetheless 
the key consideration is the ability for the rapid analysis approach to reduce analysis time to 
the extent that batch analysis is no longer necessary, which precludes the need for copious 
data manipulation for batch effect correction. In conclusion the results of the study presented 
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here suggest the rapid analysis methodology is well suited to the analysis of large numbers 
of urine samples. This approach is expected to be implemented in future work. 
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Investigation of the metabolism and 
potential nephrotoxicity of 2-
Bromophenol after a single dose 
Chapter Four 
Previous work by Lau et al. had identified 2-bromophenol, a phenolic 
metabolite of bromobenzene, as a potential nephrotoxin. Due to these findings 
2-bromophenol was chosen as one of the test compounds of the COMET 
studies. Here continuing on from those studies, a repeat of the original NMR 
experiments was performed, with further information UPLC-MS data acquired 
from the same samples. Application of the previously described rapid 
microbore methodology was also performed. Data analysis identified 2-
bromophenol glucuronide and 2-bromophenol sulphate as the major 
metabolites of 2-bromophenol. However no toxic metabolites were detected 
and after analysis of the histopathology and clinical chemistry, there is little 
evidence for any toxic action of 2-bromophenol after a single dose. 
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SUMMARY: 
 
 2-bromophenol, a metabolite of the hepato- and nephrotoxic compound 
bromobenzene, is a suspected nephrotoxin. 
 30 Sprague Dawley rats were split into three equal groups and were 
administered a single IP dose of either vehicle (corn oil), 100mg/kg or 
200mg/kg of 2-bromophenol. Urine was collected at regular intervals, and 
after seven days the animals were sacrificed and kidneys retrieved.  
  Urine samples were analysed by 1H NMR spectroscopy and UPLC-MS to 
determine both the effects of 2-bromophenol on urinary endogenous 
metabolite profile and the metabolic fate of the compound itself. 
 Chemometric analysis showed that the main discriminators between dosed 
and control animals were associated with metabolites of 2-bromophenol. Little 
to no evidence of toxicity was seen in terms of altered endogenous metabolite 
profiles, histophathology or clinical chemistry. 
  A number of 2-bromophenol metabolites were identified in urine, including 
with 2-bromophenol glucuronide and 2-bromophenol sulphate but there was 
no evidence for the production of reactive metabolites. 
 The conclusion from this investigation was that 2-bromophenol caused little or 
no nephrotoxicity at the dose administered after a single administration of 
either 100 or 200 mg/kg of 2-bromophenol to the rat. 
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4.1 Introduction 
As discussed in Chapter 1, the COMET project resulted in 147 studies, including many on 
toxins, being performed on rodents (rats and mice) with the specific aim of generating 
diagnostic metabolic profiles which might further illuminate the various mechanisms of the 
toxicity exhibited by the dosed compounds (Lindon et al., 2005). One of the original 
compounds selected for the COMET program is 2-Bromophenol (COMET study R16). 2-
bromphenol is a metabolite of bromobenzene, which, as described below, is a well-known 
hepato- and nephrotoxin.  
4.1.1 Toxicity and metabolism of bromobenzene 
Halogenated hydrocarbons have long been considered to be potent kidney toxins, and 
bromobenzene has been one of the compounds of choice for the investigation of the 
mechanism(s) of toxicity (Rush, et al., 1984). Administration of bromobenzene to rodents 
has been shown to induce proximal renal tubule cell necrosis in addition to covalent binding 
of bromobenzene and its metabolites to renal cell proteins (Read, 1973). Lau et al. in a 
series of studies (1984a; 1984b) have investigated the mechanisms responsible for the 
toxicity and the metabolism of bromobenzene and these are thought to have been well 
characterised by these authors. Cytochrome P450 monooxygenase (CYP) mediated 
biotransformation of bromobenzene occurs in the liver; CYP enzymes are known to 
metabolize some chemicals to highly reactive forms, such as epoxides, and two such 
products of the metabolism of bromobenzene have been observed: bromobenzene 2,3 
epoxide and bromobenzene 3,4 epoxide (Madhu et al., 1992). Bromobenzene 2,3 epoxide is 
relatively stable, although it has been shown to bind to only infrequently to blood proteins 
such as haemoglobin, and is then further metabolised into 2,3 bromo-dihydrodiol by 
microsomal epoxide hydrolase (Lau and Zannoni, 1981) after which it will then be removed 
by the traditional detoxication routes, which were discussed in chapter 1.  
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Bromobenzene 3,4 epoxide however, unlike bromobenzene 2,3 epoxide, is electrophilic and 
therefore highly reactive. It has been shown to directly bind to glutathione S-transferase 
resulting in conjugation to glutathione. This conjugation to glutathione detoxifies the reactive 
metabolites of bromobenzene but results in glutathione depletion in hepatocytes (Madhu and 
Klaassen, 1992). The epoxide can then be further hydrolysed by CYPs into 2- and 4-
bromophenol. 4-Bromophenol, and another potential metabolite 4-bromocatechol, have  
been shown to not induce toxicity (Madhu and Klaassen, 1992), but 2-bromophenol can be 
oxidised to bromohydroxyquinone as discussed below. 
4.1.2 Toxicity and Metabolism of 2-Bromophenol 
2-Bromophenol and bromohydroxyquinone are readily transported to the kidneys from the 
liver, an organ rich in glutathione S-transferase and the combination with glutathione 
produces various mono- and di- substituted molecules (Parke and Piotrowski, 1996). The 
accumulation of these conjugates, in addition to the depletion of the local glutathione pool, is 
thought to be the cause of the renal toxicity (Lau et al.1984b). Figure 4.1 describes 
schematically the biotransformation of bromobenzene to 2-bromophenol and bromo-
hydroxyquinone. The loss of intracellular protection against oxidative stress and other 
hazardous substances can also lead to indirect events further exacerbating cellular damage. 
However, there is little information about the mechanism of toxicity of 2-bromophenol and 
there is no information on the bioavailability of the compound. Bruchajzer et al. (2002) 
however, concluded that evaluation of the nephrotoxicity of 2-bromophenol should be based 
on urine analysis, as they observed changes in urine which included increased protein 
excretion and elevated epithelial cell content, despite variability in the levels of the ‘classic 
markers of nephrotoxicity’ such as creatinine.   
This study aims to utilize the original COMET samples, combining new technologies with 
previous analyses to provide a broader view on the acute nephrotoxicity of 2-bromophenol 
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after a single administration, investigate the reversibility of the effects and identify both 
biomarkers of toxicity and perturbations of endogenous metabolism. 
 
 
 
 
 
4.2 Materials and Methods  
4.2.1 Study Design and Sample Collection 
The reanalysis performed in this study was performed on the samples collected in the 
COMET study R16 where urine and serum samples were collected after the intraperitoneal 
(IP) administration of 2-bromophenol as a single dose to male Sprague-Dawley rats. The 
rats (10 animals/group) were dosed with 100 mg/kg or 200 mg/kg of 2-bromophenol in corn 
oil (control rats were dosed with corn oil). Rats were housed in metabolic cages and urine 
Figure 4.1. A visual presentation of the metabolism of bromobenzene in the rat liver and kidney.  
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was collected for metabonomic and clinical analysis. Urine samples were collected at 16 
hours pre dose, at time of dose and at 8, 24, 48 72, 120, 144 and 168 hours post dose, with 
a total of 230 samples collected. Clinical observations and body weight were recorded daily. 
Clinical chemistry was performed on study day 2, 24 hours after treatment (all rats); study 
day 3, 48 hours after treatment (group A); and on study day 8, 168 hours after treatment 
(group B). Five animals from each group were sacrificed on study day 3 and five were 
sacrificed on study day 8. Kidneys were removed and were examined histopathologically. 
Samples were stored at -40 °C prior to analysis. 
4.2.2 Sample Preparation and Experimental (NMR spectroscopy) 
The collected urine was spun down in a centrifuge and 250 μL of sample aliquoted into 2 mL 
cryo-vials and diluted 1:2 with phosphate buffer. A quality control mixture containing 10l of 
each sample was also prepared. Each urine sample was centrifuged at 12000g at 4 °C for 5 
min and subsequently 500l was transferred into 96-well plates using a Bruker Sample 
Track system and a Liquid Handler 215 preparation robot. 1H NMR spectroscopy was 
performed at a field strength of 14.1 T (1H 600.29 MHz) using a 5 mm broadband inverse 
configuration probe with a z axis magnetic field-gradient capability. The spectrometer was 
equipped with a Bruker Sample Jet system set to 5mm shuttle mode with a cooling rack of 
refrigerated tubes at 6 °C and controlled via a Bruker Avance III console. The 1H NMR 
spectra of the urine were measured using one-dimensional (1D) nuclear Overhauser 
enhancement spectroscopy (NOESY)- presat (noesypr1d) pulse sequence (Stonehouse and 
Keeler, 1995). The data were acquired using Topspin 3.2 and run under automation by 
IconNMR.  
4.2.3 1H NMR Spectroscopic Data analysis 
The same computational methodology was employed for the chemometric analysis of all of 
the various NMR datasets. After phasing to correct for first and zero-order errors, and 
baseline correction to account for distortions of the base values, the data was imported to 
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MATLAB R2012b (Natick, Massachusetts, U.S.A.) using the Metaspectra program script, 
using a resolution of 0.00055. The data were then aligned using Recursive Segment-Wise 
Peak Alignment (RSPA) (Veselkov et al., 2008) and normalised by Probabilistic Quotient to 
account for, and exclude, systematic sources of bias within samples which were not due to 
biological processes or environment. Statistical Recouping of Variables (SRV) (Blaise et al., 
2009) was then used for peak detection, and the integrated dataset was exported to SIMCA-
P+ 13.0.2 software for multivariate analysis. 
4.2.4 Sample Preparation and Experimental (LC-MS Analysis) 
Prior to analysis the sample order was randomised using the Microsoft Excel random 
number generator function. All 230 samples were included in the analysis. A 150 µL aliquot 
of urine was mixed with 300 µL water to dilute the salt concentration before protein removal 
via precipitation with acetonitrile (1:2 v/v). These samples were vortexed and left at -20 °C 
overnight before centrifugation for 5 min at 12 000 g at 4 °C. For reversed-phase 
chromatography, 50 µL of sample was taken and added to 150 µL water in 350 µL 96-well 
plates (Waters Corporation, Milford, USA). A pooled quality control (QC) sample was 
prepared (Want et al., 2010) by combining 100 µL of each sample and diluting 1:4. Dilutions 
of 1 in 2, 1 in 4 and 1 in 8 of this QC sample in water. The 96-well plates were stored at -20 
°C until the analysis by LC-MS as described below. Immediately before being placed in the 
autosampler  the plates were centrifuged at 1700 g  before being placed into the 
autosampler at 4 °C. 
Reversed-phase liquid chromatography was performed on an Acquity UPLC system (Waters 
Ltd, Elstree, UK) coupled to a Synapt G2 triple quadrupole dual time-of-flight mass 
spectrometer (Waters MS technologies, Ltd., Manchester). UPLC-MS conditions for urine 
analysis were those previously described for the reversed-phase analysis of urine (Want et 
al., 2010) where the separation was performed using a Waters HSS T3 (1.8 µm, 2.1 x 100 
mm) column and 2l per sample were injected. The chromatographic mobile phase was 
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composed of 0.1 % formic acid in water (A) and 0.1 % formic acid in acetonitrile (B).  The 
column temperature was maintained at 40 °C and linear gradient elution was performed at 
0.5 mL/min.  The starting composition was 1 % B, held for 1.0 min before increasing to 15 % 
at 3.0 min, 50 % at 6.0 min, 95 % at 9.0 min for a 1.0 min wash and returning to 1 % B for a 
2 min re-equilibration step (total cycle time 12 min).  Mass spectrometry was performed with 
electrospray ionisation operated in both positive (ESI+) and negative ion modes (ESI-) The 
instrument was operated in sensitivity mode and set to acquire data over the m/z range 50 – 
1200 with a scan time of 0.1 s. All mass spectral data were collected in centroid mode using 
the MSe data acquisition function. For mass accuracy, leucine encephalin (MW = 555.62) 
was used as a lock mass at a concentration of 200 pg/uL (in 50/50 CH3CN:H2O, 0.1 % 
formic acid) infused at a flow rate of 20 µL/min via a lock spray interface. The data were 
collected using MassLynx V 4.1 software (Waters Corportation, Milford, USA). 
4.2.5 UPLC-MS Data analysis 
Each UPLC-MS data set was pre-processed using both Transomics (Non Linear Dynamics, 
UK) and XCMS Bentobox (Tautenhahn et al. 2012) software in order to convert the three-
dimensional LC-MS raw data into time-aligned detected features of retention time, m/z ratio 
and intensity (peak area). The ion intensities for each peak detected were then normalised, 
within each sample, to the median peak intensity in that sample. The resulting peak marker 
tables, comprising m/z, RT and normalised intensity values for each variable in every 
sample, were exported to SIMCA-P+ 13.0.2 software (Umetrics, Umea, Sweden) to perform 
multi-variate statistical analysis. 
 
4.2.6 Statistical Modelling  
Prior to any statistical modelling the QC’s were evaluated, through both the use of CV and 
positioning within PCA plots. If there was gross variation within the quality control data, or if 
there was significant drift within the position of the QCs within PCA scores plots the data 
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would have been unfit for analysis. SIMCA-P+ 13.0.2 was used for the statistical modelling; 
Principal component analysis (PCA) (unsupervised) and Partial least square regression 
discriminant analysis (OPLS-DA) were utilised to explore any underlying stratification within 
the data. Scores plots were used to investigate any differences within the sample groups 
and the loadings were used to identify which (if any) variables were driving the separation. 
Validation by permutation testing was also performed to test the predictive capabilities of the 
models created. Each peak or feature of interest was then tested for significance using a 
modified Multiple Analysis of Variance (MANOVA) and the p values corrected for multiple 
testing using Beynjamini-Yekutielli correction. Metabolite assignment was then performed in 
the manner previously discussed in the introduction. 
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4.3 Results and Discussion 
4.3.1 Comparison with original data 
The samples used in this study were collected in 2003 and subsequent to the initial COMET 
NMR spectroscopy have been kept in storage at -40°C. In order to confirm the integrity of 
the samples and determine if there had been any time related changes in their composition, 
the original 1H NMR data, were compared with the new data from the analysis of the 
samples. When compared sample-to-sample, after accounting for the increased resolution of 
the newer probe used, relatively few differences were noted between the spectra, as 
illustrated for the spectra obtained for sample R006600 in 2003 and in the re-analysis in 
2014 depicted in figure 4.2. Using Statistical Recouping of Variables (SRV) for automatic 
peak detection with identical parameters, the total number of features detected in each 
sample in the reanalysis was found to be increased by approximately 10% (17 more features 
per sample) compared with the original data (discussed below). However, every feature 
detected in the original data was present on reanalysis in the present study, and the PCA 
models produced from each dataset showed the same trends. This evidence suggests that 
the storage conditions used for the samples were appropriate for maintaining their integrity, 
and supports re-analysis using more modern NMR instrumentation and UPLC-MS 
technology. From this point, all the1H NMR results discussed were generated from the 
reanalysis of the samples using data acquisition at  600 MHz.  
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Figure 4.2 A comparison between the spectral data for sample R006600 acquired in the original 
NMR run in 2003 (top) and the data from the same sample obtained in 2014 to highlight the 
chemical stability of the samples. 
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4.3.2 Hippurate and, aminohippurate as potential biomarkers of 2-bromophenol 
nephrotoxicity 
a. Original COMET results 
The results of the original COMET project have been summarised by Lindon et al. (2005) but 
are briefly reiterated here. In the case of 2-bromophenol the data produced were analysed 
using the “traditional” chemometric methods employed for metabonomics at that time and 
the metabolic signatures were compared between treatment groups. Multivariate analysis of 
the data using PCA showed that there was a general separation of the high dose group from 
the other low dose and control groups within statistical space, whereas there seems to have 
been little response to the low dose administration of 2-bromophenol. The original findings 
stated that for the high dose group the maximal response was detected to be at 48hrs post 
treatment. This response was indicated by an increase in the amounts of creatinine in the 
urine, with other smaller elevations in the concentrations of citrate and hippurate and a 
decrease in the quantity of aminohippurate. 
b. Results for the 1H NMR Reanalysis of the R16 Urine Samples 
Quality Control Samples 
To assess the analytical stability of the 1H NMR spectroscopic analysis a pooled quality 
control sample was included from which spectra were spectra at the beginning, middle and 
end of the run. These QCs can be seen tightly grouped together in the PCA scores plots 
(e.g. see Figure 4.4) indicating a good degree of consistency in the analytical process. If 
these data had showed that the QCs were not similar, i.e. showing a drift along statistical 
space then this would indicate that there had been time-related analytical changes (e.g., 
resulting from degradation whilst samples were queued for analysis). These data were 
further investigated via the calculation of the variance for each integrated feature for the QCs 
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to further examine consistency, and pinpoint any sources of variability. Variance is defined 
as: 
 
Where f(x) is the probability density function of a continuous variable and simplified in this 
case to: 
 
Here variance is the sum of the squared distances of each feature in the spectrum from the 
mean (μ), divided by the number of features detected (N). Total cumulative intensity variance 
for the QCs was 4.63 x 10 -10, which for the deviation of this data set is very low, therefore 
suggesting that the QCs were highly consistent. As the QCs are a pool, formed by mixing 
equal volumes from every sample analysed, they should represent an analytical ‘average’ 
when components are constructed in a PCA. They can also be interrogated by comparing 
the deviation of the QC samples from this theoretical average to reveal the difference 
between the weighted difference for the QC data and the predicted average of the model, 
which is presented in figure 4.3. The bars within the plot show how far each variable 
deviates from the theoretical mean, and the smaller the bars are the more consistent that 
area of the data set is. As none of the bars intersect the one standard deviation threshold we 
can be confident in the analytical comparability of the data. This procedure cannot be used 
to assess the quality of the original COMET study data as QC samples were not used). 
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Figure 4.3 Contribution plot showing the deviation of the QC samples in each integrated spectral 
region from the statistical mean of the principal component analysis expressed in standard 
deviations. The plot displays the vector vk(xik - avgik) for each variable as a bar, the orientation of 
which indicates the direction of  the deviation. As none of the bars intersect the one standard 
deviation threshold we can be confident in the analytical conditions were stable throughout the run. 
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c. Chemometric Analysis 
Chemometric analysis of the newly acquired 1H NMR data did however, highlight the same 
trends as the previous COMET analysis. Construction of PCA models indicated a general 
separation of the high dose group (200 mg/kg) from the low dose (100 mg/kg) and control 
groups within statistical space. However, when the complete dataset was used, there was 
little difference between the data acquired from the controls and for samples obtained 
following low dose administration, a trend which was echoed by supervised O-PLS 
discriminant analysis (Fig 3.4a and 3.4b). By removal of data for the low dose group from the 
analysis we attempted to identify the discriminating signals driving the separation of the 
control and high dose groups. By investigating each time point separately it was found that 
the point of maximum metabolic difference following administration of 2-bromophenol at 200 
mg/kg was seen in the samples acquired at 8 hours post dose, with a reduced response at 
24hours where the samples at this time point are situated closer in the statistical space to 
the controls (figure 4.4). There also seems to be a separate group within the low does 
animals which responded differently to the administration of 2-bromophenol. 
 
 
 
 
Figure 4.4 The scores plots from the multivariate analysis of the 
1
H NMR data obtained for the 2-
bromophenol  study A) and B) are the scores of PCA and OPLS-DA, respectively, of the whole data set. There 
seems to be a distinct trend in statistical space pushing the high dose group away from the other two. The 
samples coloured in Yellow are QC samples and these are present consistently in the middle of statistical 
space indicating good stability for the analytical platform. 
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Using the S-plot (figure 4.5) from the supervised O-PLS discriminant analysis of the data it is 
possible to identify the signals driving group differences. From examination of the data 
acquired for the samples collected at 8 hours post dose it is possible to identify the major 
changes in endogenous metabolites. These were an increase in the amount of hippurate 
(3.96/7.56/7.84, p = 7 x 10-17/3.78 x 10-18/6.16 x 10-17) and aminohippurate (6.87, p = 1.49 
x 10-17) and a decrease in 3-methylhistamine (2.84, p = 2.29 x 10-20) (these identifications 
are based on database searches and match what was previously reported by the original 
COMET report, provided in the appendices). The p-values quoted are derived from the 
ANOVA significance testing, after Benjamini-Yekutieli multiple testing correction.  A variance 
plot depicting the intensities of the integrated region of the three metabolites mentioned 
above for each of the samples has been constructed for each metabolite signal and also 
presented below (figure 4.6). Through interrogation of the 600 MHz 1H NMR spectra no 
parent compound/metabolites was seen, possibly because the signals from the 2-
bromophenol/metabolites were obscured by other larger peaks. While the PCA trends 
identified here might also be expected to occur due to the excretion of dosed compound and 
its metabolites in the urine, which are known to be present as discussed later, statistically 
there seem to be other areas driving the differences. 
 
 
Figure 4.5 S plot derived from the OPLS model comparing high dose and control groups at 8 hours post dose. 
Variables clustered towards the bottom left are variables which represent metabolites more abundant in 
the high dose group, whereas variables in the top right are down regulated in the treatment group. 
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Figure 4.6 Xvar plot of the levels of the indicated metabolites in the various animals. The yellow threshold in 
the graph is 1 standard deviation whereas the second red threshold is the second deviation from the 
theoretical mean. There are clear trends in the amounts of hippurate and p-aminohippurate, whereas there 
seems to be greater within group variability in 3-methylhistamine concentrations. 
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The OPLS model was able to provide convincing test statistics with an R2 of 0.95 and a Q2 
of 0.91). The R2 shows the amount of Y variables explained by the model after cross 
validation and gives the ‘goodness-of-fit’ of the model, the Q2 gives information about the 
predictive quality of the model. 
To test for the validity of the model and assess the possibility that the results were spurious 
permutation testing was performed, with 1000 iterations recalculated every 100 permutations 
(due to technical constraints). Permutation testing compares the model generated from the 
data with random chance, which is to say that the performance of the test statistics of the 
model against randomly generated Y-data is compared. Figure 4.7 illustrates the results of 
the permutation testing. In this figure the green and blue points on the far right are the 
original R2 and Q2 values, and the points to the left of these are the values of the randomly 
generated data. The two dotted lines are the regression lines for each of the two statistics. 
The criteria for validity of the model are that all the Q2 values of the random data are lower 
than the original and that the Q2 regression line intersects the vertical axis at, or below 0; 
and in both cases the model passed these acceptance criteria. While R2 values always 
show a degree of optimisation, and will not always follow the same trend as the Q2 values, 
the fact that in the test permutation all of random data R2 values were also lower than the 
original which further adds validity to the model. 
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As a final step the significance of the model was investigated using ANOVA of the cross-
validated residuals (CV-ANOVA). This is achieved by comparing the significance level of the 
OPLS model in the variation around the mean. Table 4.1 summarises the results of the CV-
ANOVA. In the table the important number is the p value in the final column which, which is 
highly significant, meaning we can be highly confident in the validity of the models which 
were constructed. 
 
Controls vs 
High Dose 
Sum of 
Squares 
Degrees of 
Freedom 
Mean 
Squares 
F value P value 
Total corr. 19 19 1   
Regression 17.3042 4 4.32605 38.2659 1.05543e-7 
Residual 1.69579 15 0.113052   
Table 4.1 Results of the CV-ANOVA 
 
We should note that investigation of the data for pre-dose time point revealed basal 
stratification of the animals into two distinct groups, with a minor subgroup of animals 
showing inherently elevated urinary concentrations of hippurate and lower concentrations of 
Figure 4.7 Permutation plot for the model constructed. The green and blue dots represent the R2 and Q2 of 
the dummy data respectively. The permutation values are lower than the actual values suggesting that the 
model is highly robust. 
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other endogenous metabolites including 4-aminohippurate and N-acetylhistamine. While 
members of this minor group were all part of the low dose treatment (100mg/kg), and were 
therefore omitted from the majority of the analyses (due to their potential to bias the 
analysis), they could have potentially skewed the results of the PCA. Furthermore they could 
indicate inconsistencies in metabolic state of the animals prior to the start of the study, or 
differences in microbiomes, housing or feeding.  
 
d. Hippurate as a potential biomarker of the effects of 2-bromophenol administration 
The metabolite that was seen to be consistently detected as significantly changed as a result 
of administration of 2-bromophenol at 200 mg/kg, throughout the data interrogation, was  
hippuric acid or hippurate. Hippurate is the glycine conjugate of benzoic acid and has been 
shown to be readily detectable by both 1H NMR spectroscopy (Bales et al., 1984) and LC-
MS (Sakai et al., 1983) analytical platforms. In the rat the kidneys (together with the liver) 
serve as a major site of glycine conjugation as well as the main route of hippurate excretion 
via urine. During impaired renal function hippurate has been seen to accumulate in the 
serum (Niwa, 1996) coupled with a reduction of urinary concentrations (Bairaktari et al., 
2001). As such it has been identified as an indicator of active secretion competence and 
kidney amino acylase activity, as well as expression of organic anion transporters (Christians 
et al., 2008). As the main location of filtration, glomerular nephrotoxicity specifically causes 
perturbation of hippuric acid elimination; indeed reduction of urinary hippurate concentrations 
have been shown to directly correlate with lesion severity in human patients with 
glomerulonephritis, an acute nephrotic syndrome characterised by damage to the glomeruli 
(Psihogios et al., 2007). The utility of hippurate as a biomarker in metabonomic studies has 
been reviewed by Lees et al. (2013) and as such should be considered for further 
investigation. Our findings are in agreement with previous studies, and may indicate that 2-
bromphenol may localise to the glomerulus.  
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 e. p-Aminohippurate 
p-Aminohippurate is another well-established marker of nephrotoxicity and has been used to 
specifically measure renal plasma flow. Transport of organic anions, including p-
aminohippurate occurs almost exclusively in the proximal tubule cell through active anion 
exchange. This is a two part process. Initially p-aminohippurate is exchanged for intracellular 
2-oxoglutarate by the PAH/2-oxoglutarate membrane bound exchange protein PAHT (Lu et 
al., 1999); subsequently the metabolite is exported to the tubular lumen through the action of 
the multidrug resistance protein 2 (MRP2) an ATP-dependent exporter protein (Leier et al., 
2000). While PAHT has been shown to have broad substrate specificity, and is able to 
transport a variety of organic substrates (Sekine et al., 1997), MRP2 is specific to 
amphiphilic anions, such as p-aminohippurate and other endogenously formed glutathione 
and sulfate conjugates. A decrease in p-aminohippurate secretion has long been thought to 
result from the inhibition of these transport mechanisms through competitive binding to the 
transporter protein of a toxin (Berndt and Grote, 1978). 
  
 Chapter Four 
 
 
 183 
4.3.3 Insights from LC-MS analysis 
While with the 1H NMR reanalysis confirmed sample integrity and, as in the original COMET 
analysis, enabled the 2-bromophenol dose groups to be separated via e.g. PCA as well as 
highlighting a number of endogenous metabolites perturbed by 2-bromophenol 
administration it revealed little new information. Therefore UPLC-MS was undertaken to 
further characterise the effects of 2-bromobenzene administration by providing an 
orthogonal, and potentially, more sensitive analytical platform. 
a. Quality control 
As discussed in previous chapters LC-MS techniques often require more significant sample 
preparation and are also subject to the degradation of instrumental performance during 
analysis leading to the acquisition of unreliable data. For quality assurance/control aliquots 
from every sample were combined in a pooled sample and then analysed at regular intervals 
throughout the experiment (Want et al., 2010) Initial visual inspection of the QC 
chromatograms showed good consistency throughout the run. Figure 4.8 illustrates how the 
chromatograms of QCs throughout the run overlay well, with little evidence of retention time 
drift.  These trends were mirrored in the initial PCA scores plots used to scrutinise analytical 
drift. Figure 4.9 shows the initial un-filtered data for the negative electrospray ionisation (ESI) 
runs; the red points in both scores plots represent the QC samples. In the positive ESI run it 
can be seen that all the QCs cluster together in the centre of statistical space, until QC 18 
(injection 203). From this point the QCs seem to drift off in a time dependant manner with the 
final injection, QC 23 being the furthest. This seems to indicate that there was a drop in 
analytical stability after approximately 200 injections however, since the deviation was not 
statistically significant in the overall variation within the data the data was accepted as 
usable. Interestingly a similar trend was observed for the negative ESI data, with the QCs 
initially being well clustered with the same deviation occurring at QC 19 (injection 206), again 
this drift was not significant and the data were also accepted. Nonetheless the data suggests 
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that there is a typical loss of consistency after around 200 injections, perhaps indicating the 
limit of the methodology employed.  
  
Figure 4.8, chromatographic peaks of the first QC (red trace, injection 8) the 10
th
 QC (green trace, injection 
195) and the last QC (purple trace, injection 251). The chromatograms are highly consistent with no visible 
retention time drift, suggesting that the analysis achieved good analytical stability 
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To ensure that the QCs were consistent throughout, and that there were no regions of the 
acquisition where there was instrumental instability masked the overall stability of the 
metabolic profile the coefficient of variation for each of the features detected in the QCs was 
calculated. Ion intensity stability is typically poor for low intensity ions and greater the more 
Figure 4.9 PCA scores plot sowing the positioning of the QC data within statistical space, in both the positive 
and negative ionisation modes. The red dots are the QCs while the grey dots are the samples. The QCs in 
both modes tend to cluster in the centre of the plot, with a time dependant deviation after around 200 
injections.  
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intense the ion (providing it is not saturating the detector) and those features that are subject 
to ion suppression/enhancement will show greater variation than those that are resolved 
from ion suppressing matrix components. The coefficient of variation (CV) expressed as a 
percentage is defined as: 
 
Where is the standard deviation and is the expected return, in this case the mean. The 
below table (table 3.2) shows the results of the CV calculations. From this analysis it is clear 
the that negative ESI results were less stable than those from the positive ESI analysis, 
although the results could be skewed due to the fact that the negative run detected more 
features (18589 features) than the positive run (17816 features). Typically the features 
detected in negative ESI are less intense than those in positive mode, and therefore more 
subject to background noise, which can result in greater variability. 
  
<15% 
CV less than 
<20% 
 
<30% 
Negative 
29.2% 43.2% 64% 
Positive 
50.7% 64% 79.2% 
Table 4.2, CV percentage scores for the QC data. 
b. Chemometric analysis 
After computational analysis with Transomics software, the extracted metabolic signatures, 
defined by retention time and m/z ratio, both the positive and negative ESI datasets were 
investigated using multivariate statistics in a similar way to the 1H NMR spectroscopic data. 
The positive ESI data was analysed first, but did not show any trends in the PCA modelling 
scores in either the overall dataset model, or when high dose and controls were compared at 
8, 24 and 48 hours (figure 4.10), although this does match expectations, as it was predicted 
that bromophenol and its metabolites would ionize better in negative mode. However, there 
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were some time related trends between the pre dose time point and the 8 hour time point in 
the high dose group. These trends appeared to be due to changes in the endogenous 
metabolite profile.  
 
 
 
 
 
 
 
Figure 4.10 PCA scores plot of the model comparing dose groups, acquired by positive mode ionisation.  
Coloured by dose group, yellow being controls, blue low dose and red high dose. There does not seem to be 
overall good discrimination between the groups. 
Figure 4.11 PCA scores plot of the model comparing dose groups (controls green and high dose red), at 8 
hours post dose, acquired by positive mode ionisation. Maximal response seems to be at 8 hours, with 
reasonable separation between the groups.  
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The negative ESI data proved to be more interesting. Initial PCA modelling of the complete 
dataset revealed distribution patterns within the models which were remarkably consistent 
and presented an identical separation to those resulting from the 1H NMR spectral data. 
Maximal “response” for the high dose group was observed at 8 hours post dose with a 
diminishing effect at 24 hours after which the metabolic profiles of the animals returned to 
‘normal’ (Figure 4.12).  Furthermore, due to the greater sensitivity of MS analysis, more 
subtle differences were detected leading to some differentiation between the low dose and 
control classes which were previously undetected by 1H NMR spectroscopy. Subsequent 
OPLS modelling of the 8 hour time point provided very strong models (R2 = 0.99, Q2 = 
0.71), which we used to identify the signals driving the separation. 
 
  
Examination of the MS data revealed both changes in endogenous compounds and also 
showed the presence of brominated metabolites of the dosed 2-bromophenol which were 
readily detected as a result of the characteristic bromine isotope pattern. These data were 
further examined with OPLS modelling to determine the nature of the excreted metabolites.  
Figure 4.12. PCA scores plot of the model comparing dose groups, acquired by negative mode ionisation. 
There is good separation between the groups and the distance the samples deviate from the controls seems 
to be dose dependant. 
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The results showed that the two main avenues of phase two xenobiotic metabolism for 2-
bromophenol in these animals, as seen via the metabolites excreted in the urine, involved 
sulfation and glucuronidation. Thus, from both the mass chromatograms and the statistically 
Figure 4.13 Composite plot highlighting the two most prominent 2-bromophenol metabolites. Inspection of 
the s-plot (bottom) derived from the OPLS model comparing low dose and controls, the ions influencing 
discrimination relate to 2-bromophenol sulphate (m/z 252.9) and 2-bromophenol glucuronide (m/z 348.97). 
The chromatographic peak extraction (top) and the related mass spectra are also provided. 
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discriminating variables within the OPLS models the ions at m/z 252.93 and 348.97 were 
identified as the key differentiating masses. These ions corresponded to 2-bromophenol 
sulfate and 2-bromophenol glucuronide respectively (fig 4.13) with both showing the 
distinctive bromine 1:1 isotope pattern and appropriate losses of 80 and 176 Da, diagnostic 
for the sulphate and glucuronic acid moieties respectively, due to fragmentation in the ion 
source. A 2-bromophenol glucuronide dimer, pertaining to m/z 718.94, with a similar 
retention time to the glucuronide was also seen. However, this was most likely a result of in 
source dimerization as this reaction is highly unlikely in biology (and elution of both the 
glucuronide and the dimer, if real, at the same retention time is also highly unlikely). In order 
to see how well the statistically discriminating variables within the OPLS models had 
extracted the bromophenol metabolites the LC-MS data were also examined using more 
traditions mass spectrometric approaches as described below. 
4.3.4 Extraction of “isotopobromatograms” from the LC-MS data, application to 
metabolite profiling and identification 
Compounds containing bromine have a very distinctive isotope pattern in mass spectra, with 
the 79Br and 81Br isotopes present at a ratio of approximately 1:1. This isotopic signature 
enables the chromatographic data to be searched for this characteristic mass difference, 
providing a powerful tool for detecting and identifying bromine-containing metabolites. An 
example is illustrated in Figure 4.14, where an 0-8 hr  high dose urine sample (negative ESI 
data) has been used to generate the chromatogram (Figure 4.14A) by extracting all ions 
containing an isotopic pattern with a mass difference of 2 Da at a ratio of 1:1, thereby 
resulting in a “isotopobromatogram” showing only ions containing the bromine isotopic 
pattern. This selective trace highlights 6 bromine-containing peaks, for which the spectra are 
detailed in Figure 4.14B. 
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The peaks detected with the isotopobromatogram and their masses are listed below in table 
4.5. The masses and the presence of the bromine, plus the MS/MS data, have led us to 
postulate some putative assignments but further work would be necessary to confirm the 
identity of some of these minor 2-bromophenol metabolites (e.g. isolation and 1H NMR 
spectroscopy), which appear to be further hydroxylated versions of 2-bromophenol that have 
also been glucuronidated and sulphated.  Peaks 4 and 5 from the above figure 
corresponded to the 2-bromophenol sulphate and glucuronide metabolites respectively, 
which is in concordance with the rest of our findings. The MS/MS of the sixth peak contained 
both the characteristic sulphate 80Da loss; this in addition to the m/z ratio led to the 
assignment of this compound as 2-hydroxy(3-methoxy)bromophenol sulphate. The 
methylation of vicinal aromatic diols is quite common within the cell, by enzyme such as 
Figure 4.14. Isotopobromatogram (top) and the related mass spectra (bottom). The chromatographic peaks 
are numbered and match up to the numbered mass spectra. 
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catechol-O-methyltransferase (Huotari et al., 2002). Thus if the parent 2-bromophenol 
undergoes initial hydroxylation in the 3 position this would produce a vicinal diol which can 
be readily methylated, and then undergo sulphoconjugation. This would also fit the longer 
retention observed as the methyl group would increase the lipophilicity of the compound. 
The MS/MS spectra for the above ions are provided in the appendix.  
The standard for 2-bromophenol was also run on the system to ascertain whether we could 
detect the parent compound however, the compound was not detected under the conditions 
used. It should be noted that there was no evidence of the presence of glutathione 
conjugates, nor were any mercapturic acid derivatives detected in the urine. Glutathione 
conjugates are one of the major indications of potential toxicity via reactive metabolites as 
they are a direct result of GHS-transferase attack on electrophilic intermediate metabolites 
(Boyland and Chasseaud, 1969). This suggests that 2-bromophenol, at these doses and in 
this strain of rat, does not produce reactive intermediates following I.P. administration.  
Metabolite Measured Mass Retention Time Formula IBG  
Hydroxy 2-bromophenol 
glucuronide 
 
362.97 3.01 C12H15O9 1 
Hydroxy 2-bromophenol 
sulphate 
268.89 3.09 C6H7O5BrS 2 
Hydroxy 2-bromophenol 
sulphate 
268.89 3.39 C6H7O5BrS 3 
2-bromophenol sulphate 252.90 4.47 C6H6O4BrS 4 
2-bromophenol glucuronide 348.98 4.43 C12H14O8 5 
 
2-bromophenol glucuronide 
dimer 
718.94 4.46 -- 5 
Hydroxy (3-methoxy) 2-
bromophenol sulphate 
282.91 5.14 C7H8O5BrS 6 
 
 
Table 4.3 2-Bromophenol metabolites detected: Putative assignments. IBG: 
Isotopobromatograam peak number.  
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4.3.5 Endogenous Metabolic Changes 
To investigate any potential changes in endogenous metabolites that had been masked by 
the presence of the 2-bromophenol metabolites the ions for the sulphate and glucuronide 
conjugate ions were removed from the MS data and the statistical analysis was rerun. This 
reanalysis showed that, by both by PCA and OPLS, it was still possible to discriminate the 
groups, and the signals detected as being responsible are listed in the table below (table 
4.4). MS/MS analysis of the ions detected this way allowed for the identification of hippurate, 
the main discriminating endogenous metabolite detected by 1H NMR spectroscopy, and 
citrate to be elevated in the dose group.  
 
Endogenous Metabolites Lower in dose group 
 m/z Retention time P(cor) 
Unassigned 1 418.12 4.83 0.49 
Unassigned 2 253.05 4.44 0.87 
 Higher in dose group 
 m/z Retention time P(cor) 
    
Citric Acid 191.02 0.99 0.68 
Hippurate 178.05 3.84 0.65 
Table 4.4, Endogenous metabolites altered on 2-Bromophenol administration 
From the Analysis of the LC-MS data the clear discriminating factor seems to be the 
presence of the 2-bromophenol sulphate and glucuronide. The graph below, figure 4.15, 
depicts the time course of excretion of both metabolites over time in each of the two dose 
groups. The control samples were blank. It is interesting to note that while these animals 
were only dosed once, there seems to have been an initial rapid phase of excretion shortly 
after dose administration, and a second spike after about 48 hours.  
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It may also be of worth to note that there seems to be significant inter animal variation in 
terms of the metabolic fate of 2-bromophenol within the high dose group. Indeed when 
scrutinising the contribution plots of the high dose samples we can see that there are 
significant differences from rodent to rodent. The main difference seems to be the ratio 
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Figure 4.15 Line charts showing the average relative, total volume corrected, intensities for each dose 
group, across the various time points.  
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between the sulphate and glucuronide, with some profiles indicating a much higher relative 
signal from the sulphate conjugate and other animals with more similar signals of the two 
(figure 4.16). While, due to the varying levels of ionisation being the determinant of peak 
height, it is not possible to deduce the absolute quantitative ratio, although it is possible to 
surmise that some animals are saturating their sulphate conjugation pathway capacity much 
more than others, causing this ‘high responder’ metabotype. This between-animal variation 
may due to differential metabolism, due to variations in exposure as a result of the route of 
administration, genetic, or microbiome differences etc.  
 
 
c. Model validation and significance testing 
Figure 4.16 Intensity plot showing the contribution of the 2-bromophenol sulphate (highlighted red) and 2-
bromophenol glucuronide (highlighted light blue) to the between group discrimination for two different 
high dose animals at 8 hours post dose from the negative ESI data. The y axis is the scores contribution 
value for each variable. The fact that the contribution differs greatly between samples at the same time 
point suggests that the response to bromophenol administration differs between animals. 
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To validate the model the same permutation testing was employed as in the 1H NMR 
spectroscopic data. This is of critical importance for mass spectrometry data as the platform 
detects many more features than samples and therefore the data is highly multi-collinear. 
The same 1000 iterations recalculated every 100 permutations were used for each of the 
models and comparisons performed; the below figure (figure 4.16) presents the permutation 
plot for the comparison of the high dose and controls at 8 hours post dose (permutation plots 
for the other models available in the appendices). The criteria for validity are once again that 
all the Q2 values of the random data are lower than the original and that the Q2 regression 
line intersects the vertical axis at or below 0. Indeed once again our model fulfils these 
criteria.  Also included are the CV-anova statistics in the table below for completeness (table 
4.5). 
 
 
 
Control vs 
High Dose 
(8hours) 
Sum of 
Squares 
Degrees of 
Freedom 
Mean 
Squares 
F value P value Standard 
Deviation 
Total corr. 17 17 1     1 
Regression 15.5075 4 3.87686 33.7672 9.40394e-
007 
1.96898 
Residual 1.49255 13 0.114812     0.338839 
Table 4.5 Results of the CV ANOVA significance test 
Figure 4.17 Permutation plot for the model constructed. The green and blue dots represent the R2 and Q2 
of the dummy data respectively. The permutation values are lower than the actual values suggesting that 
the model is highly robust. 
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4.3.6 Histopathology and Clinical Chemistry 
The main objective of the original COMET study was to identify the main metabolic changes 
related to 2-bromophenol induced nephrotoxicity and determining this was also assessed 
using classical toxicological methods. Both kidney and liver samples were taken from the 
animals in the study for histopathological assessment, as were clinical chemistry tests 
undertaken on both the urine and blood samples. These data were provided by the 
companies in the COMET group who performed the live phase of the study. 
 
a. Histopathology  
The administration of bromophenol has been previously found to cause nephrotoxicity 
characterised by necrotic damage to the proximal tubule cells. Information on whether 
toxicity was achieved by the current study was provided by the histopathology report (see 
appendix). It was expected that the high dose would cause changes in the kidney but no 
mortality. The high dose group showed mild clinical signs, including transient tremors, slight 
laboured respiration and inactivity; however these effects were minor and the animals had 
recovered by days 2-3 post dose. 
Inspection of the kidneys revealed that there was minimal general non-specific nephropathy 
present in the kidneys of all animals (dosed and control), which was however, not severe 
enough to cause any symptoms, although two low dose group animals did show signs of 
minimal localised inflammation. Two animals out of ten from the High dose group showed 
evidence of slight tubular regeneration, characterized by pale basophilic epithelial cells and 
necrotic cellular debris within the lumen of the proximal tubules. However, this is a low 
number and the rest of the animals in the group showed no kidney damage whatsoever. 
Furthermore one control animal and one high dose animal also showed signs of hyaline 
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droplet formation. Hyaline droplets are cytoplasmic vesicles containing amorphous materials 
surrounded by a membrane and are thought to originate from a loss of glycocalyx in normal 
apical vesicles. Hyaline droplets have been linked to tubular necrosis and are thought to be 
indicative of degenerating proximal tubular epithelium (Sato et al. 2005). This finding would 
indicate a low level background of tubular damage in the test animals. Overall, there seemed 
to be no difference between the kidney tissues of any of the groups. 
While bromophenol is thought to be a kidney toxin, for completeness the livers were also 
collected and inspected. Surprisingly the livers of every animal in the study, except one low 
dose animal, showed the presence of cytoplasmic vacuolation of hepatocytes and 
inflammation. This cytoplasmic accumulation of glycogen in liver cells is seen consistently 
after mild acute liver injury or the introduction of hepatotoxins. This alteration is believed to 
protect the cells from further damage by increasing toxin resistance and blocking cellular 
degeneration (Nayak et al. 1996). This observation raises questions about the overall health 
of the animals in the study, as these signs cannot be related to the administration of the 
bromophenol.   
b. Clinical Chemistry 
Clinical chemistry showed that there were negligible pathology changes in the low dose 
group, and only one of the animals in the high dose group. This particular animal showed 
increased blood urea nitrogen and glucose, in addition elevated total bilirubin, serum 
potassium, serum phosphorus and decreased serum sodium, chloride, and altered 
albumin/globulin ratio. The clinical chemistry of the urine samples showed no trends and all 
animals were within the normal ranges for each test. The overall results of the clinical 
chemistry are summarised in table 4.6. 
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Treatment Dose 
mg/kg/day 
Protein glucose Creatinine Potassium 
8 Hours      
Vehicle (corn oil) 0 0.23 ± 0.11 1.19 ± 0.38 8.55 ± 1.33 236.4 ± 37.6 
2-Bromophenol 100 0.18 ± 0.04 1.05 ± 0.27 6.92 ± 1.43 217 ± 43.9 
2-Bromophenol 200 0.27 ± 0.12 0.8 5± 0.27 5.21 ± 1.77 164.7 ± 51.6 
DAY 1      
Vehicle (corn oil) 0 0.31 ± 0.2 1.52 ± 0.28 9.85 ± 1.23 389.5 ± 52 
2-Bromophenol 100 0.239 ± 0.06 1.43 ± 0.35 8.18 ± 1.4 340.8 ± 71.2 
2-Bromophenol 200 0.44 ± 0.13 1.45 ± 0.32 8.57 ± 2.03 317 ± 81.6 
Table 4.6, Clinical chemistry data from the COMET report 
4.4 Summary and Conclusions  
Previous work had identified 2-bromophenol, a phenolic metabolite of bromobenzene, as a 
potential nephrotoxin (Lau et al, 1984b). This study in Sprague Dawley rats, was part of the 
COMET 1 program and was performed to assess the nephrotoxicity of the compound. After 
combined 1H NMR spectroscopic and UPLC-MS metabolic profiling, statistical analysis 
showed that there was a significant metabolic perturbation due to administration of the 
compound, but clinical chemistry and histopathological examination of the kidneys showed 
that the toxic effects of the compound were minimal. Effects were noted on endogenous 
metabolites such as hippuric  and p-aminohippuric acids by 1H NMR spectroscopy and 
statistical analysis of the LC-MS data also showed effects of  2-bromophenol administration. 
However, in the case of LC-MS the major discriminating ions were due not to changes in 
endogenous compounds but to the detection of the excretion of the sulphate and 
glucuronide conjugates of 2-bromophenol. More detailed analysis of the urine via bromine-
isotope specific detection revealed the presence of a number of minor, hydroxylated 
conjugates of 2-bromophenol but there was no evidence of glutathione cysteinyl or 
metcapturic acid conjugates. The absence of these “markers” of the formation of reactive 
metabolites is consistent with apparent absence of kidney damage indicated by 
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metabonomic phenotyping, clinical chemistry and histopathology. Statistical interrogation of 
the data obtained in this study shows that, whilst the major xenobiotic metabolites was 
revealed reasonably efficiently, the  detection of minor metabolites required a more targeted 
approach. 
The overall conclusion from this study with respect to nephrotoxicity was therefore that, after 
single doses of either 100 or 200 mg/kg, 2-bromophenol is not a nephrotoxin. While these 
results do agree with the conclusions reached during the original COMET project (see 
internal report, appendix) they are in contrast to previous work by Lau et al. It is, however, 
possible that achieving toxicity requires greater exposure to 2-bromophenol, either through 
higher single doses or repeated administration. To investigate the potential for repeat dosing 
of 2-bromophenol to cause nephrotoxicity it was therefore decided to do a repeat dose study 
as described in chapter 5.  
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Investigation of the metabolism and potential nephrotoxicity of 2-
bromophenol after chronic exposure 
Chapter Five 
Previous work described in chapter 4 found that there were no toxic effects of 
2-bromophenol after a single dose in Sprague Dawley rats. A repeat study was 
therefore performed to identify the effects of 2-bromophenol after chronic 
exposure. UPLC-MS and 1H NMR spectroscopy was performed on urine and 
plasma samples acquired from Han Wistar rats administered with 2-
bromophenol for 3 days. ICP-MS was also performed to identify total bromine 
concentrations. Data analysis identified 2-bromophenol glucuronide and 2-
bromophenol sulphate as the major metabolites of 2-bromophenol. However 
no toxic metabolites were detected and after analysis of the histopathology 
and clinical chemistry, there was still little evidence for any toxic action of 2-
bromophenol even after repeated dosing. 
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SUMMARY: 
 2-bromophenol, a metabolite of the hepato- and nephrotoxic compound 
bromobenzene, was also suspected of being a nephrotoxin. However, 
previous work showed only limited effects after a single dose. 
 In a further study 20 Han Wistar rats were split into five equal groups and 
were administered three IP doses of vehicle (corn oil), 100mg/kg or 200mg/kg 
of 2-bromophenol at 24 hour intervals. Urine and blood were collected at 
regular intervals. Three groups (12 rats) were sacrificed after four days and 
the remainder after seven days and the kidneys retrieved.  
  Urine samples were analysed by 1H NMR spectroscopy and UPLC-MS to 
determine both the effects of 2-bromophenol on urinary endogenous 
metabolite profiles and the metabolic fate of the compound itself. 
 Chemometric analysis showed that the main discriminators between dosed 
and control animals were associated with metabolites of 2-bromophenol. Little 
evidence of toxicity was seen in terms of altered endogenous metabolite 
profiles, histophathology or clinical chemistry. 
  The same 2-bromophenol metabolites were identified in urine as shown in for 
the single dose study reported in Chapter 4, and included 2-bromophenol 
glucuronide and 2-bromophenol sulphate. Again there was no evidence for 
the production of reactive metabolites. 
 ICP-MS was performed to determine total bromine concentrations in urine. 
The resulting data showed that there was the expected elevation of bromine 
containing compounds in the dose groups. Bromine concentrations remained 
elevated in the recovery group suggesting that 2-bromophenol related 
material is excreted slowly.  
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5.1 Introduction 
As discussed in Chapter 4 Lau et al., (1984a; 1984b), in a series of studies in Sprague 
Dawley rats have previously investigated the mechanisms responsible for the toxicity and 
the metabolism of bromobenzene. These studies had concluded that 2-bromophenol was 
one of the toxic downstream metabolites of bromobenzene (the metabolism of 
bromobenzene and 2-bromophenol has already been discussed in Chapter 4, and will not be 
repeated here).  
However, as described, analysis of samples also obtained from Sprague Dawley rats dosed 
with 2-bromophenol after administration of a single dose of 2-bromophenol at either 100 or 
200 mg/kg, as part of the COMET program, failed to reveal any discernible toxic effects. 
Thus, histopathological examination of the kidneys of these animals did not indicate any 
tissue damage nor were there any indications of raised amounts of traditional clinical 
chemistry markers of kidney damage. Both 1H NMR spectroscopy and LC-MS were 
employed to metabolically phenotype the urine samples collected from control and dosed 
animals but, while LC-MS (but not 1H  NMR spectroscopy) was able to detect metabolites of 
2-bromophenol, there were no elevations of the typical biomarkers of toxicity, such as 
glucose or lactate. The major metabolites of 2-bromophenol were identified by LC-MS to be 
the glucuronide and sulphate conjugates and, with respect to endogenous compounds, there 
were notable effects on the excretion of hippurate, p-aminohippurate, 3-methylhistamine and 
citric acid. 
 5.1.2 Cumulative Toxicity 
Clearly these results do not align with the findings of Lau et al., who reported “mild toxicity” 
on administration of 2-bromophenol. One potential limitation of the COMET study that could 
be advanced to explain this difference is that the exposures achieved failed in some way to 
replicate those obtained by Lau et al, and that either an increased dose, or multiple 
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administration of 2-bromophenol might be required to produce a toxic effect. Indeed, the 
toxic effects of a wide variety of compounds are cumulative. Many chemicals thought to be 
either innocuous, or of low order toxicity, such as the agricultural compounds ethylene oxide 
aerosols (Klonne et al., 1987) and methomyl (Tanaka et al., 1988) have been shown to be 
toxic after repeated exposure. Furthermore many well studied drugs, such as the cancer 
drugs cisplatin (Goren et al., 1986) and ifosfamide (Loebstein and Koren, 1998) have been 
shown to exhibit cumulative toxicity. In fact, the pre-clinical toxicity evaluation of ifosfamide 
failed to detect any significant toxic effects, and it’s potential for nephrotoxicity was not 
discovered until much later (Barnen, 1982). Therefore, it followed logically from the previous 
single dose study that there was a need to assess the potential for cumulative 2-
bromophenol toxicity following multiple doses. As such the aims of the work presented here 
were to investigate the effects of the repeated administration of 2-bromophenol on both on 
the metabolism of the compound itself and its effects on the kidney.  
 
5.2 Materials and Methods 
 5.2.1 Study Design 
Urine and serum samples were collected from a 2-bromophenol toxicology study where the 
compound was administered intraperitoneally as a repeated dose, every 24 hours for three 
administrations, to male Han Wistar rats. The rats were treated with 100 mg/kg (4 rats) or 
200 mg/kg (8 rats) in corn oil. Control rats were treated with corn oil only (8 rats). Rats were 
housed in metabolic cages for 6 hours daily (between 08:00 and 14:00) and urine was 
collected for metabonomic analysis. 0.3ml of whole blood was collected from the tail vein at 
0.1, 6, 9, 24 and 48hrs post dose for the sacrifice group A (three dose groups) and at 24, 48, 
72, 96, 120 and 144hrs post dose for sacrifice group B (two dose groups). Blood samples 
were taken in lithium heparin tubes and centrifuged for 3 minutes at 1500 g under 
refrigeration (2 to 8°C). Plasma was transferred into 0.5 mL polypropylene tubes and kept 
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frozen at -80°C until analysis. There were four animals for each of the 5 dose groups. 
Selected organs were examined histopathologically, and the kidneys removed and stored for 
analysis. 
A more detailed description of the study design in given in the Protocol in the appendix. 
 
 5.2.2. Sample Preparation and Experimental for 1H NMR spectroscopy 
1H NMR (750 MHz) of the plasma and urine was performed at AstraZeneca, Alderley Park, 
using a flow-injection process.   
a. Plasma 
The collected plasma samples were centrifuged for 10 min at 10621 g at 4 °C. 400µl of each 
sample was aliquoted and 100µl of D20 added. The samples were then manually transferred 
into 5mm NMR tubes.  
b. Urine 
The collected urine samples were centrifuged for 10 min at 10621 g at 4 °C in Eppendorf 
tubes. Then 400 µl of each sample was aliquoted into an Eppendorf tube and 100µl of 0.1% 
TSP/D20 and phosphate buffer at pH added. The samples were then manually transferred 
into 5mm NMR tubes.  
A subset of samples (n = 18) for both plasma and urine samples was then selected which it 
was hoped would be representative of the whole study. These samples included controls 
(pre-dose and 24 hours), high dose (pre-dose and 24 hours) and recovery animals (24 and 
144 hours). Both plasma and urine samples were then run on a 5 mm Prodigy TCI 
cryogenically cooled probe in a Bruker Avance III Spectrometer operating at 700 MHz. The 
1H NMR spectra of the urine were measured using one-dimensional (1D) nuclear 
Overhauser enhancement spectroscopy (NOESY) presat (noesypr1d) pulse sequence 
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(Stonehouse and Keeler, 1995); NOESY was preferred over CPMG as this is not routinely 
used for water suppression in urine and plasma. The data were acquired using Topspin 2.1. 
5.2.3 1H NMR Spectroscopic Data analysis 
The same computational methodology was employed for the chemometric analysis of both 
the urine and plasma 1H NMR datasets. After phasing to correct for first and zero-order 
errors, and baseline correction to account for distortions of the base values, the data was 
imported to MATLAB R2012b (Natick, Massachusetts, U.S.A.) using the Metaspectra 
program script, using a resolution of 0.00055. The data were then aligned using Recursive 
Segment-Wise Peak Alignment (RSPA) (Veselkov et al., 2008) and normalised by 
Probabilistic Quotient to account for, and exclude, systematic sources of bias within samples 
which were not due to biological processes or environment. Statistical Recouping of 
Variables (SRV) (Blaise et al., 2009) was then used for peak detection, and the integrated 
dataset was exported to SIMCA-P+ 13.0.2 software for multivariate analysis. 
 5.2.4 Sample Preparation and Experimental for UPLC-MS 
UPLC-MS analysis was performed at Imperial College London. 
Prior to analysis the sample order was randomised using the Microsoft excel random 
number generator function. Only urine samples were included in the analysis. A 150 µL 
aliquot of urine was mixed with 300 µL water to dilute the salt concentration before protein 
removal via precipitation with acetonitrile (1:2 v/v). These samples were vortexed and left at  
-20 °C overnight before centrifugation for 5 min at 12 000 g at 4 °C. For reversed-phase 
chromatography 50 µL of sample was taken and added to 150 µL water in 350 µL 96-well 
plates (Waters Corporation, Milford, USA). A pooled quality control (QC) sample was 
prepared (Want et al., 2010) by combining 100 µL of each sample and diluting 1:4 with 
water. The 96-well plate was stored at -20 °C until the analysis by LC-MS as described 
below. Immediately before being placed in the autosampler the plate was centrifuged at 
1700 G before being placed into the autosampler at 4 °C. 
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Reversed-phase liquid chromatography was performed on an Acquity UPLC system (Waters 
Ltd, Elstree, UK) coupled to a Synapt G2 triple quadrupole dual time-of-flight mass 
spectrometer (Waters MS technologies, Ltd., Manchester). UPLC-MS conditions for urine 
analysis were those  previously described for the reversed-phase analysis of urine (Want et 
al., 2010) with the separation performed using a Waters HSS T3 (1.8 µm, 2.1 x 100 mm) 
column. For sample analysis aliquots of 2 µL per sample were injected. The 
chromatographic mobile phase was composed of 0.1 % formic acid in water (A) and 0.1 % 
formic acid in acetonitrile (B).  The column temperature was maintained at 40 °C and linear 
gradient elution was performed at either 0.5 mL/min for the 2.1 x 100 mm column or 0.4 
mL/min for the 1 x 50 mm column.  The starting composition was 1 % B, held for 1.0 min 
before increasing to 15 % at 3.0 min, 50 % at 6.0 min, 95 % at 9.0 min for a 1.0 min wash 
and returning to 1 % B for a 2 min re-equilibration step (total cycle time 12 min).  Mass 
spectrometry was performed with electrospray ionisation operated in negative ion mode 
(ESI-). The instrument was operated in sensitivity mode and set to acquire data over the m/z 
range 50 – 1200 with a scan time of 0.1 s. All mass spectral data were collected in centroid 
mode using the MSe data acquisition function. For mass accuracy, leucine encephalin (MW 
= 555.62) was used as a lock mass at a concentration of 200 pg/uL (in 50/50 CH3CN:H2O, 
0.1 % formic acid) infused at a flow rate of 20 µL/min via a lock spray interface. The data 
were collected using MassLynx V 4.1 software (Waters Corportation, Milford, USA). 
5.2.5 UPLC-MS Data analysis 
The UPLC-MS data set was pre-processed using Transomics (Non Linear Dynamics, UK) 
software in order to convert the three-dimensional LC-MS raw data into time-aligned 
detected features of retention time, m/z ratio and intensity (peak area). The ion intensities for 
each peak detected were then normalised, within each sample, to the median peak intensity 
in that sample. The resulting peak marker tables, comprising m/z, RT and normalised 
intensity values for each variable in every sample, were exported to SIMCA-P+ 13.0.2 
software (Umetrics, Umea, Sweden) to perform multi-variate statistical analysis. 
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5.2.6 Statistical Modelling  
Prior to any statistical modelling the QCs were evaluated, through both the use of CV and 
positioning within PCA plots. If there was significant variation within the quality control data, 
or if there was significant drift within the position of the QCs within PCA scores plots the data 
would have been unfit for analysis. SIMCA-P+ 13.0.2 was used for the statistical modelling; 
Principal component analysis (PCA) (unsupervised) and Partial least square regression 
discriminant analysis (OPLS-DA) were utilised to explore any underlying stratification within 
the data. Scores plots were used to investigate any differences within the sample groups 
and the loadings were used to identify which (if any) variables were driving the separation. 
Validation was also performed to test the predictive capabilities of the models created. Each 
peak or feature of interest was then tested for significance using a modified Multiple Analysis 
of Variance (MANOVA) and the p values corrected for multiple testing using Benjamini-
Yekutielli correction. Metabolite assignment was then performed. 
 5.2.7 ICP-MS 
ICP-MS data was provided by Dr David Thompson, Keele university. Concentrations of Br 
containing material in the urine were calculated in reference to a standard curve prepared 
using o-bromophenol. Ten calibration standards were prepared in control urine covering the 
range 0.00004 to 4 mg mL–1. 50 μL of each standard was directly injected, into a NexION 
350 ICP mass spectrometer (Perkin Elmer UK Ltd.), set to monitor 79Br and 81Br, and the 
response measured over 1.5 minutes. The NexION ICP-MS was operating at the conditions 
as described in Duckett et al., (2015). The measured peaks were then used to construct a 
standard curve. Urine samples were then directly injected, in duplicate, into the ICP-MS, set 
to detect both 79Br and 81Br in addition to 192Ir as an internal standard. The responses were 
measured over 1.5 minutes and then total bromine concentrations were determined by 
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utilising the reference curve. The data were collected using MassLynx V 4.1 software 
(Waters Corportation, Milford, USA) 
5.3 Results and Discussion 
 5.3.1 Cryogenically cooled 1H NMR spectroscopy 
The 1H NMR spectroscopic analysis of 2-bromophenol described for the COMET sample set 
in Chapter 4 was performed on conventional 600 Mhz instruments. As there were few 
discriminating signals detected from this methodology the application of a cryoflow probe 
aimed to improve coverage as it has been shown to have the ability to improve the limit of 
detection (Spraul et al., 2003). By supercooling the radio-frequency coils of the instrument, 
the signal to noise ratio is substantially increased. Furthermore by cooling the tuning and 
matching circuits the random thermal motion of electrons in the conductors is reduced and 
the resistivity of the pure metals also decreases with lower temperature, all of which 
additionally reduces the noise. The preamplifier, filters and transmit-receive-switch are also 
cooled in order to improve the noise figure of the electronic components. This also allows for 
the use of smaller volumes of sample (100 l as opposed to the 500l that was necessary 
for conventional 1H NMR spectroscopy) which was crucial as there were limited sample 
volumes available and a wide range of analyses were planned. It was also hoped that the 
application of cryoprobe technology would result in the detection of 2-bromophenol and its 
metabolites which, whilst readily detected by UPLC-MS, were not observed using 1H NMR 
spectroscopy for analysis of the COMET samples, and were assumed to be previously 
below the limit of detection. 
a. Plasma 
Analysis of plasma samples via the cryoprobe study showed that the detection of low 
concentration endogenous metabolites was substantially increased and sharper peaks were 
produced when compared to the 1H NMR spectral data from the COMET study.  
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Figure 5.1 A comparison of the typical control (top) and high dose (bottom) NMR spectra of plasma 
obtained at 24 hr post dose with either corn oil or 200 mg/kg 2-bromophenol.  
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Chemometric analysis of the plasma data identified a clear separation between the high 
dose treatment groups (200 mg/kg) and the controls in statistical space when PCA modelling 
was employed (figure 5.2a). Maximal response was identified to be 24 hours post dose, as 
seen in figure 5.2b, which is in agreement to the results presented for urine in Chapter 4 for 
the single dose study. 
This trend was also mirrored in the OPLS-DA modelling performed, and comparisons of the 
control and high dose group at 24 hours (figure 5.2c) showed a clear metabolic difference 
between the animals. However, when investigating any time related effects it became 
apparent that there was little metabolic difference between high dose and recovery group 
(96hrs after dosing termination/144hrs post initial treatment) (figure 5.2d) This would suggest 
either that the systemic metabolic changes from the xenobiotic administration are irreversible 
or insufficient time had passed for significant metabolic reversal. The OPLS-DA statistical 
models produced achieved high correlation values and predictive power (R2= 0.78, 
Q2=0.61) (figure 5.2) and allowed for the identification of the signals influencing the 
separation most. However, due to low sample size (n=18), despite the clear metabolic 
difference, individual variables failed to pass the multiple testing correction, with the 
exception of 3.54, Glycine (p= 0.036) which was increased in the high dose group (figure 
5.3c). 
The role glycine may have in the response to 2-bromophenol administration is not clear. 
Glycine is a non-essential amino acid and has various roles in metabolism, including bile 
acid conjugation and other endogenous metabolic pathways (Robert, 1986). Biologically it 
has a role in inflammation and protects against renal and hepatic toxicity. Glycine possess 
vasodilatory activity in renal vessels and can increase renal blood flow and glomerular 
filtration rates (Brezis et al., 1984). Glycine also is involved in the protection of hepatic cells 
from oxidative stress and attenuates the glutathione depletion caused by many hepatotoxins 
(Deters et al., 1998).  
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Figure 5.2. The scores plots from the multivariate analysis of the 
1
H NMR spectral data obtained from 
the plasma of the multiple dose 2-bromophenol study, coloured by dose group. A) Is the PCA scores 
plot comparing the high dose and control groups. B) Is the PCA scores plot comparing the high dose 
and control animals at 24 hours post initial dose, which is the time point of maximal response. There is 
a clear metabolic difference between the two dose groups. C) Is the OPLS-DA scores plot of the same 
comparison, further highlighting the dose related trend. D) is the PCA scores plot comparing the 
controls with the two different time points of the recovery group. There is little difference between 24 
hours (maximal response) and 144 hours (3 days after dosing has ended) indicating that the metabolic 
perturbation has not resolved.  
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b. Urine 
 
Figure 5.3. The loadings plot (a) from the plasma OPLS-DA analysis displaying a pseudospectrum 
overlaid with a heat map representation of the correlation scores for each variable and the spectrum of 
a high dose sample (b) with the x axis (ppm) aligned for comparison. There are few areas of high 
correlation, and the majority of the variables of influencing peaks failed the multiple testing correction. 
C) Is the enlarged glycine peak (red) overlaid with a control sample of the region (blue). Glycine is the 
only metabolite which was of statistical significance.  
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Chemometric analysis of the urine 1H NMR spectroscopic data showed a strong difference in 
metabolic profiles between control and treatment groups with these differences more 
pronounced than those seen for plasma. Construction of PCA models indicated a strong 
separation of the high dose group (200 mg/kg) from the low dose (100 mg/kg) and control 
groups within statistical space. On initial observation it may seem as if there are a number of 
high dose samples mixed with the controls in statistical space however, when coloured by 
time point to show the pre-dose and recovery times points, as well as the post dose 
samples, it is possible to visualise the ‘metabolic journey’ through time from a “normal” pre-
dose profile to metabolic events at 24 hours post dose and back to equilibrium after the end 
of the treatment (figure 5.4). 
 
 
 
Figure 5.4. PCA scores plot of the urine samples, coloured by both dose group and time point. Using 
this colouring scheme it is possible to visualise the ‘metabolic journey’ journey of the animals, as 
indicated by the coloured arrows. Initially all samples are similar to the controls (pre dose). Compound 
dosing alters the metabolic profiles. After dosing has ended the effects gradually diminish until the 
metabolic profiles have returned to equilibrium. 
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OPLS-DA modelling was also performed, and comparisons of the control and high dose 
group at 24 hours (figure 5.6a) illustrate the significant metabolic differences between the 
animals. The statistical models produced achieved very high correlation values and 
predictive power (R2= 0.99, Q2=0.98) and allowed for the identification of the signals driving 
the separation. Figure 5.6b illustrates the OPLS-DA s-plot, with the enlarged region 
indicating which spectral signals are most influential. Despite the low sample size the 
differences in variables were large enough for the identified peaks to pass multiple testing 
correction and were highly significant.  
 
 
 
Figure 5.5. A) is the OPLS scores plot of the urine samples comparing the high dose and control 
animals, coloured by dose group. There is a clear distinction between the treatment groups. B) Is the 
OPLS-DA s-plot indicating which are the variables contributing most to the separation. The integrated 
peak regions in the top right of the plot are those which are elevated in the high dose. This area is 
zoomed in at the bottom and the chemical shift is also indicated. 
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After identifying the regions of interest putative assignments could be made using both 
results from the previous studies but also database information. Key analytes were the 
glucuronide and sulphate conjugates (5.16/7.16/7.27/7.43/7.66) of 2-bromophenol and 
the endogenous metabolite hippuric acid (3.91/7.52/7.54). A comparison of the high dose 
and control 1H NMR spectra is included below (Figure 5.7) together with a zoomed in region 
of the putative 2-bromophenol/glucuronide/sulphate assignment (figure 5.8).  
Figure 5.6 The loadings plot (B) from the Urine OPLS-DA analysis displaying a pseudospectrum 
overlaid with a heat map representation of the correlation scores for each variable. A), C) and D) are 
zoomed in representations of the real peaks in the regions indicated (red = High dose, blue = control). 
Asterisks above peaks indicate MANOVA significance levels:   ** p < 10-10, * p < 10-5 
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Figure 5.7 A comparison of the typical control (top) and high dose (bottom) 
1
H NMR spectra, with 
putative assignments included on the high dose spectrum obtained at 1 hr post initial dose. 
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These results, which show very high concentrations of 2-bromophenol-related compounds in 
the urine of these Han Wistar rats at should be contrasted with the low (undetectable) 
amounts seen in the COMET study samples obtained after dosing Sprague Dawley animals. 
There is an analytical difference, as these data were obtained using a 700 MHz NMR 
spectrometer with a cryoprobe as to an instrument operating at 600 MHz with a conventional 
probe. However the reason for the differences observed is unclear considering dose, dose 
formulation and dose route was the same, but may reflect strain differences in the handling 
of the compound. Irrespective of the reason for these differences it is evident that kidney 
exposure to the potential toxicity of 2-bromophenol, as measured by urinary excretion, is 
much higher here than in the COMET study (see also the UPLC-MS urinary data discussed 
below). 
 
 
Figure 5.8 A zoomed in representation of the aromatic region of a typical high dose sample, at 1 hour 
post first dose. Putative assignment of the signals from 2-bromophenol sulphate and 2-bromophenol 
glucuronide. 
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5.3.2 UPLC-MS Quality Control  
Standard QC based quality control of the analytical stability of the experiment was performed 
on the dataset. The reasons for the need of such quality assurance have been extensively 
discussed in previous chapters. Initial visual inspection of the QC chromatograms showed 
good consistency throughout the run. Figure 5.9 illustrates how the chromatograms of the 
QCs throughout the run overlay, with no evidence of retention time drift. These trends were 
mirrored in the initial PCA scores plots used to scrutinise analytical drift. Figure 5.10 shows 
the initial un-filtered data for the negative ESI MS run; the red points in the scores plot 
represent the QC samples. It can be seen that all the QCs cluster together almost perfectly 
in the centre of statistical space. It was concluded that the data acquired was of very good 
quality and suitable for further statistical analysis.  
 
 
 
 
 
Figure 5.9 chromatographic peaks of the QCs throughout the run. The chromatograms are highly consistent 
and overlay well, with no visible retention time drift, suggesting that the analysis achieved good analytical 
stability.  
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To ensure that the QCs were consistent throughout, the coefficient of variation for each of 
the features detected in the QCs was calculated. Ion intensity stability is typically poor for 
low intensity ions and greater the more intense the ion (providing it is not saturating the 
detector) and those features that are subject to ion suppression/enhancement will show 
greater variation than those that are resolved from ion suppressing matrix components. The 
CV was calculated in the same manner as previous chapters, and the results are in the table 
below (Table 5.1). The high percentage of ions passing even the stringent 15% CV threshold 
gave a high level of confidence in the analytical stability of the run.  
 
  
<15% 
CV less than 
<20% 
 
<30% 
Negative Mode 
71.7% 80.8% 90.2% 
Figure 5.10 PCA scores plot showing the positioning of the QC data within statistical space, in the negative 
ionisation mode. The red dots are the QCs while the grey dots are the samples. The QCs cluster well towards 
the centre of the plot.  
Table 5.1 CV percentage scores for the QC data. 
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5.3.3 UPLC-MS Chemometric analysis 
After computational analysis with Transomics software, the extracted metabolic signatures, 
defined by retention time and m/z ratio, were investigated using multivariate statistics in a 
similar way to the previous chapter. Initial observation of the chromatograms showed that 
there were peak differences between the high dose and low dose groups. Of special note 
was a huge peak, of an intensity suggesting probable detector saturation, eluting after 4.5 
minutes which seemed to dominate the peak profile as shown in figure 5.11.  
 
 
 
This large peak represents bromophenol metabolites (see below) and should also be 
compared to the results obtained on the samples from the COMET study undertaken in 
Sprague Dawley rats. These results confirm, if confirmation were necessary given the 1H 
Figure 5.11 A comparison between the chromatograms of a typical control (top) and a high dose 
urine (obtained from animal 10M39) at 24 hours post administration of 2-bromophenol. The large 
peak highlighted in red is the major difference between the profiles. 
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NMR spectroscopic data on these samples, that much higher kidney exposure to 2-
bromophenol-related material was attained in this study in the Han Wistar rat. 
Initial PCA modelling produced scores plots which showed a convoluted distribution of the 
samples across metabolic space. There was no immediately discernible trend, and there 
seemed to be complicated responses from both the high dose and low dose animals. 
However, when time points were taken into account it became apparent that maximum 
response to bromophenol administration was at 24 hours post dose, and when the profiles of 
the high dose group at this time were compared to the controls there was a significant 
discrimination as seen in figure 5.12. 
 
 
 
 
Subsequent OPLS modelling of the 24 hour time point provided very strong models (R2 = 
0.95, Q2 = 0.86), which were used to identify the signals driving the separation. Figure 5.13 
shows the OPLS-DA scores plot and the S-plot used to identify the critical ions. The ions 
highlighted are m/z 252.9, m/z 175.02 and m/z 348.97 which match the mass to charge 
Figure 5.12 PCA scores plots. A) Is the model which includes all the data, coloured by dose group. 
There is no obvious separation although there is a time related trend as shown by the black arrow. 
B) is the comparison of just the high dose group and controls at 24 hours post dose. There is now a 
clear separation between the treatment groups, and this proves to be the timepoint of the maximum 
statistical difference between the groups. 
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ratios of 2-bromophenol sulphate, 2-bromophenol (parent) and 2-bromophenol glucuronide 
respectively, and also match previous findings (see chapter 4.4.3). The retention times of the 
signals also showed that they were all found to be the peaks eluting in the large distinctive 
peak highlighted previously. Given the likely large differences between the physico chemical 
properties of the 2-bromophenol the presence of the 175.02 ion probably resulted from in 
source decomposition of the sulphate and glucuronide metabolites (see below) rather than 
the presence of any of the free aglycone itself. This pattern of metabolites was similar to that 
seen for the Sprague Dawley rats used for the COMET study and described in Chapter 4. To 
ensure that these assignments were consistent with the previous, evaluation of the mass 
spectra of the ions identified the distinctive bromine 1:1 isotope pattern and appropriate 
losses of 80 and 176 Da, diagnostic for the sulphate and glucuronic acid moieties 
respectively, due to fragmentation in the ion source, and are highlighted in figure 5.14 
together with the chromatographic peak.  
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Figure 5.13. a) scores plot of the OPLS-DA model comparing the high dose and control group 
animals at 24 hours post first dose, showing clear separation between the classes. Inspection of the 
s-plot (b) derived from the OPLS model comparing low dose and controls, the ions influencing 
discrimination are m/z 252.9, m/z 175.02 and m/z 348.97.  
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5.3.4 Model validation and significance testing 
To validate our model the same permutation testing employed previously was again used. 
This is of critical importance for mass spectral data as the platform detects many more 
features and therefore the data is highly multi-collinear. Once again 1000 iterations 
recalculated every 100 permutations were used for each of the models and comparisons 
performed and presented below in figure 5.15. The permutation plot for the comparison of 
the high dose and controls at 24 hours post dose is presented. Also included are the CV-
anova statistics in the table below for completeness (table 5.2). 
 
 
Figure 5.14 The mass spectra of 2-bromophenol sulphate (top right) and 2-bromophenol 
glucuronide (lower right) together with their respective chromatographic peaks (left). The mass 
spectra revealed the appropriate losses of 80 and 176 Da, for the sulphate and glucuronide 
moieties respectively, supporting these assignments. The higher mass ions seem to be the same 
source related dimer as described in Chapter 4. 
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OPLS-DA Sum of 
Squares 
Degrees of 
Freedom 
Mean of 
Squares 
F value P Value Standard 
Deviation 
Total corr. 13 13 1   1 
Regression 10.2453 4 2.56132 8.3681
1 
0.0042196 1.60041 
Residual 2.75473 9 0.306081   0.553246 
Table 5.2 CV ANOVA scores for the significance test. 
5.3.5 Extraction of “isotopobromatograms” from the LC-MS data 
As discussed in the previous chapter, compounds containing bromine have a very distinctive 
isotope pattern in their mass spectra, with the 79Br and 81Br isotopes present at 2 Da apart 
and at a ratio of approximately 1:1. This isotopic signature enables the chromatographic data 
to be searched for this characteristic mass difference and ratio. This selective tracing 
highlighted 6 bromine-containing peaks, for which the spectra are detailed in figure 5.16. 
Figure 5.15 Permutation plot for the model constructed. The green and blue dots represent the R2 
and Q2 of the dummy data respectively, and the dashed line is the median value trend for the 
dummy values. The permutation values are lower than the actual values suggesting that the model 
is highly robust. 
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These are the same bromine containing-compounds which were identified in the previous 
study, and their (repeated) assignments are summarised in table 5.3. As the ions, and their 
fragments, matched those examined in the previous chapter further MS/MS was not 
performed. 
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Figure 5.16. Isotopobromatogram (top) and the related mass spectra (bottom). The chromatographic peaks 
are labelled and match up to the mass spectra. All the mass spectra show the distinctive 1:1 bromine 
isotope pattern. 
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Metabolite Measured Mass Retention Time Formula IBG  
2- hydroxy bromophenol 
glucuronide 
364.96 3.00 C12H15O9 F 
2- hydroxy bromophenol 
sulphate 
268.89 3.25/3.52 C6H7O5BrS D/E 
2-bromophenol sulphate 253.90 4.47 C6H6O4BrS B 
2- bromophenol Glucuronide 349.97 4.43 C12H14O8 C 
2- hydroxy (3-methoxy) 
bromophenol sulphate 
282.91 5.14 C7H8O5BrS A 
Table 5.3 Assignments of the analytes identified by the bromine isotope pattern recognition. 
 
5.3.4 Inductively Coupled Plasma Mass Spectrometry (ICP-MS) 
As discussed in the introduction, ICP-MS is a powerful elemental detection that allows for 
the direct quantification of the target element. ICP-MS allows studies on the metabolic fate of 
compounds, without the need for the copious and expensive synthesis of radiolabelled 
standards which are otherwise necessary for this type of experiment. By using 79/81 Br-
ICPMS for quantification in this study, it was possible to determine concentrations of total 
bromine in the urine samples. Figure 5.17b below presents the progression of bromine 
concentrations in a typical high dose animal, with a clear decrease in 2-bromophenol-related 
material present in the urine following the cessation of dosing. A comparison between the 
control and high dose (and recovery) groups show that the baseline bromine urinary 
concentrations are 0.55 ± 0.3 mg/mL whereas at 24 hours, the time of maximum response, 
bromine concentrations reached 3.01 ± 0.8 mg/mL in the high dose group. In the recovery 
group, 4 days after dosing had stopped the concentrations of bromine were only slightly 
reduced, to 2.57 ± 0.8 mg/mL, suggesting that perhaps 2-bromophenol and its related 
metabolites are excreted relatively slowly. Figure 5.17a illustrates the average urinary 
bromine concentrations for the three groups. 
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5.3.5 Histopathology and Clinical Chemistry 
As for the single dose study described in Chapter 4 “traditional” toxicology assessments, 
including histopathology on the kidneys removed from the animals at termination and clinical 
chemistry tests were undertaken on both the urine and blood samples. These data were 
provided by Kim Maratea, from DSM Boston, Astrazeneca. 
a. Histopathology 
Lau et al. (1984) reported that the administration of 2-bromophenol resulted in nephrotoxicity 
characterised by necrotic damage to the proximal tubule cells. Information on whether 
toxicity was achieved by the current study was provided by the histopathology report (see 
appendix). Again it was hoped that the high dose would cause changes in the kidney but no 
mortality. However, neither the low nor the high dose groups showed any clinical signs, and 
Figure 5.17. Results from the bromine ICP-MS. A) is the adjusted averages for the total bromine 
concentrations for each treatment group. There is a baseline bromine level indicated by the controls, 
however, administration of 2-bromophenol greatly increases urinary bromine levels as expected. There is 
however little difference between the concentrations at 24 hours (high dose) and recovery (144 hours, 3 
days after dosing has stopped), suggesting that the compound and its major metabolites are excreted 
slowly. B) The typical bromine excretion curve for a high dose animal over the 6 day study. 
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the rats appeared comfortable and in good health throughout the experiment. One low dose 
rodent exhibited signs of very minor tubular degeneration, and one high dose recovery 
animal showed mild mononuclear cell damage coupled with minor tubular degeneration. 
However, this is a low number and the rest of the animals in the group showed no kidney 
damage whatsoever. An overview of the total histopathology findings are detailed below 
(table 5.4). 
 
 
b. Clinical chemistry 
Haematology clinical chemistry data (provided in the appendix) showed no changes in the 
haematology parameters after 2-bromophenol administration and all animals were within the 
normal ranges for each test.  Urinary clinical chemistry, shown in table 5.5, showed a slight 
overall elevation in urinary protein concentrations, although creatinine, glucose and urea 
levels remained unaffected.  
   Table 5.4 Histopathology observations  
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Testing for the detection of any salient kidney injury biomarkers was also performed, to 
ensure that any kidney injury which was not detectable by histopathological inspection was 
not missed. Key biomarkers investigated were a-glutathione-S-transferase (aGST), 
indicative of glutathione depletion, rat glutathione-S-tranferase Yb1 (GSTYb1) a glutathione 
transferase which is localised to the renal tubule cells, renal papillary antigen (Rpa-1) 
specific for collecting duct cell damage and also a biomarker of 2-bromoethanamine 
nephrotoxicity (Price et al., 2010), clusterin, indicative of toxicant induced acute kidney injury 
in the rat (Vaidya et al., 2009),  neutrophil gelatinase-associated lipocalin (NGAL, also 
known as lipocalin-2) an early indicator of nephrotoxicity (Devarajan, 2008), osteopontin, 
shown to be indicative of glomerular damage and inflammation (Panzer et al., 2000) and 
kidney injury molecule-1 (Kim-1) one of the major diagnostic markers for renal proximal 
tubule injury (Han el al., 2002). While the biomarker testing was extensive there were no 
overall trends within the data, suggesting that there had been no kidney damage. The results 
of the analysis are presented in table 5.6 below. 
Table 5.5 Urine clinical chemistry parameters in the rats on Days 1, 2 and 6. Data are expressed as 
Mean ± Standard Deviation.  
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5.4 Summary and Conclusions  
Previous work had identified 2-bromophenol, a phenolic metabolite of bromobenzene, as a 
potential nephrotoxin (Lau et al, 1984b). The previous chapter described a 2-bromophenol 
toxicity study in Sprague Dawley rats, as part of the COMET program. That study assessed 
the nephrotoxicity of the compound by combining 1H NMR spectroscopic and UPLC-MS 
metabolic profiling. While there was evidence of extensive metabolism of 2-bromophenol, 
with key 2-bromophenol metabolites and changes in endogenous metabolism identified, the 
overall conclusion was that there was no nephrotoxicity at the doses administered.  
This chapter describes the continuation of this research avenue with the investigation of the 
effects of chronic 2-bromophenol exposure, this time in Han Winstar rats. After combined 1H 
NMR spectroscopic and UPLC-MS metabolic profiling, statistical analysis showed that there 
was a significant metabolic perturbation due to administration of the compound. However, 
once again, even with a longer dosing schedule, the histopathology and clinical chemistry 
analysis still showed no evidence of kidney damage. Use of cryoprobe technology with the 
1H NMR spectroscopy, combined with the urinary excretion of significantly higher 
concentations of 2-bromophenol-related material, did allow for the identification of the major 
Table 5.6 Summary of kidney injury biomarkers in the rats on Days 1, 2 and 6. Data are expressed 
as Mean ± Standard Deviation. 
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2-bromophenol metabolites, the glucuronide and sulphate conjugates, which were also the 
key discriminating signals together with hippuric acid. The analysis of the urine-derived LC-
MS data revealed that the major discriminating ions were not the result of changes in 
endogenous compounds but to the detection of the sulphate and glucuronide conjugates of 
2-bromophenol. Further detailed analysis of the urine via bromine-isotope specific detection 
revealed the presence of a number of minor, hydroxylated conjugates of 2-bromophenol, 
replicating the previous results. There was once again no evidence of glutathione 
conjugates, generally agreeing with the theme of no toxic value.  
The overall conclusion from both this and the previous study, with respect to nephrotoxicity, 
was that after administration of 100 or 200 mg/kg, either as a single dose or repeated, 2-
bromophenol is not a kidney toxin. There is overwhelming evidence supporting this 
conclusion as three separate studies (including the original COMET), in different animals in 
different animal laboratories achieved the same results. It is therefore apparent that all 
current data is not in agreement with the previous work by Lau et al.; further work would be 
needed to ascertain why this discrepancy is so prominent.  
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Conclusion 
Chapter Six 
This chapter provides a summary of the work undertaken during the research 
leading to this Thesis, and also some general conclusions. Based on the 
outcomes garnered from the collective evaluation of the work presented in this 
thesis suggestions for future research are presented. 
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6.1 Summary and Conclusions 
The utility of metabonomics as a platform for studying xenobiotic metabolism and toxicity has 
been extensively discussed both in this thesis but also in the available literature. What 
separates metabonomics from other types of investigations is the fact that metabolic profiling 
enables the hypothesis free observation of the effects of exogenous compounds on whole 
organisms by utilising multiparametric measurements of the response to the exposure over 
time. In the cellular environment, every level of biomolecular organisation is mutually reliant, 
and thereby equally susceptible to external events. Downstream phenomena, be it the direct 
effect of the introduction of the foreign compound, or a metabolite thereof, or the alteration of 
the abundance of endogenous substances, can all be mapped upon a metabolic landscape. 
This landscape, constructed by the metabolic profiling of biofluids or tissues, when 
incorporated into a systems biology framework, allows an understanding of the relationships 
between the experimental inputs and real world endpoints; which is not always the case with 
other ‘omic’ fields. 
Integral to the ‘metabonomic’ process is the characterisation of these metabolic changes 
through appropriate analytical methods, with NMR spectroscopy and LC-MS predominating 
in this regard. The acquired data is then analysed using multivariate statistics by various 
chemometric and bioinformatic tools.  However, as time progresses both the analytical 
platforms and the computational resources available change. Furthermore, recent trends 
within epidemiological and toxicological studies (amongst others) indicate that there is a 
distinct focus on large-scale population level studies, requiring high-throughput technologies. 
This means that for the continuing evolution of metabonomics as a field, and indeed its 
survival, new analytical methods and computational approaches must be developed to 
satisfy this increase in demand. The work presented in this thesis has, in addition to its 
application to xenobiotic metabolism and toxicity, revolved around the expansion of the 
capacity of current experimental practice, with the onus being on surmounting the intrinsic 
limitations of the technologies employed. 
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The first experimental chapter of this thesis (Chapter Two) is centred on the application of 
‘computational’ spectrometry, utilising multivariate statistical significance, primarily PCA 
modelling, to identify which metabolic signals are relevant to the xenobiotic metabolism and 
toxicity processes under study. Traditional mass spectrometry generally requires an 
analytical chemist to manually scan through the data using both metabolic and analytical 
expertise to highlight ions of interest (although software programs exist where “expected 
metabolites” can be automatically searched for). This process is both time intensive and 
demands highly skilled individuals for good results. Furthermore, results between different 
specialists may be different as both experience and observer bias may influence areas of 
focus. Therefore using multivariate statistics to circumvent or supplement the human 
element is a highly attractive prospect.  
However, in the pilot experiment investigating the effect of diclofenac administration, at a 
relatively low “therapeutic” dose to a limited number of animals, by urinary UPLC-MS, the 
statistical approach was unable to detect diclofenac metabolites, despite a clear difference in 
overall metabolic profiles. Major diclofenac metabolites were, nonetheless, present, which 
was retrospectively confirmed by manual evaluation of the data. The signatures from the 
metabolites were being masked by unrelated biological processes which lowered the 
significance of the drug administration effects. This study was, however, a small scale 
metabolism study, typical of the type of study performed by conventional drug metabolism 
groups in early drug development, which lacked both statistical power and sufficient cohort 
size.  
When the same statistical modelling approach was employed in a large scale COMET  study 
in the rat using the drug acetaminophen, with over 600 urine samples and a high 
“toxicological” dose, the results were markedly different. OPLS modelling highlighted large 
differences between the test groups, and readily highlighted the key metabolites. Using 
model validation, the major metabolites were identified as the expected Phase II 
acetaminophen conjugates, as well as the unchanged parent and the “minor” mercapturates. 
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Manual evaluation revealed that the major metabolite peaks dominated the chromatography, 
which in turn made the variable a key contributor to the model statistics.  
In principle the statistical approach is mathematically holistic; while this does mean that it is 
able to detect subtle effects on endogenous metabolism this does not necessarily equate to 
a superior exploratory tool. The statistics are mechanically detached from any biological 
process and therefore may occlude discovery of important information because equal weight 
is given to all variables. In the diclofenac study, the major metabolic differences were due to 
unavoidable diurnal variation. The trained specialist would be able to identify this and then 
effectively exclude any signals pertaining to this process, leading to the discovery of the 
target metabolites; the computational algorithms unfortunately cannot. Ultimately it is this 
lack of adaptability that may render such methodologies inviable. While there is of course a 
place for computational metabomomics, especially in the discovery of novel biomarkers and 
the validation of animal models of disease, it’s usage should still typically be supplemented 
by relevant analytical and biological expertise.    
One of the analytical problems encountered, and subsequently explored, was the issue of 
limited continuous instrumental capacity. Thus, if the sample size of the study exceeds the 
time available on the instrument, current practice involves splitting of the samples into 
separate runs. Also, as has been frequently mentioned LC-MS is an analytically unstable 
platform, with a noticeable decrease in sensitivity as contaminants build up on the ESI 
source. After a certain point the data retrieved can become unreliable, and difficult to 
compare with previous data. However, one of the further complications is that data from 
different runs, either required by instrument cleaning or “time-constrained” batch splitting are 
impossible to merge as subtle differences in the analytical environment between runs 
renders the data incomparable.  
As described in the Thesis, many attempts to utilise statistical batch-correction algorithms 
have been published, and generally revolve around using the QC samples to normalise the 
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data. In the acetaminophen study described here, the samples were separated into four 
batches. Batch correction was attempted using variance stabilisation with a glog function 
prior to median fold change normalisation. While mathematically reducing multiplicative 
noise and equalising variations across the batches, this approach was unable to correct the 
data to the extent where it was suitable for combined downstream analysis. Further 
tampering with the data could result in loss of biologically important information and was 
therefore deemed an invalid approach. Indeed what could be technically suitable for one 
study or for one type of data might not be for another, which currently precludes the 
synthesis of a universally applicable method. Ultimately attempting to correct “bad” data, 
when the potential for acquiring “good” data exists, is a counter intuitive approach to 
research. As the origin of the problem lies in the analytical instability of the mass-
spectrometry platform, and as such is in essence an analytical issue, an analytical solution 
was considered to be required. 
In chapter three, a rapid gradient microbore UPLC-MS method was described to provide a 
high-throughput solution for metabolic phenotyping of large sample collections enabling all 
samples to be run as a single batch. Whilst this does not remove the need for instrument 
cleaning at some point it does, potentially, remove the need to attempt to “stich” different 
batches together. Typically in UPLC-MS a gradient separation, rather than isocratic 
chromatography, is used. The use of a solvent gradient allows for compounds of very 
different polarities to be eluted in the same analytical separation. The length, and therefore 
the steepness, of the gradient is therefore generally proportionate to the resolution of the 
analysis.  By decreasing the gradient elution time the length of the analysis of each 
individual sample can be reduced from 12 minutes to 1.5 minutes. In addition, by reducing 
the column diameter, as described here from 2.1 to 1 mm i.d., sample size can be reduced 
to maximise the use of limited samples such as those obtained from rodent toxicity studies. 
Whilst employing a more rapid gradient does inevitably reduce chromatographic resolution, 
equating to around a 70% decrease in ions detected, if there are major metabolic changes 
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present these will still be represented. Indeed when this rapid gradient method was applied 
to the previous acetaminophen study, and to a subset of the COMET 2-bromophenol study 
samples the same discrimination as conventional UPLC-MS was observed. Furthermore, in 
both sample sets, the same major metabolites were identified.  
This approach does indeed have some limitations, as many subtle yet possibly biologically 
important changes could be missed. However, the advantages of speed and the elimination 
of the need for separate batches far outweigh the disadvantages, and the rapid gradient 
approach could be employed as an exploratory investigation to ascertain whether more 
detailed profiling is required or indeed warranted. As the limitations of the LC-MS platform 
constitute an existential problem for the future of large scale metabonomic studies it is 
imperative that high throughput technologies are developed. While the rapid gradient 
described here is not a panacea of all analytical ills, it is a significant advance without being 
reliant on complex statistical manipulation of the data. 
The collective knowledge and experience gained during the metabonomic method 
development process described was then applied to a further, smaller scale, toxicology 
study concerning acute 2-bromophenol, a suspected toxic metabolite of the nephrotoxin 
bromobenzene. 2-Bromophenol was one of the test compounds of the COMET project and 
in the present investigation 1H NMR spectroscopy was combined with UPLC-MS analysis to 
investigate the toxicity and metabolic fate of this compound. Major Phase II metabolites 
identified by the UPLC-MS platform included the sulphate and glucuronide, with a number of 
minor hydroxylated metabolites also observed,  and perturbations in the endogenous 
metabolism (for e.g., hippurate) were also detected. These metabolites of 2-bromophenol 
were readily detected by multivariate statiscal analysis, and indeed represented major 
discriminating ions. However, glutathione-derived metabolites, indicative of the production of 
toxic reactive species, such as mecapturates were not detected as being present even using 
Br-specific isotopic mining of the MS  or manual interrogation of the data. This coupled with 
the histopathology and clinical chemistry results indicated that 2-bromophenol did not elicit a 
 Chapter Six 
 
 
 247 
toxic response when administered, which was in contrast to the results of the literature. 
However, the results of the study showed that, using a single metabolic profiling approach 
could be used for the investigation of both xenobiotic and endogenous metabolite profiling. 
It was, however, considered possible that achieving toxicity required greater exposure to 2-
bromophenol than achieved in the COMET study, either through higher single doses or 
repeated administration. To investigate the potential for repeat dosing of 2-bromophenol to 
cause nephrotoxicity it was therefore decided to do a chronic exposure study. After 
combined 1H NMR spectroscopic and UPLC-MS metabolic profiling, statistical analysis 
showed that there was a significant metabolic perturbation due to administration of the 
compound, with the same major metabolites of 2-bromophenol identified as before.  
Interestingly, in this study, the 2-bromophenol metabolites formed a major part of the 1H 
NMR profile of the urine, which had not been the case for the COMET samples indicating a 
potentially much higher kidney exposure to the compound. Nevertheless, once again, even 
with a longer dosing schedule, and apparently higher exposure of the putative toxin the 
target organ, the histopathology and clinical chemistry analysis still showed no evidence of 
kidney damage, nor were any reactive metabolites detected.  
The lack of toxicity exhibited by 2-bromophenol in these studies was puzzling in the context 
of the published results. The nephrotoxicity of bromobenzene, as previously mentioned has 
been well described. Furthermore the work by Lau et al. in a series of papers indicated that 
there was nephrotoxicity associated with the administration of bromophenol to the rat (Lau et 
al., 1984a). Lau clearly stated that administration of bromophenol the same doses as the 
work presented in this thesis caused nephrotic damage as well as an increase in blood urea 
nitrogen concentrations and glutathione depletion in the rat (Lau et al., 1984b). The 
presented results were also supplemented by histopathological investigation of the kidneys. 
While the techniuqes employed by Lau et al. for the measure of both BUN and glutathione 
levels (a Sigma Kit 535A) are outdated by current standards, and the fact that BUN levels 
have been shown to not be an absolute metric of kidney damage, there seems to be no 
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explanation for the differences in results especially as the Sprague Dawley rat was used for 
both Lau’s work and ours. However, it should be noted that some of the rats in the Lau study 
were pretreated with the cytochrome P450 enzyme inducer phenobarbital prior to 
administration of 2-bromophenol which has been shown to cause some level of 
hepatotoxicity and enhance the toxicity of other concurrently administered drugs (Dayrell-
Hart et al,. 1991). If this could be contributing to the toxicity is hard to determine, however, 
based on the current studies reported in this thesis the conclusion is that 2-bromophenol is 
not a nephrotoxin in the rat at the doses administered. 
In overall conclusion the work presented in this thesis highlight the utility of metabonomics in 
the field of xenobiotic metabolism and toxicology. It offers information on organism level 
functional integrity over time after xenobiotic exposure, and allows for the identification of 
characteristic changes which directly relate to the target tissues or internal processes. 
Method development effort has allowed for the evaluation of the computational pattern 
recognition methods, and the identification of limitations of current practice. Insights into 
potential solutions, both analytical and computational have been presented, with practical 
real world examples. These advances pave the way for future advances which will enable 
the continued transition of the field into the “big data” era of high throughput experiments. 
 6.2 Future Work 
A number of future directions for the application of LC-MS for the evaluation of xenobiotic 
metabolism and toxicity follow from the research described in this Thesis. 
1) The development of the rapid UPLC-MS methodology offers the potential to re-
analyse the remaining COMET samples for biomarker discovery with respect to 
mechanisms of toxicity and also for xenobiotic metabolites. Combination of this new 
data with that generated via 1H NMR spectroscopy will provide a more holistic view of 
both the changes in endogenous metabolism and its relation to exposure to the 
various toxins used in COMET.  
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2)  Whilst the rapid UPLC-MS method does offer advantages of speed and analytical 
stability over batch-driven analysis further work on improving the analytical 
methodology to enable statistical methods of normalisation for batch correction would 
undoubtedly be of value. 
3) The rapid UPLC-MS methodology used here worked well for urine samples, but it 
would also be of value to validate the approach for other sample types such as tissue 
extracts and blood-derived samples such as serum and plasma. 
4) In the specific case of 2- bromophenol it would be interesting to expand upon the use 
of the presence of bromine and obtain further information by ICP-MS on the plasma 
and urine Br concentrations (and metabolite profiles). Such information might enable 
the pharmacokinetics, and therefore relative exposures to 2-bromphenol and its 
metabolites, in the single and multiple dose studies, to be performed. Such 
information might provide further insights into the disposition and effects of 2-
bromophenol in the rat. 
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COMET consortium study with o-bromophenol: Justification for dose selection 
 
1. Chemical Name and Chemical Properties 
 
 o-Bromophenol or 2-Bromophenol 
 MW: 173.01 
 Liquid 
 
 Solubility in aqueous solution: Not applicable  
 Storage temperature: Room Temp 
 Available from Sigma-Aldrich at 98% purity  
 
2. Toxicity: Kidney toxicant 
 
 
 
o-Bromophenol, a toxic phenolic metabolite of  bromobenzene, undergoes further metabolic 
transformation to form a toxic metabolite, 2-bromohydroxyquinone.  Both o-bromophenol and 2-
bromohydroxyquinone are known to induce nephrotoxicity (Lau et. al 1984a).  They cause renal 
necrosis in rats and mice. The o-bromophenol is converted to 2-bromohydroquinone in the liver.  
2-bromohydroquinone is then carried to the kidney where it induces renal toxicity.  Both o-
Bromophenol and 2-bromohydroquinone deplete glutathione and may be converted to various toxic 
glutathione conjugates in the kidney (Lau et al.1984b and Monks TJ 1984). 
 
3. Proposed Dosing regimen: 
 
Route of administration: IP injection  
Dose groups: Vehicle: Sesame oil   
Low-dose: 100 mg/kg (0.58 mmol/kg)  
High-dose: 200 mg/kg (1.16 mmol/kg)  
 
Dose Selection Justification:   
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While the mechanism of o-bromophenol toxicity is well understood, the acute toxicity of  
o-bromophenol in rats is not very well defined.  Lau et. al, 1984a, reported that single dose of 
>1.28 mmol/kg (221.5 mg/kg), IP, in Sprague Dawley rats, caused increase in serum BUN levels 
and severe renal necrosis, 48 hrs after treatment. In the same study some mortality was noted at 
a dose of 1.75  mmol/kg (302.8 mg/kg) dose. Renal lesions at the 1.75 mmol/kg dose consisted of 
a striking coagulative necrosis of the renal tubular cells in corticomedullary region within 24 to 48 
hours after treatment.  At lower doses apparent regeneration of damaged tubules was noted by 
48 hours post dose.  At a higher dose of 1.92 mmol/kg (332.2 mg/kg), o-bromophenol caused 
significant decrease in renal glutathione levels within 90 minutes post dose.  The highest dose of  
2.03 mmol/kg (351.2 mg/kg), IP has been tested in rats.  There were no reports on effect of  single 
or repeated doses of o-bromophenol beyond 48 hours of treatment in rats or mice. In another 
study (Rush GF, et al., 1983),  single dose of bromophenol isomers greater than 0.2 mmol/kg (34.6 
mg/kg), IV, caused severe convulsions and death.  Convulsions were not observed at 0.14 
mmol/kg (24.2 mg/kg), IV.  No data on plasma exposure was available to correlate the IV to the IP 
dose.  
After personal communication with Dr. Lau regarding the acute effects of o-bromophenol 
following IP injection, we decided to conduct an in-house pilot study to give us a better 
understanding of the maximum tolerated dose and histopathological changes in the kidney on 
Day 7 after a single IP dose. 
Six male Sprague Dawley rats were randomly assigned to the following dose groups listed in the 
table below.  Three rats were sacrificed at 48 hrs post dose (Day 2) and the remaining three rats 
were sacrificed on Day 7 following a single intraperitoneal injection of o-bromophenol.  The 
vehicle was sesame oil.  Clinical observations were conducted daily.  Blood samples for serum 
chemistry were collected on Day 2 and 7 prior to necropsy. Only kidneys were evaluated for 
microscopic changes.   
 
 
 
Group 
Number 
of 
Animals/
group 
(M) 
Concentration 
of  
o-
bromophenol  
(mg/mL) 
 
Dose 
Volume 
(ml/kg) 
 
Dose of 
o-bromophenol 
(mg/kg) 
 
Dose of 
o-bromophenol 
(mmol/kg) 
1 6 0 1 0 (vehicle) 0 
2 6 25 1 25 0.15 
3 6 50 1 50 0.29 
4 6 100 1 100 0.58 
5 6 200 1 200 1.16 
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The dose selection  for the pilot study was based on the study conducted by Lau et al. (1984a) and 
personal communication with her, where she indicated that convulsions are noted immediately 
following dosing at doses ~0.57 mmol/kg (98.6 mg/kg). For the metabonomic study the high dose 
should cause changes in the kidney but no mortality. The doses for this study were chosen to 
evaluate the maximum tolerated dose for o-bromophenol following single i.p. administration. 
 
One animal in the 200 mg/kg dose group that was scheduled to be sacrificed on Day 7 was 
sacrificed early on Day 2 due to deteriorating clinical condition. No convulsions were noted at any 
dose, but slight transient tremors were noted in 4/6 animals at the 200 mg/kg dose immediately 
post dose, however.  Most animals in the 200 mg/kg dose group had slight labored respiration 
and inactivity. These effects were minor and recovered by Day 2-3 post dose. In lower dose 
groups, slight transient labored respiration was noted in fewer animals, mainly on the day of 
dosing.   
   
Clinical pathology changes were noted in one 200 mg/kg rat that was sacrificed early on study 
Day 2.  The changes included increased blood urea nitrogen, glucose, aspartate aminotransferase, 
alanine aminotransferase, total bilirubin, serum potassium, serum phosphorus, and globulin.  
Decreased serum sodium, chloride, and albumin/globulin ratio were also present in that animal. 
There were no compound-related clinical pathology changes at 25, 50, or 100 mg/kg.  
 
Gross pathology changes attributed to dosing with o-bromophenol included white discolored or 
pale livers in one of three animals at 200 mg/kg on Day 2 and 7, and one of three 100 mg/kg 
animals on Day 2.  Foreign material (dosing solution) was present in the peritoneal cavity or 
peritoneal skeletal muscle in several animals on Day 7.   
 
Microscopically, Day 2 treatment-related changes in the kidney consisted of slight to moderate 
tubular regeneration, with necrotic debris in tubular lumens, in two of three animals at 200 
mg/kg.  Two of three 200 mg/kg animals at Day 7 had similar minimal to slight changes.   At 100 
mg/kg, minimal tubular regeneration, with necrotic debris in tubular lumens, was present in one 
of three animals at Day 2 and two of three animals at Day 7. There were no compound-related 
anatomic pathology changes at 25 or 50 mg/kg. 
 
The clinical and anatomic pathology changes present in this study are much milder than those 
reported by Lau et al.  One high dose animal in this study had an elevated BUN, but the kidney 
changes in that animal appeared no different than the other high dose animals that did not have 
an elevated BUN.  Increase in BUN in that one animal could be due to pre-renal reasons.   The 
many other clinical pathology changes in that animal can not be explained by examination of the 
kidney sections.  Slight hemolysis present in the blood sample may have contributed to the 
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elevated AST, but not the other changes. The mild tubular changes present in the 100 and 200 
mg/kg kidneys were not severe enough to affect the clinical health of the animals.    
At 200 mg/kg (1.16 mmol/kg), the kidney changes are associated with some (but not excessive) 
clinical signs of toxicity.  Therefore a high dose of 200 mg/kg (1.16 mmol/kg) is recommended.  At 
the 100 mg/kg dose the histopathological changes were very subtle and no overt signs of toxicity 
were noted and therefore a  low dose of  100 mg/kg (0.58 mmol/kg) is recommended for the 
definitive metabonomic study.  
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COMET CONSORTIUM SUMMARY 
 
O-BROMOPHENOL 
SINGLE DOSE METABONOMICS STUDY  
IN MALE SPRAGUE DAWLEY RATS 
 
INTRODUCTION 
The objective of this study was to characterize the toxicity of o-bromophenol and to 
provide serum, urine and tissue samples for subsequent evaluation of the profile of 
endogenous metabolites using NMR spectroscopy. 
In this study, o-bromophenol was administered as a single intraperitoneal injection to 
male Sprague-Dawley rats. The following dose levels were selected: 
 
Group Dose No. of 
Rats 
Necropsy 
1 Control (corn oil) 10 48 h (Group 1A) or 168 h (Group 
1B) after dose 
2 100 mg/kg 10 48 h (Group 2A) or 168 h (Group 
2B) after dose 
3 200 mg/kg 10 48 h (Group 3A) or 168 h (Group 
3B) after dose 
VIABILITY/MORTALITY 
There were no deaths. 
CLINICAL SIGNS 
There were no clinical signs attributable to treatment with o-bromophenol. 
BODY WEIGHTS 
 
Most animals in all groups, but particularly those treated at 200 mg/kg, lost weight during 
the first 24 hours after dosing. This was attributed, in part, to the dosing procedure. 
Recovery was apparent in all groups from Day 2 although at a slightly slower rate in the 
high dose animals compared with the control and low dose animals. By Day 8, body 
weights were similar for all three groups. 
CLINICAL BIOCHEMISTRY 
 
There were no consistent patterns of variation in the clinical biochemistry parameters to 
suggest an effect of treatment with o-bromophenol. 
 
URINALYSIS 
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Statistically significant decreases in urinary osmolality, creatinine, potassium and glucose 
were observed in high dose animals between 0 and 8 hours after dosing on Day 1. 
ORGAN WEIGHTS 
There was no consistent pattern of variation in organ weight data to indicate an effect of 
treatment with o-bromophenol. 
MACROSCOPIC FINDINGS 
No macroscopic changes attributable to the administration of o-bromophenol were 
observed in animals killed at 48 or 168 hours after dosing.  
MICROSCOPIC FINDINGS 
 
For sub-group A animals (Day 3), a minor multifocal tubular degeneration/regeneration 
was observed in the kidney of two high dose animals. This finding was characterized by 
pale basophilic epithelial cells and necrotic cellular debris within the lumen of the proximal 
tubules. 
For sub-group B animals (Day 8), the spectrum of microscopic findings in the liver and 
kidney of treated animals was generally comparable with that in controls, suggesting a 
complete reversal of the findings seen in the kidney of the high dose Subgroup A animals. 
 
ASSESSMENT AND CONCLUSION 
o-Bromophenol is a toxic phenolic metabolite of bromobenzene which undergoes further 
metabolic transformation to form a toxic metabolite, 2-bromohydroxyquinone. Both  
o-bromophenol and 2-bromohydroxyquinone are known to induce nephrotoxicity in rats 
and mice, evident as renal necrosis. The o-bromophenol is converted to 2-
bromohydroquinone in the liver. 2-bromohydroquinone is then carried to the kidney where 
it induces renal toxicity. Both o-bromophenol and 2-bromohydroquinone deplete 
glutathione and may be converted to various toxic glutathione conjugates in the kidney. 
 
In this study, the decreases in urinary osmolality, potassium and glucose recorded at the 
high dose between 0 and 8 hours after dosing on Day 1 and the minor multifocal tubular 
degeneration/regeneration seen in the kidney of two high dose animals are considered to 
be representative of the expected toxic effects of the test article at sub-lethal doses. 
The study successfully completed the objectives of characterizing the toxicity of the test 
article and generating serum, urine and tissue samples for the determination of the 
metabolic profile of the test article by NMR spectroscopy.  
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 Study Plan (Discovery) 
 Study number 3844DR 
 GEL ID INF.000-156-829 
 Test compound(s) AZ13719017, AZ13647935 & 
2-Bromophenol 
 Project identifier PMB 
 Document status DRAFT 
 GLP compliance No 
 Date approved << >> 
   
Polymyxin B, Polymyxin B nonapeptide & 2-Bromophenol: 1-Day Subcutaneous 
Investigative Kidney Toxicity Study in Han Wistar Rats 
   
This is not a GLP study but all critical operations and methods will be performed according to current written 
local Standard Operating Procedures (SOPs) unless otherwise noted. 
  
Study Director/Study Manager Location of study 
Nakpangi Johnson DSM Boston 
  
Responsible Technician/Scientists Location  
Crystal Brown, Study Coordinator DSM Boston 
Letitia Cheatham, Study Co-coordinator DSM Boston 
Natalie Kierstead, Pathologist DSM Boston 
Debra Snow, Histopathology DSM Boston 
Marie Blais, Clinicial Pathology DSM Boston 
Aixiang Xue, Formulations DSM Boston 
Richard Goodwin, DMPK DMPK Alderley Park 
Peter Webborn, DMPK DSM Alderly Park 
John Swales, DMPK DSM Alderley Park 
Nick Adesina-Georgiadis, DMPK DSM Alderley Park 
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Study Timings Date(s) 
Start of pre-study period <<dd Month yyyy>> 
Proposed experiment start date <<dd Month yyyy>> 
Proposed necropsy start and finish date <<dd Month yyyy>> 
<<additional timings if needed>> <<dd Month yyyy>> 
Final Study Report <<dd Month yyyy>> 
Data Storage and Archiving Archives of DSM Boston 
OBJECTIVE 
The purpose of the study is to investigate the disposition, retention and effects of 
polymyxin B, polymyxin nonapeptide and 2-bromophenol exposure on the kidney. This 
study will also explore the endogenous metabolic profiles of the rat using metabonomic 
and tissue imaging methods with the aim of evaluating these as a means of obtaining 
suitable and specific biomarkers for polymyxin nephrotoxicity. 
STUDY DESIGN 
Species and strain Rat, Han Wistar (Charles River) 
Animal identification and conditions of housing, acclimatisation, 
environment, diet and water will be in accordance with the current 
Standard Operating Procedures 
Number and gender 48 males, housed 2/cage 
  
Age and weight at 
start of dosing 
Approximately 10 weeks old 300-325 g 
Table 1 Dose Groups and Animals 
Group Compound / 
Vehicle 
Study 
Duration 
Animal 
reference 
numbers 
Dose levels 
mg/kg/dose 
Dose 
Volume 
mL/kg 
Concentration 
of dosing 
formulation 
mg/mL 
1 
 
Vehicle (Saline) Main D3 1-4 0 5 0 
2 Vehicle (Saline) Recov D7 5-8 0 5 0 
3 AZ13719017 Main D3 9-12  2 5 0.4 
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Group Compound / 
Vehicle 
Study 
Duration 
Animal 
reference 
numbers 
Dose levels 
mg/kg/dose 
Dose 
Volume 
mL/kg 
Concentration 
of dosing 
formulation 
mg/mL 
4 AZ13719017 Main D3 13-16 6.25 5 1.25 
5 AZ13719017 Recov D7 17-20  6.25 5 1.25 
6 AZ13647935 Main D3 21-24 10 5 2 
7 AZ13647935 Recov D7 25-28 10 5 2 
8 Vehicle (corn 
oil) 
Main D3 29-32 0 5 0 
9 Vehicle (corn 
oil) 
Recov D7 33-36 0 5 0 
10 2-bromophenol Main D3 37-40 100 5 20 
11 2-bromophenol Main D3 41-44 200 5 40 
12 2-bromophenol Recov D7 45-48 200 5 40 
 
Dosing information 
Days 1 to 2: The animals in Groups 1 to 7 will be dosed 4 times daily for 2 days by 
subcutaneous injection in the intrascapular region, approximately every 6 hours; groups 8 to 
12 will be dosed once per day orally. Control animals in Groups 1 and 2 will be dosed with 
sterile saline for injection. Groups 3 to 5 will be dosed with Polymyxin B (2 or 6.25 
mg/kg/dose), groups 6 and 7 with Polymyxin nonapeptide (6mg/kg/dose). Groups 8 and 9 
will be dosed with corn oil (vehicle for 2-bromophenol) and animals in groups 10 through 12 
will be dosed with 2-Bromophenol (100 or 200 mg/kg/day). 
Day 3: All groups will be dosed once with vehicle, Polymyxin B (2 or 6.25 mg/kg/dose), 
Polymyxin nonapeptide (6mg/kg/dose) or 2-Bromophenol (100 or 200 mg/kg/day), as 
previously. All groups, with the exclusion of recovery groups 2, 5, 7, 9 and 12, will be 
sacrificed 4 hours post final dose. 
Please see table in appendix for overview of dosing, urine collection and bleeding. 
Dose justification 
Doses for both Polymyxins and 2-Bromophenol are identical to the dose levels of several 
other polymyxin analogues investigated in previous studies (in house and external). Clinical 
signs such as decreased motor activity, swollen limbs, feet and muzzles, cold extremities, 
cyanosis, excessive scratching and red discoloration of the limbs, feet and muzzles have been 
observed in Polymyxin dosing. However, it is not anticipated that signs will develop in the 
low dose groups and those in the high dose should not persist.  
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Test compound, formulation and hazard information 
 
Test Compound Batch Molecular 
weight 
(g/mol) 
Base factor Purity Formulated 
in 
AZ13719017 
Polymyxin B 
001 1203.0 1 100 Sterile saline 
for injection 
AZ13647935 
Polymyxin B 
nonpeptide 
002 963.10 1 95 Sterile saline 
for injection 
 
2-Bromophenol 
Sigma Aldrich 
Lot#/Exp Date:  
Storage 
The formulations need to be protected from light. 
Containers will be labelled with study number, ID of compound, concentration, and 
manufacturing date. 
Remaining formulations 
All remaining formulations will be sent to Aixiang Xue in LAS for disposal. 
Hazards 
All test substances undergoing safety assessment and evaluation must be regarded as potent 
pharmacologically active agents with unknown toxic properties.  Precautions for high hazard 
materials must be taken since there is insufficient data for assigning to a specific health and 
hazard group.  Handling and use of the test substances are restricted to designated areas.  Use 
these materials in laboratory fume hoods or glove boxes when preparing formulations or 
other solutions.  Wear suitable protective clothing, gloves, and safety glasses.  If any specific 
hazard is identified, appropriate precautions must be taken. 
Samples for analysis 
Appropriate samples of the dosing formulations will be taken after preparation and frozen. 
Samples may be used for future concentration verification analysis.  
Information to be provided with samples: Sample list.  Labels on the vials should be marked 
with study number, substance code or control, nominal concentration (parent form), sample 
number and sampling date. 
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GOOD STATISTICAL PRACTICE 
This study is confirmed as being a non-standard study design.  A statistician has performed a 
statistical review of the study design.  A copy of the statistical review will be archived with 
the study data.  If there are any planned changes to the study that affect GSP principles, a 
revised statistical review will be produced and archived with the study data. 
PARAMETERS TO BE MEASURED 
In-life observations 
Clinical observations 8 am and 2pm doses: Animals will be observed pre-dose and 
at least 1 to 3 hours post-dose. 
8 pm, 2 am and weekend/holiday doses: Animals will be 
observed pre-dose and at approximately 1 hour post-dose.  
Necropsy day dose: The animals will also be observed the 
morning of necropsy on Days 3 or 7 prior to dosing and 1-3 
hours post-dose. 
 
Body weight Dosing phase: Will be taken at randomization; then recorded 
daily prior to dosing and/or until necropsy. 
 
Food and water 
consumption 
Will not be recorded. 
Laboratory 
Toxicokinetics 
Groups: 1-12 
Animals per time point: 4/group 
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Time points and 
site/route/volume: 
Groups 1-3 and 5, Polymyxin B/Polymyxin Nonapeptide: 
(following the 2pm dose) 
6 (immediately prior to dosing), 7, 9, 12 (immediately 
prior to dosing), 30 (immediately prior to dosing), 31, 33 
35 & 51 (terminal) hrs post dose 1 on Day 1. 
 
Group 4, 6 and 7, Recovery: (following the 2pm dose) 6 
(immediately prior to dosing), 7, 9, 12 (immediately prior 
to dosing), 30 (immediately prior to dosing), 31, 33 36. At 
hours 6, 7, 9, 12 hrs daily thereafter once dosing has 
concluded. 
 
Group 8-9, 2-Bromophenol (following the single dose) 
6, 7, 9, 12, 30, 31, 33 35 & 51 (terminal). 
Groups 10-11, Recovery: (following the single dose) 6, 7, 9, 
12, 30, 31, 33 36. At hours 6, 7, 9, 12 hrs daily thereafter once 
dosing has concluded. 
 
Tail vein*, 0.2 mL whole blood 
*Saphenous veins and/or retro-orbital sinus will be used if tail vein 
attempt is unsuccessful.  If an alternate route is used or partial 
sample collected, the TK timesheet and platemap will contain a 
note detailing the collection problem. 
Sample preparation/storage 
and anticoagulant: 
Samples will be taken in lithium heparin tubes and kept on 
ice.  Samples will be centrifuged for 3 minutes at 1500 g 
under refrigeration (2 to 8°C) within approximately 0.5h of 
collection.  Plasma will be transferred into 0.5 mL 
polypropylene tubes with snap caps and immediately frozen.  
The plasma samples will be kept frozen at 
approximately -70°C until analysis. 
Samples will be analysed for: AZ13709017, AZ13649735, 2-Bromophenol 
Parameters calculated: Cmax, AUC(0-24), t1/2 
Estimated sample ship date:  
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Samples sent to: Nick Adesina-Georgiadis c/o 
Peter Webborn 
Mereside 
35/F/11  
Alderley Park, Macclesfield,  
Cheshire, England 
SK10 4TF  
+44 1625 233101 
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Clinical pathology 
 
Groups / Animals Days Sampling route, volume, anti-coagulant and 
Time points 
1-12/1-48 -1,2,3 Urine chemistry and DIKI Biomarkers. 
1, 3, 4, 6, 8, 10, 11/ 1-4, 9-16, 
21-24, 29-32, 37-44 
3 Vena cava, isoflurane, plasma chemistry up to 
4.0 mL (lithium heparin) hematology up to 2.0 mL 
(EDTA) 
2, 5, 7, 9, 12/5-8, 17-20, 25-
28, 33-36, 45-48 
4-7 Urine chemistry and DIKI Biomarkers. 
2, 5, 7, 9, 12/5-8, 17-20, 25-
28, 33-36, 45-48 
7 Vena cava, isoflurane, plasma chemistry up to 
4.0 mL (lithium heparin) hematology up to 2.0 mL 
(EDTA) 
 
Hematology 
Erythrocytes (RBC) Platelets (PLT) 
Hemoglobin (HGB) Leukocytes(WBC) 
Hematocrit (HCT) Absolute Neutrophils(ANEUT) 
Mean red cell volume (MCV) Absolute Lymphocytes(ALYM) 
Mean red cell hemoglobin (MCH) Absolute Monocytes(AMONO) 
Mean red cell haemoglobin concentration 
(MCHC) 
Absolute Eosinophils(AEOS) 
Red cell distribution width (RDW) Absolute Basophils(ABASO) 
Reticulocytes (RET%) Absolute Large unstained cells (ALUC) 
Absolute Reticulocytes (ARET) 
 
 
A peripheral blood smear will be made on all hematology samples but only examined where 
automated analysis indicates this is necessary or at the discretion of the Pathologist or Study 
Director. 
Plasma chemistry 
Creatinine: CREA Blood Urea Nitrogen: BUN 
Total Protein: TP Albumin: ALB 
Cholesterol: CHOL Triglycerides: TRIGS 
Total Bilirubin: TBIL Glucose: GLU 
Sodium: NA Potassium: K 
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Alanine aminotransferase: ALT Alkaline phosphatase: ALP 
Globulin: GLOB
1
 Aspartate transferase: AST 
Albumin/Globulin ratio: AG
1
 Total Calcium: CA 
Inorganic phosphorus: IPHOS Abnormal color and lipemia to be noted 
1
 Calculated parameter 
 
Urine analysis 
Baseline urines will be collected on Day –1 for all animals.  All animals will also have 
individual urine samples collected on ice, daily on Days 1 to 3. The rats will be placed in 
metabolic cages immediately after dosing for 6 hours. 
For the recovery groups 2, 5, 7, 9 and 12, individual urine samples will be collected daily on 
Days 4 through 7, every 24hr by placing rats in metabolic cages for 6 hours. 
Water will be available during the collection period but food will be withdrawn. 
Urine Chemistry 
Volume
1 
Glucose
 
Urea
 
Protein
 
Creatinine 
 
1
Measured by graduated conical tube 
 
Urinary Biomarkers 
ΑGST (alpha glutathione-s-transferase) Albumin 
GSTYb1 (glutathione-s-transferase Yb1)
 
Creatinine 
TIM-1 (KIM-1, kidney injury molecule)
  
Clusterin  
 
 
 
 
 
Urine aliquots for analysis (All Groups) 
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If sufficient volumes are available, remaining unprocessed urine will be transferred to labeled 
microcentrifuge tubes and stored at -70°C or below until transfer to DMPK for analysis. 
 
Pathology 
Necropsy and histopathology: Day 3 (Groups 1, 3, 4, 6, 8, 10, 11); Day 7 (Groups 2, 5, 7, 9, 
12) 
Study animals in Groups 1 to 12 will be subjected to necropsy.  Animals will have free access 
to food and water overnight before the necropsy.  The body weight will be recorded prior to 
scheduled necropsy.  Animals will be euthanized by exsanguination from the caudal vena 
cava under isoflurane anesthesia.  External features of the animal, the thoracic and abdominal 
cavities and contents will be examined.  Macroscopic abnormalities will be recorded and 
collected.  
Moribund and Decedent animals: The study director and study pathologist must be 
contacted in the event of a moribund or decedent animal.  Moribund and decedent animals 
from Groups 1 to 12 will be necropsied when possible and study plan required tissues 
collected. Additional tissues will be collected at the discretion of the study pathologist.  In 
both cases, collected specimens will be processed and examined at the discretion of the study 
pathologist. Organ weights will not be taken from moribund or early decedent animals.  
Blood samples will only be drawn on moribund animals, not decedents and will be stored on 
ice until the plasma is separated.  In the event of moribund animals on the weekend/holiday, 
hematology and plasma chemistry samples will be collected. The hematology (EDTA) whole 
blood samples will be refrigerated at 2-8°C and the plasma chemistry samples (Lithium 
heparin) will be spun down and the plasma frozen at -70°C by LAS.  
The following tissues will be sampled, processed and examined: 
Kidney 
 
Tissues processed and examined by light microscopy: All preserved tissues will be 
processed to paraffin blocks.  Blocks will be sectioned, stained with hematoxylin and eosin 
and examined.  Additional sections and stains may be requested by the study pathologist to 
determine the significance of any observed findings. 
Organ Weights (Groups 1-12) 
The following organs will be weighed intact and unfixed at scheduled necropsy:  
Kidneys 
Paired organs will be weighed together and combined weight recorded.  Organ weights will 
not be taken from decedents or moribund animals.  
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 DMPK Sampling (Groups 1-12) 
The following tissue will be collected for MALDI and exposure.  Upon collection, the tissue 
should be weighed and recorded. Tissue will be kept frozen until transfer to DMPK for 
analysis.  
MALDI 
Groups 1-12 
Animals in groups 1-12 will have half of the right kidney (transverse 
section) collected. Organs will be snap frozen slowly by free floating in 
chilled isopentane (2-methybutane) in disposable weigh boats on dry ice. 
Once frozen they should be placed in aluminium foil, transferred on dry 
ice and stored at -80ºC 
Samples will be sent to: 
Richard Goodwin  
35F53/6 
Mereside,  
Alderley Park, Macclesfield,  
Cheshire, England 
SK10 4TG  
+44 1625 518751 
 
Bioanalysis 
Groups 1-12 
The other half of the right kidney will be snap frozen in liquid nitrogen. 
Samples will be sent to:  
Nick Adesina-Georgiadis c/o 
Peter Webborn 
Mereside 
35/F/11  
Alderley Park, Macclesfield,  
Cheshire, England 
SK10 4TF  
+44 1625 233101 
 
REPORTING AND STATISTICAL ANALYSIS 
A summary study report will be prepared according to the current Discovery Reporting 
guidelines.  Statistical analysis will be performed at the discretion of the Study Director 
following review of the data.  Any analysis done will be recorded in the study file. 
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